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Abstract
The synthesis of adenophostin A, a recently discovered exceptionally potent 
agonist at the lD-myo-inositol 1,4,5-trisphosphate [Ins(l,4,5)P3] receptor, and a series of 
adenophostin A analogues is described. The key adenosine intermediate, 5 -O-benzyl-TV6- 
dimethoxytrityl-2-<9-;?-methoxybenzyl adenosine was made via a route involving 
selective N6 dimethoxytritylation in the presence of a free 5'-hydroxyl, and regioselective 
reduction of a 2',3'-0-/?-methoxybenzylidene acetal. Glycosidation of this intermediate 
with a protected glucopyranoside phosphite donor followed by selective deprotection, 
phosphorylation and complete deprotection resulted in adenophostin A. This synthetic 
adenophostin A was found to be pharmacologically equipotent with a sample of natural 
adenophostin A. In addition a sample of our synthetic adenophostin A was examined by 
a collaborator using potentiometric and NMR titrations. The binding orientation of 
adenophostin A at the Ins(l,4,5)P3 receptor was investigated by means of the synthesis 
and biological evaluation of two sugar modified analogues in which the glucose portion 
of adenophostin A was replaced by mannose and xylose. 3-0- a-D-Mannopyranosyl 
adenosine 2',3",4"-trisphosphate was found to have greatly reduced Ca2+ releasing 
activity compared with adenophostin A, while 3 O- or-D-xylopyranosyl adenosine 
2',3",4"-trisphosphate was found to be almost equipotent with adenophostin A. Methyl 
3-0-«-D-glucopyranosyl-/2-D-ribofuranoside 2,3 ,4 -trisphosphate (ribophostin), in which 
the adenine ring of adenophostin A has been effectively deleted was synthesised in a 
convergent route from D-glucose and D-ribose, utilising a trichloroacetimidate 
glycosidation strategy. Ribophostin was found to be almost equipotent with Ins(l,4,5)P3. 
Further reduction of the adenophostin A structure led to the design and synthesis of 
[(3S,4R)-3-hydroxytetrahydrofuran-4-yl] or-D-glucopyranoside 3,3',4-trisphosphate 
(furanophostin) an analogue in which the O-methyl and 4-hydroxymethyl moieties have 
been deleted. Like ribophostin, furanophostin was almost as active as Ins(l,4,5)P3. To 
enable the synthesis of base modified adenophostin A analogues a versatile disaccharide 
intermediate, l,2,3',4'-tetra-0-acetyl-2',5,6'-0-benzyl-3-0-ar-D-glucopyranosyl-D-
ribofuranose was synthesised. Vorbruggen condensation of this intermediate with purine 
and imidazole led to the synthesis of 3'-0-a-D-glucopyranosyl-9-/?-D- 
ribofuranosidopurine 2',3",4"-trisphosphate (purinophostin) and 3'-0-a-D- 
glucopyranosyl)-1 - /^D-ribofuranosidoimidazole 2',3",4"-trisphosphate (imidophostin) 
respectively. Purinophostin was equipotent with adenophostin A, while imidophostin 
exhibited activity similar to that of Ins(l,4,5)P3. These data contribute to the 
construction of a general binding model for adenophostin A at the Ins(l,4,5)P3 receptor.
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The importance of Ca in cellular function is reflected in the way in which levels 
of free intracellular Ca2+ in the cells of eukaryotic organisms are tightly controlled by a 
large number of coordinated regulatory mechanisms.1'4 This regulation is crucial to 
many specialised functions of cells; for example changes in cytoplasmic Ca2+ levels have 
been shown to be responsible for events such as fertilisation and muscle contraction.2 
There are two sources of Ca2+ available to increase the cytoplasmic Ca2+ concentration; 
an unlimited extracellular supply and a more finite intracellular store in the endoplasmic 
and sarcoplasmic reticulum.
1.1.1 Mobilisation of calcium from intracellular stores
The intracellular stores of Ca are mobilised from one of two different receptors:
1.1.1.1 Ryanodine receptor
^  I •} i
Ca Release through sarcoplasmic reticulum Ca -release channels (ryanodine 
receptors) was first observed in 19765 but it was not until 1985, when it was found that a 
plant alkaloid ryanodine bound with high specificity and affinity to these proteins in the 
sarcoplasmic reticulum, that the isolation and incorporation into planar lipid bilayers of 
the ryanodine receptor was achieved. The resulting Ca2+-channels were found to be 
activated by Ca2+, caffeine, adenine nucleotides and inhibited by Mg2+ and ruthenium 
red. ’ Further work saw the identification of three different genes in mammals —ryrl, 
ryr2, and ryr3—encoding skeletal (Ryrl), cardiac (Ryr2), and brain (Ryr3) ryanodine
Q
receptor isoforms respectively. Their individual structure and properties have been 
reviewed in detail9and therefore will not be elaborated here.
Of particular note here is the identification of a physiological ligand for the
^ I
ryanodine receptors located in sea urchin eggs that releases Ca . This ligand was 
identified as a cyclic derivative of nicotinamide adenine dinucleotide (NAD+) called 
cyclic ADP-ribose (cADPR, l ) 10 (Figure 1.1). The properties of cADPR and its 
stimulation of Ca2+ signalling in several higher eukaryotic cell systems have also been 
investigated with the suggestion that it acts as a second messenger signalling molecule.11
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However some aspects of the properties of Ca2+ release by cADPR in these systems 
appear to be different to those originally characterised in sea urchin eggs, suggesting that 
other target proteins may also be involved in mediating the effects of cADPR.
*0—R=0
OH 0 P 0 3
Figure 1.1: Cyclic ADP-ribose
1.1.1.2 lns(1,4,5)P3 receptor
The other intracellular receptor responsible for Ca2~ release into the cell
_ icytoplasm is stimulated by D-mj/o-inositol 1,4,5-trisphosphate [Ins(l,4,5)P3] and is 
consequently termed the Ins(l,4,5)P3 receptor. Formation of Ins(l,4,5)P3 is mostly 
regulated by mechanisms in the cell plasma membrane which may be divided into two 
different categories, those regulated by the GTP binding protein (G-protein) linked 
receptors, and those regulated by tyrosine kinase receptors. These pathways however 
both involve the activation of phospholipase C (PLC) and its cleavage of 
phosphatidylinositol 4,5-bisphosphate [PtIns(4,5)P2], to Ins(l,4,5)P3 (2) and








Figure 1.2: Cleavage of PtIns(4,5)P2 by phospholipase C to give Ins(l,4,5)P3 and DAG 
1.2.2 G-protein linked plasma membrane receptors
Most G-protein linked receptors have seven transmembrane domains, consisting 
of hydrophobic amino acid residues. The binding site is located in a pocket near the 
centre of the lipid bilayer. On binding of a specific ligand to the receptor’s extracellular 
binding site, it undergoes a conformational change, that is transmitted to the cytosolic 
loops II and III. An associated heterotrimeric G-protein is activated by this 
conformational change, and dissociates into the Ga and GpY subunits. After exchanging 
GTP for bound GDP, the Ga subunit interacts with PLC-/71, (PLC has three isozymes, 
PLC-J3, PLC-£ and PLC-/, each of these has more than one subtype of which PLC-/71 is 
an example). Once activated PLC-/71 interacts with PtIns(4,5)P2 and causes its cleavage 
to Ins(l,4,5)P3 and DAG (Figure 1.3). Activation of PLC ceases when the GTP 
associated with the G-protein is hydrolysed to GDP by the intrinsic GTP-ase activity of 








Figure 1.3: The G-protein linked receptor mediated generation of Ins(l,4,5)P3 and DAG
1.2.3 Tyrosine kinase plasma membrane receptors
A simpler single transmembrane-spanning domain makes up the tyrosine kinase 
receptor. Binding of ligands such as platelet-derived (PDGF), and epidermal growth 
factor (EGF), cause the receptor to dimerise, allowing the cytoplasmic domains of the 
two receptors to phosphorylate each other on tyrosine residues. This forms a docking 
site for the SH2 domain of PLC-/1, which on translocation from the cytosol, binds and is 
phosphorylated on specific tyrosine residues.12 Localisation from the cytosol to the 
membrane brings PLC-^1 into close proximity with PtIns(4,5)P2, providing the 
conditions for its cleavage into Ins(l,4,5)P3 and DAG.4
It has also been shown that signalling from tyrosine kinase receptors through 
PLC-/1 may involve stimulation of PtIns(4,5)P2 3-kinase and generation of 
PtIns(3,4,5)P3, which could contribute, directly or indirectly, to a growth factor 
stimulation of PLC activity and subsequent Ins(l,4,5)P3 formation.13 Other cell 
responses to receptor stimulation that appear to be regulated by PtIns(3,4,5)P3 formation 
include: i) insulin-stimulated glucose uptake by target tissues, notably adipose and 
skeletal muscle;14 ii) the maintenance of cell survival in response to survival factors such
5
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as insulin-like growth factor;15 and iii) activation of lamellipodia formation on the 
leading edge of migrating cells.14
The two cleavage products of PtIns(4,5)P2, both have roles as second messengers. 
DAG itself has two possible functions; it may be cleaved to release arachidonic acid, 
which either acts as a messenger in its own right or may be used in the synthesis of 
eicosanoids. But more importantly for cell signalling, DAG can activate a family of 
protein kinase C isozymes, which catalyse protein phosphorylation.16
1.2 The l n s ( 1 , 4 ,5 ) P 3  Receptor, its structure and 
regulation
Ins(l,4,5)P3 diffuses into the cell cytosol where it binds to Ins(l,4,5)P3 receptors. 
By far the greatest concentration of receptors are found in the membrane of the 
endoplamic reticulum (ER). Ins(l,4,5)P3 Receptors have also been found in the plasma 
membrane of Jurkat T-lymphocytes,17,18 epithelial cells,19 and Purkinje cells;20 and not 
surprisingly, since the ER is contiguous with the outer membrane of the nuclear 
envelope, Ins(l,4,5)P3 receptors have been found there too.21
The presence of a family of Ins(l,4,5)P3 receptors has now been established. 
Three mammalian receptor isoforms are known,22 corresponding to three distinct 
Ins(l,4,5)P3 receptor encoding genes. The tissue distribution studies carried out so far 
show that all cells contain multiple receptor isoforms but that one isoform may be 
predominant in a particular tissue or cell type (Table 1.1). Isolated Ins(l,4,5)P3 receptor 
protein proved to be a tetramer, forming an Ins(l,4,5)P3-gated ion-channel.22 At least 
four genes code for the different Ins(l,4,5)P3 receptor isoforms, all of which share 
significant similarity to each other, have partial homology with the ryanodine receptor 
(discussed previously), and no significant homology with voltage-dependent Ca2+ 
channels 4
Finally it has been found that different Ins(l,4,5)P3 receptor isoforms can 
combine to form heteroligomers, complicating the study of Ins(l,4,5)P3 signalling even 
further. This was shown experimentally by a single isoform-specific antibody co- 
immnoprecipitating additional isoforms from cell extracts.
6
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Family Predominant tissue distribution
Type-1 Brain, A7r5 smooth muscle cells, uterus, peripheral tissue
Type-2 lung, hepatocytes, testis, spleen
Type-3 intestine, kidney, pancreatic islets
Table 1.1: Location of Ins(l,4,5)P3 receptor isoforms.
Several subtype-specific properties of Ins(l,4,5)P3 receptors have been identified 
and these have been discussed in great detail in a review by Patel et a lP
Each of the four subunits of the Ins(l,4,5)P3 receptor consists of three domains. 
Contained in the large amino terminal portion of the receptor, which projects into the 
cytoplasm, there is the Ins(l,4,5)P3 binding domain, and the regulatory domain. Located 
near the carboxy terminus and embedded in the ER membrane is the transmembrane 















Figure 1.4: Cross section of a generalised Ins(l,4,5)P3 receptor, showing proposed site of 
action of some antagonists.24 THA+=tetrahexylammonium ion
1.2.1 The lns(1,4,5)P3 receptor binding domain
The binding affinity of Ins(l,4,5)P3 for the N-terminal segment varies between 
different receptor isoforms. Two different groups have found different rank orders for
7
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the binding affinity of Ins(l,4,5)P3 to the receptor isoforms. Using monomeric N- 
terminus fusion proteins of the Ins(l,4,5)P3 receptor Newton et al.25 found affinities in 
the following order: type-2 > type-1 > type-3. Meanwhile Wojcikiewicz and Luo26 
utilised subtype-specific antibodies to immunoprecipitate pure homotetrameric 
Ins(l,4,5)P3 receptor populations, and they found a rank order of type-1 « type-2 > type- 
3.
The antagonists heparin and decavanadate are believed to act at the Ins(l,4,5)P3 
binding site, although the usefulness of heparin as a competitive antagonist has its
97*98 OQlimitations, ’ as it has also been reported to stimulate L-type Ca channels, uncouple 
receptors from their G-proteins, inhibit the kinase responsible for Ins(l,3,4,5)P4 
formation, inhibit binding of Ins(l,3,4,5)P4, and stimulate Ca release through the 
ryanodine receptor.33
1.2.2 The lns(1,4,5)P3 receptor regulatory domain
Physiological control over the Ins(l,4,5)P3 receptor occurs at the regulatory 
domain where Ca interacts and phosphorylation occurs. It has been noted that the 
homology between different Ins(l,4,5)P3 receptor subtypes is the lowest in the regulatory 
domain, suggesting that differential regulation may occur amongst different subtypes.34 
The regulation of ligand binding by Ca2+ is complex and tissue dependent.33 
Phosphorylation of the regulatory domain by A-kinase,35 G-kinase,36 and tyrosine 
kinase37 has been observed in intact cells. Studies carried out in the liver have found that 
the effect of A-kinase phosphorylation is to potentiate the action of Ins(l,4,5)P3 in 
hepatocytes.35 However other investigations propose that the activation of G-kinase, 
resulting from increased cGMP levels, is to inhibit Ca2+ release. Since the level of nitric 
oxide appears to mediate increased cGMP levels it is concluded that ultimately nitric
9-1-oxide has an inhibitory effect on Ca release. The regulatory domain also has two 
binding sites for ATP, and caffeine is thought to be a non-competitive antagonist acting
97at these binding sites. In addition it has recently been demonstrated that neither 
adenophostin A nor cADPR bind to these sites.39
The ubiquitous Ca2+-binding protein calmodulin has been shown to modulate the
9  I
mobilisation of Ca from cerebellar microsomes. Each Ins(l,4,5)P3 receptor subunit 
was found to bind two molecules of calmodulin in the presence of Ca2+ and one in its 
absence40. Binding of calmodulin was shown to decrease the affinity of the receptor for
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Ins(l,4,5)P3, and hence markedly reduce the potency of Ins(l,4,5)P3 (by ca. 10-fold) in 
mobilising Ca2+ from cerebellar microsomes. This effect was independent of the Ca2+ 
concentration.41
Another protein which has been found to be tightly associated with the 
Ins(l,4,5)P3 receptor is FKBP12 (FK506-binding protein). Treatment with FK506 
disrupts this association and dramatically increases the Ca2+ releasing ability of 
Ins(l,4,5)P3 from cerebellar microsomal preparations 42
1.2.3 The lns(1,4,5)P3 receptor transmembrane domain
The calcium channel domain is currently thought to form six transmembrane 
helices, with a proposed hydrophobic hairpin loop between the fifth and sixth helices. 
This loop is probably embedded in the membrane where it could be part of the ion- 
conducting pore. The ion-channel seems to exhibit poor discrimination between divalent 
and monovalent cations, and experiments have demonstrated that this channel behaves as 
a single file ion pore.22 Polyamines are able to inhibit Ca2+ release from the Ins(l,4,5)P3 
receptor with the potency of a polyamine being directly related to the number of positive 
charges on the molecule. It is thought that as a result of their charged nature they may
9-4-block Ca release by interacting with the negatively charged amino acids found in the 
Ca2+ channel.27
1.2.4 Properties of Ca2+ release
When treated with suboptimal doses of Ins(l,4,5)P3 it was found that only 
fractions or “quanta” of calcium were released from the cellular calcium stores; only 
when higher levels of ligand are used does the full calcium store become accessible 43 
Proposed mechanisms for this type of release either involve heterogeneity of the 
receptors expressed in the cell, differing receptor sensitivity to Ins(l,4,5)P3, or both.27
Progress in imaging technology has also allowed the visualisation of Ca2+ release
9+in individual cells. It is now clear that Ca signals often have different spatiotemporal 
properties, thereby eliciting different physiological outcomes.2,44 Localised signals
9  »
referred to as elementary events, such as Ca puffs or sparks, are dependent on the 
nature and location of the Ins(l,4,5)P3 receptors involved. It has been found that these 
elementary events can either activate highly localised cellular processes in the vicinity of
9
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the channels, or by recruiting channels throughout the cell, they can activate either a 
global Ca2+ wave inside the cell or a global Ca2+ wave across several cells.45






Global Ca2+ wave (intracellular)
fertilisation
smooth muscle contraction 
liver metabolism 
cell proliferation





Table 1.2: Spatial aspects of Ca + signalling adapted from Berridge, Bootman, et al.2
1.2.5 The modulation of lns(1,4,5)P3 receptors by Ca2+
The most immediate effects of released Ca2+ on the surrounding Ins(l,4,5)P3 
receptors and the current knowledge of the mechanisms involved have been reviewed 
recently.46 It has been established that the regulation of the Ins(l,4,5)P3 receptors by 
Ca2+ in most cells is biphasic, with low concentrations of Ca2+ resulting in rapid 
stimulation of the receptors, and higher concentrations resulting in a slower inhibition.47 
Taylor proposes that the mechanism for the regulation involves binding of Ins(l,4,5)P3 to 
an Ins(l,4,5)P3 receptor subunit binding domain, which causes a large conformational 
change that both exposes a Ca2+-binding site and initiates the inactivation process. This 
leads to the receptor binding Ins(l,4,5)P3 with increased affinity and becoming less 
capable of opening to its fully active state. It is thought that it is only when all four 
subunits of the receptor have bound Ins(l,4,5)P3 and Ca2+ in their respective binding
^  I
sites that the channel pore opens. It is then thought that as the cytosolic [Ca ] increases 
it binds to a second binding site on the Ins(l,4,5)P3 receptor resulting in the relatively 





The term Pleckstrin Homology (PH) domain was first used in 1993 to describe 
homologous regions of approximately 120 amino acids found in a number of proteins 
involved in functions such as intracellular signalling and cytoskeletal organisation. 
These regions or domains were termed PH domains because the domain was first 
identified in the phosphoprotein pleckstrin.
Although the primary sequence of PH domains varies considerably, their 
secondary structure is quite similar, this being one of the criteria for a PH domain. They 
comprise seven /2-strands and a C-terminal cr-helix. The loops between these strands are 
variable in length and sequence. Furthermore NMR spectroscopy and X-ray 
crystallography has revealed a common tertiary structure. Each domain is a /2-sandwich 
formed by two nearly orthogonal antiparallel /2-sheets comprising four and three /2- 
strands respectively, and the C-terminal a-helix closes one end of the /2-sheets. It has 
been proposed that the diversity in the primary structure of these domains provides the 
means for their functional diversity that is currently receiving a great deal of attention.
1.3.2 Function
In 1994 Harlan et al.4S reported that the PH domains of several proteins including 
pleckstrin, /2-adrenergic receptor kinase (/2ARK), ras-GTP-activating protein and T-cell 
specific-kinase, bound phosphatidylcholine vesicles containing PtdIns(4,5)P2 in vitro. 
Moreover it was shown that a large excess of Ins(l,4,5)P3 could inhibit the 
phosphoinositide-PH domain interaction. Since then, these and other proteins have been 
found to bind a number of different phosphoinositides and inositol phosphates. These 
findings are summarised in Table 1.3.
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Table 1.3: Summary of proposed ligands for PH domains.49’50
Of particular interest is the interaction of PLC-^i with Ins(l,4,5)P3 and 
PtdIns(4,5)P2. Antibody-tagged fluorescence studies have been used to show that PLC- 
S\ requires its PH domain for membrane attachment. Single amino acid substitutions in 
the PH domain of PLC-£i have been shown to affect its ligand binding, phospholipase 
and membrane binding activities. Furthermore after agonist stimulation green 
fluorescent protein-labelled PH domains of PLC-<Si have been shown to localise at the 
plasma membrane and then transiently become cytosolic upon depletion of 
PtdIns(4,5)P2. Consideration of these results has led to the suggestion that the PLC-<5j 
PH domain serves to anchor PLC-^i to the plasma membrane via a PtdIns(4,5)P2-PH 
domain interaction. This is followed by the cleavage of PtdIns(4,5)P2 to Ins(l,4,5)P3 and 
DAG. Ins(l,4,5)P3 is then thought to compete with PtdIns(4,5)P2 for the PH domain 
binding site, resulting in the release of the enzyme from the plasma membrane. It is 
thought that this regulation of the PH domain interaction with PtdIns(4,5)P2 may
g-Ptd!ns(4,5)P2 is l-(ar-glycerophosphoryl)inositol 4,5-bisphosphate
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represent an important feedback mechanism by which excessive PtdIns(4,5)P2 hydrolysis 
by PLC-^1 is avoided.
Previous discussion has implicated PtdIns(4,5)P2 3-kinase activity in the 
regulation of PLC-/i. The role of PtdIns(4,5)P2 3-kinase has been investigated with the 
use of confocal fluorescence microscopy and green fluorescent protein-labelled PLC-/1 
PH domain51. It was demonstrated that PtdIns(4,5)P2 3-kinase activity can induce 
membrane localisation of the PLC-/1 PH domain in vivo. Such localisation is thought to 
result in the cleavage of PtdIns(4,5)P2 to give Ins(l,4,5)P3 and DAG. Such results 
suggest that PtdIns(4,5)P2 3-kinase plays a role in the formation of Ins(l,4,5)P3 catalysed 
by PLC-/1.
1.3.3 X-ray crystal structures of lns(1,4,5)P3 and lns(1,3,4,5)P4 bound 
to PH domains
The X-ray crystal structure of Ins(l,4,5)P3 bound to the PH domains of /2- 
spectrin and PLC-<5l were reported in 1995. This has been followed by the 
publication of the X-ray crystal structure of Ins(l,3,4,5)P4 bound to the PH domain of 
Bruton's tyrosine kinase.54
The two PH domain-Ins(l,4,5)P3 complexes were found to be quite different. To 
begin with Ins(l,4,5)P3 bound to different regions of the respective PH domains. In /2- 
spectrin Ins(l,4,5)P3 was bound between loops /2-1/2 and /2-5/6, while in PLC-^i 
Ins(l,4,5)P3 bound to residues from loops /2-1/2 and >0-3/4. Figure 1.5 shows a schematic 
representation of the key residues involved in holding Ins(l,4,5)P3 at the respective 
binding sites. It is immediately clear that there are large differences in the number and 
arrangement of interactions, which probably accounts for the differences in stability of 
the two complexes. The complex formed between Ins(l,4,5)P3 and the PH domain of 
PLC-<51 was 200-fold more stable than that formed between Ins(l,4,5)P3 and /2-spectrin. 
The most noticeable difference between the two complexes concerns the Ins(l,4,5)P3 5- 
phosphate, which has twice the number of hydrogen bonds to amino acid residues in the 
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Arg 21.
Figure 1.5: Schematic representation of the Ins(l,4,5)P3 binding site of A) /2-spectrin and 
B) PLC-<Si PH domains. Adapted from Hyvonen et al. and Ferguson et al. 
respectively.
A schematic representation of the binding site of Ins( 1,3,4,5)P4 in the PH domain 
of Bruton's tyrosine kinase is depicted in Figure 1.6, like the PLC-<Si Ins(l,4,5)P3 
complex, the Ins(l,3,4,5)P4 binding site was found between the /2-1/2 and /?-3/4 loops of 
the PH domain. The PH domain of Bruton's tyrosine kinase has been shown to exhibit 
specificity for Ins(l,3,4,5)P4 over Ins(l,4,5)P3 and the reason for this preference was 
clear from the crystal structure, in which the 3-phosphate was found to be held by a 
significant number of hydrogen bonds to the amino acid residues of the PH domain. The 
report by Baraldi et al.54 also investigated the binding of Ins(l,3,4,5)P4 to mutants of the 
Bruton's tyrosine kinase PH domain, since they have been associated with an X 
chromosome linked immunodeficiency caused by a mutation in the murine Btk gene. 
They concluded that the mutant phenotype has different causes, with different mutations 
resulting in different structural changes in the PH domain and thus affecting 












Figure 1.6: Schematic representation of the Ins(l,3,4,5)P4 binding site of the Bruton's 
tyrosine kinase PH domain. Adapted from Baraldi et al.54
The preceding examples of PH domain function in known phosphoinositide 
signalling pathways, together with the X-ray crystal structures of Ins(l,4,5)P3 and 
Ins(l,3,4,5)P4 bound in PH domains are just part of the research in this field. As a result 
of the great interest in PH domains and their interactions with other cellular molecules 
the rate of progress in understanding their role in cellular signalling has been, and 
continues to be, very rapid. The current knowledge pertaining to the phosphoinositide 
signalling pathway has been discussed here, but for a more detailed consideration of PH 
domain-phosphoinositide interactions the reader is referred to two comprehensive 
reviews published within the last year.49,50
1.4 Mechanisms for entry of extracellular Ca2+ into the 
cell
Entry of extracellular Ca2+ through the plasma membrane into the cell occurs 
through three different channels: i) voltage-operated Ca2+ channels (VOCs) in excitable 
cells such as neurones or muscle cells, ii) receptor-operated Ca2+ channels (ROCs) in 
response to neurotransmitters, and iii) store-operated Ca2+ channels (SOCs) which open 
when the intracellular Ca2+ stores have been depleted and are mainly found in non- 
excitable cells. These channels mainly function to provide Ca2+ for increases in the 
cytoplasmic free Ca2+ concentration and to replenish Ca2+ stores in the sarcoplasmic and 




It has been found that depletion of the intracellular stores of Ca2+ following Ca2+ 
release through the Ins(l,4,5)P3 receptor, activates a mechanism by which the SOCs in 
the plasma membrane are opened to allow extracellular Ca2+ into the cell55 (Figure 1.7). 
This phenomenon, termed the capacitative model for Ca2+ entry, has been demonstrated 
through the depletion of stores with both phospholipase C-linked agonists and specific 
experiments with inhibitors of intracellular Ca2+ transport ATPases that mediate the 
active accumulation of Ca2+ in the endoplasmic and sarcoplasmic reticulum. A 
particularly effective example of such an inhibitor is thapsigargin;56 when applied to 
cells it results in a relatively rapid passive depletion of intracellular Ca2+ stores. 
Although this depletion has been shown to induce the opening of SOCs, the mechanism 
by which it does so remains unclear. Consequently several hypotheses have been 
proposed for the mechanism of activation of SOCs and these have been summarised in 
the table below since the subject has been extensively reviewed by several authors.57'61 
Also of note here is a recent review by Shuttleworth challenging the capacitative model 
of Ca2+ entry.62
Agonist
Figure 1.7: Capacitative Ca2+ entry. Agonist activation of a surface receptor (R) coupled 
through a G-protein (Gp) to phospholipase C (PLC) leads to the production of 
Ins(l,4,5)P3 which causes Ca release. The depletion of endoplasmic reticulum Ca 





Hypothesis Summary Comments and references
Conformational
coupling
A protein-protein interaction 
between the Ins(l,4,5)P3 receptor 
or another protein in the ER and 
the SOC protein in the plasma 
membrane43,59,63
Recent experiments suggest 
that thapsigargin activation of 
SOC's is independent of 
Ins(l,4,5)P3 receptor 
proteins.64,65 However 
interactions between SOC 
proteins and another ER 
proteins are possible
Diffusable messenger
A diffusable messenger released 
by the ER interacts with the SOC 
to induce Ca2+ entry.66,67






The insertion of vesicles rich in 
SOC proteins into the plasma 
membrane.73
Most unlikely mechanism, 
probably not universal.74
G-Protein coupling
Coupling of the decrease in 
cytoplasmic Ca2+ to the SOC by a 
monomeric or trimeric G- 
protein.75"79
It is more likely that G- 
proteins play a more 
permissive role even though 
they are necessary for SOC 
activation in some cell types80
Table 1.4: Summary of the proposed mechanisms of SOC activation adapted
O 1
from a paper by G. J. Barritt.
^  I
Investigations into the flow of Ca through the plasma membrane has seen the 
characterisation of a depletion-activated calcium-selective current ( I c r a c ) ,  and its
9+ R9relationship to the depletion of intracellular Ca stores. It has also been found that a
94- 89slow feedback inhibition of I c r a c  by Ca entry exists which accounts for up to 70% of 
the total inactivation of I c r a c - Furthermore it has been proposed that sphingosine 
directly blocks I c r a c  and it is therefore suggested that the sphingomyelin pathway is 
involved in I c r a c  regulation.84
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The actual identity of the SOC-protein has also received considerable attention. 
Some studies have found evidence for the involvement of the type 3 Ins(l,4,5)P3- 
receptor. One example of such a study demonstrated that the expression of the type 3
94- o cIns(l,4,5)P3-receptor in Xenopus oocytes specifically augments Ca entry, without
94-affecting Ca release. This finding certainly gives credence to the idea of type 3 
Ins(l,4,5)P3-receptors acting as SOCs in some instances, but the greatest amount of 
interest in this area has been in a protein product of the transient receptor potential (trp) 
gene in Drosophila photoreceptors. The Drosophila photoreceptor mutant termed trp is 
characterised by an inability of the photoreceptors to sustain an influx of Ca2+ during 
intense illumination. These photoreceptors use a phospholipase C signalling system and
94-so it was thought that trp may encode a component of the Ca entry pathway. Several 
trp proteins have now been identified and although some have clearly demonstrated the
9  *
mediation and augmentation of capacitative Ca entry, their electrophysiology did not 
match that of known depletion-activated calcium-selective currents ( I c r a c )  (reviewed58). 
Thus investigation into the properties of this family of proteins and their involvement in
94-capacitative Ca entry needs further work to define their true role.
1.5 Metabolism of Inositol phosphates
Once extracellular stimulation ceases, there needs to be a mechanism to turn off 
the intracellular response and return the cell back to its basal level, ready for the next 
stimulus. Ins(l,4,5)P3 itself needs to be removed from the cell in some way, and this 
function is fulfilled by inositol phosphate metabolising enzymes. The main metabolic 
pathways are outlined in Figure 1.8, although this is a somewhat simplistic view of what 


































Figure 1.8: Metabolism of receptor generated Ins(l,4,5)P3 in mammalian cells (MIPP 
Multiple Inositol Polyphosphate Phosphatase)
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1.6 Structure-Activity Relationships at lns(1,4,5)P3 
Receptors
Equatorial 3-hydroxyl
Enhances binding, but less 
important than 6-hydroxyi.
May have H-bond interactions 
with binding site probably via 
oxygen lone pair electrons.
Deletion or changing to axiai 
for the 6-hydroxyl.
> Replacement with fluorine 
reduces activity only slightly.
> Axial hydroxyl together 
withphosphorothioates at 1,4,5 
gives a partial agonist.
> Increasing molecular volume 
with hydrophobic substituents 
is thought to correlate inversley
Axial 2-hydroxyl
The least important part o f 
lns(l,4,5)P3. O f only minimal 
importance for binding.
> Can be deleted, changed
to equatorial or replaced with 
fluorine with only slight effect 
on activity.
> C-2 can be replaced with 
pyranoside oxygen.
> Bulky substituents or phosphate 
group are tolerated. Presence o f an 
axial 1 -phosphate increases affinity.
> Equatorial 2-OH together with 
phosphorothioates at 1,4,5
and axial 3 or 6-OH gives low 
intrinsic activity partial agonists.
Equatorial 1 -phosphate
Less important than the 4- 
and 5-phosphates. Enhances 
binding, but not essential. May 
have a long-range interaction 
with the receptor binding site.
> Deletion greatly reduces 
activity, but replacement with 
axial phosphate or a phosphate 
more distant from the ring
is tolerated.
> large groups can be tolerated 
without major loss o f  activity.




> Equatorial or axial phosphate 






The most important part o f  lns( 1,4,5)P3 and essential for activity. 
Can be replaced with a bisphosphorothioate. Linking the 4- and 
5 phosphates to give a cyclic pyrophosphate abolishes activity
Equatorial 4-phosphate Equatorial 5-phosphate
Informationis lacking on 
analogues selectively 
modified at this position.
> Deletion abolishes 
activity, changing to axial 
greatly reduces activity.
> Replacement with 
phosphorothioate has less 
effect on potency than 
replacing the 5-phosphate
Ionisation state correlates with 
the affinity o f  Ins( 1,4,5)P3 for 
its receptor.
> Deletion abolishes activity, 
effect o f axial not known.
> Can be replaced with 
methylenephosphonate or 
phosphorothiate, to give 
metabolically resistant 
analogues causing prolonged 
Ca2+ release.
Equatorial 6-hydroxyl
Very important for binding. May have 
H-bond interactions with binding site 
and/or affect conformation/ionisation 
state o f  5-phosphate, probably via 
hydroxyl hydrogen rather than lone 
pair electrons.
> Deletion or changing to axial 
greatly reduces activity, but
in combination with phosphoro­
thioate at 1,4,5 gives partial agonists.
> Bulky substituents,




Figure 1.9: Structure-activity relationships for Ins(l,4,5)P3 receptors. 24
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Over the past fifteen years there has been a great deal of interest in the synthesis 
ofIns(l,4,5)P3 analogues. As a result we now have a good appreciation of the structure- 
activity relationships of Ins(l,4,5)P3 binding and potency. These are summarised in 
Figure 1.9, and are comprehensively reviewed elsewhere.86,87
Since these reviews were written there have been several interesting 
developments in this field. A ring contracted cyclopentane-based Ins(l,4,5)P3 analogue 
(4) derived from D-xylose, in which the relative stereochemistry and substitution of 
positions equivalent to positions 4,5,6 and 1 of Ins(l,4,5)P3 was retained, has been 
reported by Jenkins and Potter.88 This is the latest in a series of cyclopentane 
Ins(l,4,5)P3 analogues designed to investigate the tolerance of the Ins(l,4,5)P3 receptor 
to a smaller ring size by means of an effective deletion of the 2-position.89,90 Biological 
data pertaining to the activity of this analogue have yet to be published.
Remarkable binding affinity for the Ins(l,4,5)P3 receptor has been described by 
Takanari et al.91 for a 1-position modified Ins(l,4,5)P3 analogue (5). Modification of this 
1-phosphate with the dye molecule malachite green resulted in a compound with a IQ of 
1.17 nM in the Ins(l,4,5)P3-binding domain of human type-1 Ins(l,4,5)P3 receptor. In 
the same study the corresponding binding of Ins(l,4,5)P3 (IQ 195nM) was found to be 
167-fold weaker. However, there was no Ca2+ release data reported in this paper, and 
therefore the agonist/antagonist properties of (5) cannot be commented upon.
Finally the synthesis and properties of three phosphofluoridate analogues (6,7,8)
Q9ofIns(l,4,5)P3 have recently been published with a phosphofluoridate at either the 4 or 
5-position or both (Figure 1.10). This report was particularly interesting as it 
investigated the ionic interaction of the 4,5 bisphosphate of Ins(l,4,5)P3 with the 
Ins(l,4,5)P3 receptor and the active sites of the two metabolising enzymes, Ins(l,4,5)P3 
3-kinase and Ins(l,4,5)P3 5-phosphatase. Substitution of one phosphate hydroxyl for 
fluorine was chosen because fluorine provides a steric bulk similar to that of an ionised 
hydroxyl and is an acceptor for a hydrogen bond in the same way as an ionised hydroxyl, 
but cannot be involved in ionic bonding interactions. This investigation found that the 4 
and 5-phosphates of Ins(l,4,5)P3 are independently recognised in the binding process, 







OH 8 R = F, R 1 = HHO
OH q  R = M alachite g reenHO
Figure 1.10: Recently reported Ins(l,4,5)P3 analogues
1.6.1 Partial agonists
It has been demonstrated that some of the Ins(l,4,5)P3 analogues that fully 
displace [3H]Ins(l,4,5)P3 from its receptor, are not able to mobilise the full Ca2+ store. 
Analogues with such biological properties are referred to as partial agonists. The first 
analogue found to exhibit this activity was Ins(l,3,4,6)P4 (9). When tested in 
neuroblastoma cells it mobilised 80-90% of the available Ca2+ store.93
The introduction of phosphorothioate groups at positions usually substituted with 
phosphate groups has been used to prepare Ins(l,4,5)P3 analogues stable to the two 
Ins(l,4,5)P3 metabolising enzymes. Two of these phosphorothioate analogues, L-chiro- 
Ins(2,3,5)PS3 (10) and D-6-deoxy-Ins(l,4,5)PS3 (11), have also been reported to exhibit 
partial agonist activity, fully displacing [3H]Ins(l,4,5)P3 from its binding sites on adrenal 
cortical membranes, and yet only mobilising 34% and 42% respectively of Ca2+ 
mobilised by Ins(l,4,5)P3.94 Further phosphorothioate-based partial agonists d l -  
Ins(l,3,4)PS3 (12) and DL-Ins(l,4,6)PS3 (13) were then synthesised and found to release 
around 30% and 20% of Ca2+ mobilised by Ins(l,4,5)P395.
D-3-Amino-3-deoxy-wyo-Ins(l,4,5)P3 (14) is an unusual partial agonist, in that it 
exhibits pH dependence, behaving as a full agonist at pH 7.2 and 7.6, and behaving as a 
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Figure 1.11: Class I partial agonists at Ins(l,4,5)P3 receptors.
From the biological activity of the above Ins(l,4,5)P3 analogues it was proposed 
that structural perturbation at the 3-position combined with phosphorothioate substitution 
at the 4 and 5-positions of Ins(l,4,5)P3 were the key elements to partial agonist activity. 
This was investigated by Fauq et al?1 who reported the synthesis of D-3-deoxy-3-fluoro- 
wyo-inositol 1-phosphate-4,5-bisphosphorothioate (15) along with D-3-deoxy-3-fluoro- 
m^o-inositol l,5-bisphosphate-4-phosphorothioate and D-3-deoxy-3-fluoro-myo-inositol 
l,4-bisphosphate-5-phosphorothioate. The bisphosphorothioate was indeed found to be a 
partial agonist when evaluated in SH-SY5Y cells, with both the monophosphorothioates 
acting as full agonists, the most potent of these being the 4-phosphorothioate.97,98
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At a similar time another report described the partial agonist behaviour for 3- 
deoxy-rajyo-inositol 1,4,5-trisphosphate (16), 2,3-dideoxy-myo-inositol 1,4,5- 
trisphosphate (17), 2,3,6-trideoxy-myo-inositol 1,4,5-trisphosphate (18) and myo-inositol 
2,4,5-trisphosphate (19)" (Figure 1.12). Although these analogues were shown to 
mobilise the full Ca2+ store, they did so at a slower rate than Ins(l,4,5)P3. This activity 
was defined as class II partial agonism, with the analogues that cannot mobilise the full 
Ca2+ store being defined as class I partial agoinists, to avoid confusion.
Figure 1.12: Class II partial agonists at Ins(l,4,5)P3 receptors.
1.6.2 Antagonists
Heparin and decavanadate have been the only known Ins(l,4,5)P3 antagonists at 
the Ins(l,4,5)P3 receptor for several years. But as mentioned previously they are 
relatively non-selective and therefore not ideal for use as pharmacological agents.
Recently, however, Gafni et al.m  reported the antagonist activity at the 
Ins(l,4,5)P3 receptor of a series of membrane permeable xestospongins, isolated from 
Australian sponges of the Xestospongia species. The most potent xestospongin tested 
was Xestospongin-C (20) which inhibited Ins(l,4,5)P3-dependent Ca release with an 
IC50 of -0.3 pM in rat cerebellar microsomes. These compounds however block Ca2+ 
release from the ryanodine receptor with a potency 30 times lower than that at the 
Ins(l,4,5)P3 receptor.
The activity of another antagonist at the Ins(l,4,5)P3 receptor, 2- 
aminoethoxydiphenyl borate (2APB, 21) has also been described.101 This membrane- 






release. 2APB was shown to inhibit [3H]Ins(l,4 ,5 )P3 binding to its receptor in cerebellar 
microsomal preparations, although the IC50 concentration of 2APB (42pM) for inhibition 
of Ins(l,4,5)P3 (lOOnM) induced Ca2+ release, with further increases in 2APB 




Figure 1.13: The structure of two antagonists at the Ins(l,4,5)P3 receptor.
Both the xestospongins and 2APB (Figure 1.13) are thought to bind to the 
Ins(l,4,5)P3 receptor at a site other than the Ins(l,4,5)P3 binding site, since they did not 
affect [3H]Ins(l,4,5)P3 binding to the receptor. They are therefore non-competitive 
agonists of the Ins(l,4,5)P3 receptor.
Ca2+ Release from the Ins(l,4,5)P3 receptor has also been blocked by antibodies. 
For example a paper published within the last few months by Matsuki et al.]02 describes 
the inhibition of binding of Ins(l,4,5)P3 to its receptor binding site by an antibody 
against a peptide sequence found in the PH domain of PLC-^1. Further investigation 
suggested that it was the Fab fragment of the antibodies that was responsible for 
inhibiting the binding of Ins(l,4,5)P3 to its receptor, although treatment of permeabilised 
rat basophilic leukemic cells with the Fab fragment failed to completely inhibit Ca2+ 
release from the Ins(l,4,5)P3 sensitive stores of the ER. The main draw back with this 




1.7 The synthesis of inositol phosphates
1.7.1 From inositol
Several problems are inherent in the preparation of inositol polyphosphates from 
inositol starting materials:
I) Regioselective protection of hydroxyls.
II) Resolution or desymmetrisation of enantiomeric intermediates.
IQ) Phosphorylation of free hydroxyls.
IV) Deprotection of hydroxyls and protected phosphates.
V) Purification of the free inositol polyphosphate.
The manner in which these issues are currently addressed has been reviewed in
oyr_____________________________________________________________ _
detail elsewhere. But they are briefly considered here too, since all but point Q) are 
also relevant to the synthesis of the compounds in this thesis, (the compounds described 
in this thesis are almost all made from chiral starting materials, therefore no resolution 
step was necessary).
An elegant example of the preparation of an inositol polyphosphate is the 
synthesis of myo-inositol-l,3,4,5-tetrakisphosphate [Ins(l,3,4,5)P4] (shown in Figure 
1.14), a metabolite of Ins(l,4,5)P3, by Riley et al. Its synthesis demonstrates the 
techniques used to overcome the difficulties outlined above.
Using ffiyo-inositol (a meso compound) as the starting material initial 
regioselective protection of three of the hydroxyl groups was achieved with an 
orthoformate to give (22), which was subsequently desymmetrized by the regioselective 
introduction of two camphanate esters. Thus in one step the molecule was 
desymmetrised, since separation of the resulting diastereoisomers gave the D and L 
isomers 23a and 23b. After cleavage of the orthoformate the four exposed hydroxyl 
groups were phosphorylated using P (III) methodology. This involved phosphitylation 
with bis(benzyloxy)(diisopropylamino) phosphine activated as the tetrazolide followed 
by oxidation with MCPBA to the phosphate. A two step deprotection was then carried 
out. The advantage of this approach to deprotection was that once deprotected the free 
phosphates were not able to migrate. Finally two methods of purification of the 
enantiomers of Ins( 1,3,4,5)P4 (26a and 26b) were reported. They were either isolated as 
the cyclohexylammonium or potassium salts or subjected to ion exchange 
chromatography to give the triethylammonium salts.
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Figure 1.14: Synthesis of D-Ins(l,3,4,5)P4 (26a) and L-Ins(l,3,4,5)P4(26b).
1.7.2 From monosaccharides
The synthesis of inositol intermediates from simple monosaccharide starting 
materials is also possible, and several have been reported in the literature. The first 
synthesis of optically active inositol derivatives from carbohydrate starting materials was 
reported in 1987 by Watanabe et al. from D-glucurono-6,3-lactone.104 Since then inositol 
intermediates and polyphosphates have been prepared from D-glucose105-107 and D- 
galactose.108’110 Although the starting materials for such syntheses are cheap and readily 
available, the vast majority of inositol polyphosphates are still made in the conventional 
way from inositol.
When carbohydrates are used in the synthesis of inositol intermediates there is no 
need for a resolution or desymmetrisation step which can often be difficult, tedious and 
expensive. This is a distinct advantage in the synthesis of Ins(l,4,5)P3 analogues 
(although, in some instances the L-enantiomer of an inositol polyphosphate may also be
27
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required, as in the case of myoinositol 1,3,4-trisphophate111), therefore the preparation 
Ins(l,4,5)P3 analogues based on carbohydrate starting materials is still very attractive.
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1.8 Adenophostin A and B
Discovery and Biological activity
Despite all the synthetic interest in Ins(l,4,5)P3 since 1983, none of the 
Ins(l,4,5)P3 analogues prepared so far has had greater potency than Ins(l,4,5)P3 itself. 
However, a new development came in 1993 when two new molecules, adenophostin A 
and adenophostin B, were isolated from the cultured broth of Penicillium 
brevicompactum SANK 11991 and SANK 12177.112 These two molecules attracted
9 -1-considerable interest because the Ca release from cerebellar microsomes by the
11 9adenophostins was demonstrated to be 100-fold greater than that of Ins(l,4,5)P3. (A
subsequent paper reported an almost 10-fold increase in Ca2+ releasing activity from the
11^type 1 Ins(l,4,5)P3 receptor in artificial membrane vesicles ). In a competition assay, 
both adenophostins were found to inhibit [ H]Ins(l,4,5)P3 binding in a more potent 
manner than Ins(l,4,5)P3 with a high positive cooperativity.113 The results also 
suggested that binding of at least four molecules of adenophostin to each type I 
Ins(l,4,5)P3 receptor were needed for Ca2+ release. Further observations indicated that
*yi
suboptimal concentrations of adenophostin, released submaximal amounts of Ca ; this is
9 -4-indicative of the quantal Ca release behaviour of Ins(l,4,5)P3, and suggests that this 
type of behaviour is an intrinsic property of the Ins(l,4,5)P3 receptor. The pattern of Ca2+ 
release was also similar to Ins(l,4,5)P3 in that it was biphasic, with fast and slow release 
components.
^  I •
A recent investigation into the kinetics of Ca puffs evoked in Xenopus oocytes 
by different Ins(l,4,5)P3 receptor agonists,114 reported that adenophostin A was the first 
compound found to modulate the time-course of receptor activity during Ca puffs.
9 +Unlike Ins(l,4,5)P3, adenophostin A consistently failed to evoke repetitive Ca spikes 
and oscillatory Ca2+-activated Cl" currents. There was also an absence of abrupt, 
regenerative Ca2+ release in response to gradually increasing concentrations of 
adenophostin A. In addition, Ca2+ release through the Ins(l,4,5)P3 receptor evoked by
91
adenophostin A was described as discrete Ca puffs or as being more continuous than 
that invoked by Ins(l,4,5)P3, without resolvable elementary events.
Several groups have investigated the ability of adenophostin A to release Ca2+ 
from intracellular stores, to activate influx Ca2+ entry and to activate calcium-release 
activated calcium currents ( I c r a c ) . 115 119 In general adenophostin A has been shown to
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behave in a similar way to Ins(l,4,5)P3 and activate Icrac  as a consequence of release of 
Ca release from intracellular stores, rather than directly opening SOCs., although the
I
kinetics of Ca release exhibited by adenophostin A were found to be somewhat 
different to those of Ins(l,4,5)P3. In addition low concentrations of adenophostin A were 
shown to stimulate Ca2+ influx without stimulating a large Ca2+ release.115 Further 
investigations with adenophostin A and Ins(l,4,5)P3 by Gregory et al.m  proposed that 
there is a functionally distinct subregion of the endoplasmic reticulum with a different 
apparent affinity for, or accessibility to, Ins(l,4,5)P3 that is involved in the activation of 
SOCs in hepatocytes.
i on 9+An interesting investigation by Bird et al. examined the spatial features of Ca 
signalling in Xenopus laevis oocytes using different concentrations of /wyo-inositol 2,4,5- 
trisphosphate, a metabolically stable Ins(l,4,5)P3 analogue, and adenophostin A (also 
metabolically stable). They reported that when extremely low concentrations of 
adenophostin A were introduced into the oocytes (-10 pM), stable regions of Ca2+ 
release were observed, that did not expand to peripheral regions. When the Ca2+ release
9 +was restricted to central regions, compartmentalised Ca oscillations were sometimes
9+ 9+observed. Restoration of extracellular Ca caused a rise in cytoplasmic Ca restricted 
to the region of adenophostin A-induced Ca2+ mobilisation. These observations led to 
the suggestion that adenophostin A might be a useful tool in the examination of Ca2+ 
signalling processes under spatially restricted conditions, which may in turn lead to
9 . 9 .
insights into mechanisms of intracellular Ca oscillations and capacitative Ca entry.
191Another use for the adenophostins has been demonstrated by Sato et al., who 
found that a single injection of adenophostin A into mouse oocytes produced Ca2+ 
oscillations lasting for at least 3 hours similar to those observed at fertilisation. 
Simultaneous injection of adenophostin A and a round spermatid resulted in fertilisation 
of over half of the oocytes. From these experiments it was concluded that adenophostin 
A might be useful in parthogenetic oocyte activation in animal reproduction, in particular 
it may be applicable to assisted conception therapy for patients with defective 
spermatogenesis.
Structure
The structures of adenophostin A and B (Figure 1.15) were elucidated by 
Takahashi et al}22 shortly after their discovery. Purified and separated by preparative
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HPLC, 30mg of adenophostin A and lOOmg of adenophostin B were isolated from six
i  1 *y
hundred and eighty litres of cultured broth. The molecular formula of adenophostin A
and B were determined from elemental analysis and HRFAB-MS spectra. UV spectra
indicated the presence of an N-9 substituted moiety, and this was confirmed by signals in 
1 1 ^both the H NMR and C NMR spectra which also indicated the presence of an adenine 
motif. In addition there was a fragment ion at m/z 136 in the FAB-MS spectrum which 
corresponded to an adenine structure. The presence of an adenine structure was further 
corroborated by deamination of adenophostin A by treatment with NaNC>2 in acetic acid 
to give the inosine derivative which exhibited a typical UV absorption maximum at 248 
nm.
Adenophostin B was identified as the acetyl derivative of adenophostin A from 
the NMR spectrum in which there was an additional acetyl signal. Adenophostin B 
was treated with aqueous NaOH solution to give a compound identical to adenophostin 
A. Comparison of the !H NMR spectra of adenophostin A and B determined that 
adenophostin B was substituted at position 6", since the 6"-CH2 signal in the spectrum of 
adenophostin B was observed 0.5~0.7 ppm further down-field than in the spectrum of 
adenophostin A.
Further NMR correlation experiments on adenophostin B established that part of 
the adenophostins structure was made up of a combination of a five carbon and six 
carbon sequence. Alkaline phosphatase was utilised to give phosphorus free product, 
and after modification of conditions, a bisphosphorylated structure. 3IP and ]H NMR of 
this product determined that the free hydroxyl was at the 2 '-position.
The dephosphorylated material treated with 10% HC1 in MeOH and the products 
trimethylsilylated. GC-MS allowed the identification of these trimethylsilyl derivatives 
as adenine, ribose and glucose. Thus the adenophostins were assigned as a-glucosyl 
adenosine derivatives, with the position of the glucosyl linkage being determined as the 
3'-position. Finally the positions of the other two phosphate groups were deduced to be 









Adenophostin A (27) R = H 
Adenophostin B (28) R = COCH3
Figure 1.15: The structure of adenophostin A and adenophostin B.
Even though the structures o f the adenophostins are quite dissimilar to 
Ins(l,4,5)P3, as previously discussed they exhibit a marked increase in Ca2+ mobilising 
ability. We now have a reasonable understanding of the structure-activity relationships 
of Ins(l,4,5)P3, and on comparison of its structure with the adenophostins there is clear 
similarity between the adenophostin 3",4"-bisphosphate/-2’-hydroxy motif and the 
Ins(l,4,5)P3 4,5-bisphosphate/-6-hydroxy motif central to receptor binding and Ca2+ 
mobilisation. These common characteristics, while giving an indication to potency at the 
Ins(l,4,5)P3 receptor, do not explain the exceptional ability of the adenophostins to 
mobilise Ca2+ through the Ins(l,4,5)P3 receptor. Thus, further information was required 
about the structure-activity relationships of the adenophostins. Although it is known that 
the deletion of the 2' phosphate reduces the affinity of adenophostin A for the 
Ins(l,4,5)P3 receptor by a factor of almost 2000,122 little is known about the features of 
the adenosine moiety that enhance activity.
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1.9 Aims of this work
Some of the basic structure-activity relationships of adenophostin A and B have 
been alluded to in the preceding discussion, but a more complete understanding is clearly 
required to aid the design of more effective pharmacological modulators of the 
Ins(l,4,5)P3 receptor, possibly even antagonists.
It has already been stated that the synthesis of Ins(l,4,5)P3 analogues from chiral 
carbohydrate starting materials is an attractive prospect. Thus the discovery of the 
adenophostins provides an excellent opportunity for the design and synthesis of 
carbohydrate-based compounds active at the Ins(l,4,5)P3 receptor.
To investigate the exciting structure-activity relationships of the adenophostins 
the following aims were identified:
■ An efficient synthesis of adenophostin A.
■ The synthesis of minimal structure analogues lacking the adenine base of 
adenophostin A.
■ The synthesis of sugar modified adenophostin A analogues, with modification at the 
2"-hydroxyl and the 5"-hydroxymethyl.
■ The synthesis of base modified adenophostin A analogues from a common 
disaccharide intermediate.





Synthesis of Adenophostin A 
and its biological evaluation
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2 Synthesis of Adenophostin A and its biological 
evaluation
2.1 Introduction
To confirm the structural assignment given for the adenophostins by Takahashi et
199al. their total synthesis was vital. It was deduced that the basic backbone of their 
structure consisted of adenosine connected through its 3’-position to a glucopyranose ring 
via an a-glycosidic linkage. In addition they were found to be trisphosphates, with a 
vicinal 3,4-bisphosphate on the glucopyranose ring, and a further phosphate placed at the 
2'-position of the adenosine portion of their structure. Adenophostin B was also found to 
be the 6"-acetate of adenophostin A.
It was decided that the synthesis of adenophostin A would be attempted and that 
the synthetic strategy would be based around the glycosidation of a regioselectively 








R1 = protecting 
group sem i- 
orthogonal to Bn
BnO r
R = suitable 
leaving group
Figure 2.1: Retrosynthetic analysis of adenophostin A.
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2.2 Synthesis of adenosine-based glycosyl acceptors
As discussed in chapter 2 adenosine presents a number of problems in 
regioselective protection with orthogonal groups. Four differently protected adenosine 
acceptors were made, one of which was found to be the most suitable for coupling to the 




The stimulus for this protecting group strategy came from a paper describing the 
regioselective protection of the 2'-hydroxyl of adenosine with a /?-methoxybenzyl 
ether.123 The surprising selectivity for the 2 -secondary hydroxyl in this reaction was 
attributed to a favourable 7i-stacking interaction between the adenine purine ring and the 
phenyl ring of the p-methoxybenzyl group. Since the 3,4-vicinal diol of the glucosyl 
donor would be protected as /7-methoxybenzyl ethers, it followed that protection of the 
adenosine 2'-position should be with the same group. Future selective deprotection of 
the /7-methoxybenzyl groups would then lead to a triol suitable for phosphorylation to 
give adenophostin A.
The most widely (and routinely) used protecting group at the N6-position of 
adenine is the benzoyl amide and it was deemed suitable for this role in the proposed 
adenosine acceptor. It is easily introduced with benzoyl chloride in pyridine, and easily 
removed with methanolic ammonia or sodium methoxide. The synthesis of this 
intermediate has been reported using trimethylsilyl groups to transiently protect free 
ribosyl hydroxyl groups124 followed by benzoylation and subsequent cleavage of the silyl 
ethers with concentrated aqueous ammonia. However, in this synthetic route alkaline 
cleavage of unwanted esters was employed, since it has also been reported that any 
undesired esters (which in this case would be formed at the adenosine 5- and 3- 
positions) are easily cleaved selectively by short exposure to base leaving the relatively 
stable N^-benzoyl amide in place.125 This adenine-based amide remains intact because 
the ionisation of an amide group in an aromatic system which occurs at alkaline pH 
extends the resonating system and thus stabilises the acyl on the amino function.
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Finally it was decided that the 5'-hydroxyl should be protected as a benzyl ether 
as this would be stable to the conditions required for the cleavage of the p- 
methoxybenzyl ether and the amide at positions 2' and N6 respectively. It was reasoned 
that this primary hydroxyl would be alkylated in preference to the 3'-hydroxyl to give the 
desired acceptor for coupling.
OH OH OH OPMB
N(H)Bz N(H)Bz
BnO.
OH OPMB OH OPMB
Figure 2.2: Proposed route to adenosine based acceptor 32.
2.2.2.2 Discussion of synthetic work
Adenosine (29) was converted into the 2'-0-/?-methoxybenzyl derivative 30 with 
melting point 153°C (lit.,123 155-156°C) by a method adapted from the literature 
procedure. The resulting product's ’H NMR spectrum corresponded with the published 
data and substitution at the 2'-position could easily be ascertained from the 'H -1!! COSY 
NMR spectrum in D6 DMSO. Couplings of the 3'- and 5'-hydroxyl protons to methine 
and methylene protons respectively was apparent, but no such signal or coupling was 
observed for a 2'-hydroxyl. The yield was somewhat lower than that published (32%, cf. 
65%) and this was mainly attributed to the use of the commercially available p- 
methoxybenzyl chloride instead of the less stable bromide. The former reagent is less 
reactive and therefore required a slightly higher temperature for reaction to take place,
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which in turn led to decreased selectivity for the 2-position and incomplete conversion 
of starting material into product.
Attention then turned to protection of the N6-position. Using a method adapted
1 i
from Schaller, et al., 2 -0-/?-methoxybenzyl adenosine was converted into the 3'-<9-,5'- 
O-JS/6, A^-tetrabenzoyl derivative. Careful alkaline hydrolysis of this intermediate with 
1M aqueous sodium hydroxide solution in ethanol furnished the desired A^-benzoyl 
product (31). Inspection of the *H NMR spectrum soon confirmed the presence of the 
desired amide at N6 with the appearance of a very deshielded proton at da 11.23, 
corresponding to the amide proton which exhibited D2O exchange. The rest of the !H 
NMR spectrum was also found to be in agreement with that reported in the literature.
Finally, benzylation of the 5'-hydroxyl of A/6-benzoyl-2 -0-p-methoxybenzyl
adenosine was attempted using sodium hydride and benzyl bromide in DMF. The
reaction yielded two unexpected products, one major (66%), and one minor (30%). On
examination of their lH NMR spectra (solvent D6 DMSO) it was apparent that the
pseudo triplet of the 5 hydroxyl of the adenosine ribose ring was still present, yet signals
in the aromatic region indicated alkylation with a benzyl group. On closer examination it
became apparent that neither !H NMR spectrum had signals from the N6 benzoyl amide
11proton, which suggested that alkylation had occurred at this amide. Furthermore the C 
NMR spectra indicated the appearance of PI1CH2 signals at 51-53ppm, typical of 
alkylation at nitrogen, as opposed to oxygen. Finally UV analysis revealed two very 
different spectra. The minor product gave a similar spectrum to the starting material, 
with a small bathochromic shift, whereas the major product seemed to exhibit a loss of 
conjugation in the purine ring, with a consequent loss of the absorption maxima 
exhibited by the starting material and minor product. This would suggest that the major 
product was alkylated at one of the nitrogens in the purine ring system, probably N1 (33), 
and the minor product was alkylated at N6 (34).
The explanation for the formation of these two products lies in the relative pKa 
values of the N6amide proton and the 5'-hydroxyl proton. Ionisation of an amide group 
in an aromatic system occurs at alkaline pH which extends the resonating system through 
the adenine amine and in this case it led to alkylation at either N1 or N6 (see Figure 2.3) 
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Figure 2.3: The isolated alkylation products of 31.
Further attempts to selectively benzylate the adenosine 5’-position of 31 and 30 
with reduced temperature,126 bis(tributyltin) oxide, silver oxide127 and benzyl 
trichloroacetimidate128 all failed. At this point it was decided that a monomethoxytrityl 
group was the best protecting group for protection of the 5 -hydroxyl. Treatment of 31 
with 1.5 equivalents of monomethoxytrityl chloride in pyridine gave the 5’-0- 
monomethoxytrityl derivative in high yield. (While this work was in progress the first 
synthesis of adenophostin A was published using this adenosine acceptor129). 
Glycosidation reactions with this acceptor however were unsuccessful and will be 




Figure 2.4: Revised 5’-O-protection of 31.
2.2.2 S-O-Benzyl-A^-dimethoxytrityl^-O-p-methoxybenzyl adenosine
2.2.2.1 Synthesis of 2,3-O-p-methoxybenzylidene adenosine (36)
The main shortcoming of the above adenosine-based acceptor was the steric bulk 
of the 5'-0-monomethoxytrityl ether. Benzyl protection at this position was thought 
desirable but not achieved, so a different approach was adopted. In the synthesis o f the 
methyl /?-D-ribofuranoside based acceptor of ribophostin the 2-0-/?-methoxybenzyl ether
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was introduced by reductive cleavage of a 2,3-O-p-methoxybenzylidene acetal. The 
principal advantage of this approach was that the 2,3-O-p-methoxybenzylidene protected 




Figure 2.5: Route to 38.
Similar protection of the 2* and 3'-positions of adenosine would therefore enable 
alkylation at the 5'-position once N6 had been adequately protected. A search of the 
literature found three slightly different methods for the preparation of 2 ,3 -O-p- 
methoxybenzylidene nucleosides. Both 2',3'-0-p-methoxybenzylidene uridine130 and 
2',3'-0-p-methoxybenzylidene inosine131 were prepared by essentially the same method 
first published by Michelson and Todd132 for the synthesis of 2',3'-0-benzylidene 
adenosine, where starting material was stirred with a mixture of the Lewis acid zinc 
chloride and p-methoxybenzaldehyde. The desired products were formed by 
nucleophilic attack by the 2'- and 3'-hydroxyl groups on the p-methoxybenzaldehyde- 
zinc chloride complex. It must be noted here that although Michelson and Todd reported 
their acetal as the 3',5'-<9-benzylidene, they had in fact made the 2',3'-0-benzylidene, and 
subsequently in the literature it is referred to as such. It has been established that the 
trans configuration of the 3- and 5-hydroxyls in a ribofuranose ring discourages acetal 
formation, while the cis relationship of the 2,3 cis-diol favours it.
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In the second method 2',3'-0-/?-methoxybenzylidene adenosine133 and 2\y~0-p- 
methoxybenzylidene 8-azaadenosine134 were prepared from a mixture of p- 
methoxybenzaldehyde, triethyl orthoformate and hydrogen chloride solution in dioxane. 
The mechanism for this reaction is different to that described above and was investigated 
in the above paper describing the synthesis of 2',3'-0-p-methoxybenzylidene adenosine. 
The authors discuss two roles for triethyl orthoformate; firstly as a dehydrating agent, 
and secondly under acidic reaction conditions it activates the /?-methoxybenzaldehyde as 
a diethyl acetal which reacts by acetal exchange.
Finally a slight modification of the previous method with pTSA instead of 
hydrogen chloride solution was reported by Morley and Hogenkamp.135 The use of tosic 
acid as the proton source led to shorter reaction time and greater yields without the 
rigorous drying of reactants.
Formation of a 2,3-0-acetal in a ribofuranoside (such as that found in adenosine) 
by reaction with an aldehyde generates a new stereogenic centre. The configuration of 
the two benzylidene acetal diastereoisomers formed at this position has been investigated 
and unambiguously assigned by using NOE NMR spectroscopy.136 The exo isomer 
acetal H lies underneath the ribosyl ring, and therefore irradiation at the H-4' frequency 
led to an enhancement of this acetal H signal (Figure 2.6). The other diastereoisomer 
{endo) exhibited no such enhancement. This assignment confirms an early report 
outlining the preparation of both benzylidene diastereoisomers by variation of reaction
1 1 7temperature. Low temperature yielded one isomer, while high temperature yielded 
another; these were assigned as the endo and exo diastereoisomers and designated the 











Figure 2.6: Diagram of the acetal diastereoisomers of 2 ,3 -0-p-methoxybenzylidene 
adenosine.
The required 2,3 -0-/?-methoxybenzylidene adenosine was initially prepared by a 
modification of the Michelson and Todd method where the /?-methoxybenzaldehyde-zinc
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chloride complex was preformed before the addition of dry adenosine in order to 
118maximise the yield. Following the initial work up most of the product was isolated by 
precipitation from p-methoxybenzaldehyde and found to be a single diastereoisomer by 
*H NMR. After addition of diisopropyl ether the remaining product was isolated by 
precipitation and was found to be a mixture of diastereoisomers in a ratio of 2:1 as 
indicated by the !H NMR integrals of the /?-methoxybenzylidene CH signals (combined 
yield of 66%). Their configurations were assigned by comparison of their !H NMR data 
to that published for the benzylidene equivalents. The major isomer was assigned as 
endo, the kinetic product. This reaction was repeated with elevated temperature to 
explore the acetal-equilibrium associated with /?-methoxybenzylidene diastereoisomers. 
The resulting product was an inseparable diastereoisomeric mixture in a ratio of 3:2 exo : 
endo as indicated by the !H NMR integrals of the p-methoxybenzylidene CH signals. As 
this result was contrary to that reported by Baggett et al.ul for the benzylidene acetal, the 
experiment was repeated using benzaldehyde. In the author's hands the endo isomer was 
prepared successfully, but the high temperature preparation lead to a mixture of 
diastereoisomers in a ratio of 3:2 exo : endo as indicated by the JH NMR integrals of the 
benzylidene CH signals. So, it is probable that the ratio of 3:2 exo : endo is the point at 
which equilibrium is reached with no further equilibration in favour of the exo product. 
This was substantiated by taking the /?-methoxybenzylidene endo diastereoisomer and 
exposing it to the same reaction conditions at elevated temperature. The isolated product 
from this reaction was again a mixture of diastereoisomers in a ratio of 3:2 exo : endo.
The reported method of Morley and Hogenkamp135 was also employed in an 
effort to improve the yield of the 2 ,3 -0-/?-methoxybenzylidene derivative and to 
establish whether this method furnished a similar diastereoisomeric mixture to that of 
Michelson and Todd. The product was isolated in improved yield and the ]H NMR 
spectrum (Figure 2.7) displayed the same mixture of diastereoisomers (in a ratio of 3:2 
exo : endo) as that obtained from the elevated temperature experiments above.
Finally a method to prepare 2,3 -O-p-methoxybenzylidene adenosine by direct 
acetal exchange was attempted,139,140 since it had proved successful for the preparation of 
methyl 2,3-0-/?-methoxybenzylidene-/?-D-ribofuranoside in the synthesis of 
ribophostin.141 /?-Methoxybenzaldehyde dimethyl acetal, tosic acid and adenosine in 
DMF were heated to 50°C in a flask fitted with an air condenser to remove any liberated 
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Figure 2.7: Part of the H NMR spectrum of 36.
For reasons that will be outlined in future discussion endo 2 ,3 -O-p- 
methoxybenzylidene adenosine and the diastereoisomeric mixture were both carried 
forward and used in subsequent reactions.
2.2.2.2 Selective protection of N6
Alkylation of the 5’-hydroxyl could not take place until N6 had been protected. 
Work previously discussed indicated that the benzoyl group was unsuitable for this 
purpose and so a protecting group was sought to block N6 totally and which would be 
stable in the strongly basic conditions required for alkylation. After searching the 
literature it was found that the trityl group was sometimes used to protect N6,142 and 
references therein, although it was found that tritylation at N6 involved forcing 
conditions and long reaction times. In 1968 Smith et al.]3° reported two new 
modifications of the trityl group. They substituted either one or two of the trityl phenyl 
rings with a p-methoxyphenyl ring. For each p-methoxyphenyl added they found an 
approximately 10-fold increase in the rate of acid hydrolysis. Each substitution with a p-
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methoxyphenyl ring is also associated with an increase in reactivity of the corresponding 
chloride; consequently the reaction conditions needed for its introduction are much 
milder, even at N6. Thus it is the presence of added /^-methoxyphenyl groups that confer 
both increased reactivity of their respective chlorides and increased acid sensitivity by 
stabilising the trityl carbocation.
The properties of the dimethoxytrityl group therefore seemed ideal for the 
protecting group needed to mask N6 in the manner described above. However one 
potential problem remained, i.e. the protection of N6 in the presence of a free 5- 
hydroxyl. A transient protecting group was needed. Use of the trimethylsilyl group to 
transiently protect free ribosyl hydroxyls is well established124,143 to facilitate selective 
N6-benzoylation in a simple one-pot procedure. Addition of chlorotrimethysilane to a 
solution of the starting material in dry pyridine prior to the addition of benzoyl chloride 
results in the desired N6 benzoylation, and the trimethylsilyl ester(s) are later easily 
cleaved by adding concentrated aqueous ammonia solution. To the best of the authors 
knowledge use of trimethylsilyl transient protection had not been attempted in 
conjunction with N6-dimethoxytritylation and was therefore investigated. Thus a 
mixture of 2,3 -0-/?-methoxybenzylidene adenosine with chlorotrimethylsilane in dry 
pyridine was stirred for 2 hours before the addition of dimethoxytrityl chloride, and the 
resulting reaction mixture was left overnight. Subsequent addition of concentrated 
aqueous ammonia solution cleaved the trimethylsilyl group to furnish the desired N6 
protected material in 97% yield after column chromatography.
The !H NMR spectrum of 37 in DMSO exhibited a D2O exchangeable triplet 










Figure 2.8: Part of the !H NMR spectrum of 37 indicating the free 5'-hydroxyl signal.
2.2.2.3 5'-0-Alkylation
Alkylation of the 5'-hydroxyl group proved more difficult than expected. 
Treatment of A6-dimethoxytrityl-2 ,3 -0-/?-methoxybenzylidene adenosine with sodium 
hydride and benzyl bromide in DMF at room temperature in the usual manner gave no 
discemable product by TLC. Heating to 70°C with a large excess of alkylating reagents 
gave a poor yield (39%). A search of the literature revealed a benzylation procedure for 
adenosine derivatives by refluxing with benzyl chloride and potassium hydroxide in a 
mixture of dioxane and benzene144for 15 minutes. A^-Dimethoxytrityl-2 ,3-0-/?- 
methoxybenzylidene adenosine was subjected to these conditions and the desired 
material (38) isolated in 95% yield after column chromatography. The 13C NMR 
spectrum displayed a CH2 signal at Sc 73.45 in the region for CH20  resonances thus 
confirming alkylation at the 5-hydroxyl with a benzyl ether. This was substantiated by 
the C-5' signal being deshielded to 70.10 (the a-effect of alkylation).
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2.2.2A Reductive cleavage of the 2',3l-0-p-methoxybenzylidene acetal of 38
Investigations into regioselective cleavage of p-methoxybenzylidene acetals to p- 
methoxybenzyl ethers have resulted in conditions that fall into two groups. 
LiAlItyAlCls, BH3NMe3/AlCl3, BH3, THF, heat, or NaBH3CN/TMSCl, CH3CN all 
result in cleavage at the least hindered side of the acetal, giving the more hindered ether, 
whereas treatment with NaBH3CN/HCl, NaBH3CN/TFA/DMF and DIBAL-H results in 
the formation of an ether at the least hindered hydroxyl.145
Since the conditions above mainly relate to ether formation from six-membered 
rings acetals (1,3-dioxanes) as opposed to five membered ring acetals (1,3-dioxolanes) as 
found in 38, it was difficult to predict the direction of its cleavage with any of the 
preceding reagents. Nevertheless successful cleavage of a 2,3-O-p-methoxybenzylidene 
derivative of ribose (a 3:2 diastereoisomeric mixture) has been reported with DIBAL-H 
to yield predominantly the desired 2-0-ether.141 Similar treatment of the inseparable 3:2 
exo : endo diastereomeric mixture of 38 with DIBAL-H in DCM at 0°C met with little 
success, and only traces of the desired product were isolated. Further experimentation 
established that the correct temperature was crucial; if the temperature was too high there 
was complete cleavage of the acetal to the diol, whereas if the temperature was too low 
there was no reaction at all. Thus addition of DIBAL-H at -78°C followed by slow 
warming to ca. -25°C over 2 hours gave reductive acetal cleavage in high yields. The 
product was found to be a mixture of regioisomers in a 3:2 ratio with the desired T-O-p- 
methoxybenzyl ether (40) predominating. This mixture was inseparable so it was 
acetylated with acetic anhydride in pyridine under standard conditions (yield over two 
steps 93%). It was then possible to separate the two products by careful flash column 
chromatography. Not only did the introduction of an acetyl group aid purification of the 
regioisomers, but it also made their identification easier. In both ]H NMR spectra of 41 
(yield 38%) and 42 (yield 55%) there were deshielded protons corresponding to the 
respective acylated positions. Once identified, the 3-O-acetyl derivative was then 
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Figure 2.9: Reductive cleavage of 38 with DIBAL-H and acetylation of the product 
mixture.
This reduction was investigated further to ascertain whether its regioselectivity 
was dependent on the starting diastereoisomer configuration. Treatment of the endo 
diastereoisomer of 38 with DIBAL-H resulted in conversion mainly to the undesired 3'- 
O-p-methoxybenzyl ether.
Discussion in the literature is in general agreement that reductive cleavage of an 
acetal to an ether with DIBAL-H as reducing agent is highly dependent on the 
stereochemical environment of the molecule.146,147 DIBAL-H is thought to coordinate to 
the least hindered acetal oxygen with subsequent acetal cleavage occurring at that 
position. Therefore DIBAL-H is an ingenious reagent in that it acts both as the Lewis 
acid and the hydride donor. From the regioselectivity o f the reductions of the endo and 
endolexo mixture of diastereoisomers of 38 this would suggest that DIBAL-H 
coordinates mainly with the 2’- and 3'-oxygens of the endo and exo diastereoisomers 
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Figure 2.11: Part of the ‘H-’H COSY spectrum of 42 indicating the acylation of the 3 - 
hydroxyl.
Attempts at the acetal reduction with other literature reagents mentioned earlier 
had little success and none gave the desired regioisomer in anything more than a trace 
amount as judged by TLC.
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2.2.3 Synthesis of other potential acceptors
2.2.3.1 A^A^-Dibenzoyl-S-O-benzyl^-O-p-methoxybenzyl adenosine (46) 
and A^-benzoyl-5 -0-benzyl-2'-0-p-methoxybenzyl adenosine (32)
While suitable conditions to reductively cleave the p-methoxybenzylidenc of 38 
to the desired regioisomer were being sought, this intermediate was converted into two 
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Figure 2.12: Proposed route to 32 and 45.
It was quickly realised that if suitable reductive cleavage conditions were not 
found intermediate 38 could be used to make acceptors by an alternative route, p- 
Methoxybenzylidene and dimethoxytrityl groups are both susceptible to acid hydrolysis, 
in fact a p-methoxybenzylidene is about ten times more labile to acid than the more 
frequently used isopropylidene and benzylidene acetals.130 After treatment with acid it 
was proposed that regioselective p-methoxybenzyl ether formation at the 2'-hydroxyl 
with p-methoxybenzyl bromide followed by either mono- or di- N6 benzoylation would 
furnish two new glycosyl acceptors.
2.2.3.3 Discussion of synthetic work
Cleavage of the dimethoxytrityl and p-methoxybenzylidene groups of 38 was 
achieved easily with 80% aqueous acetic acid at 100°C for 45 minutes in good yield to 
give 43 as a fine white powder. Attempts at selective alkylation of 43 with p-
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methoxybenzyl chloride failed so p-methoxybenzyl bromide was freshly prepared by the 
literature method of Uwaydah et a/.148 Careful addition of p-methoxybenzyl bromide in 
DMF to a solution of the pre-formed alkoxide in DMF gave selective p-methoxybenzyl 
ether formation at the 2-hydroxyl. The position of this ether was confirmed by 
acetylation of 44 with acetic anhydride. ]H NMR revealed a deshielded doublet of 
doublets at 5n 5.46 with coupling constants (J 5.1 Hz, 2.4 Hz) corresponding to 
acetylated H-3\
Initially the A^^-dibenzoyl derivative (45) was prepared143 because it was 
thought that introduction of two benzoyl groups would enhance solubility in the 
glycosylation solvent. The free 3-hydroxyl was transiently protected with 
chlorotrimethylsilane before acylation of N6 with benzoyl chloride. Subsequent addition 
of water cleaved the trimethylsilyl group in less than 30 minutes to give the desired 
product.
Preliminary glycosylation experiments with 45 indicated that some reaction 
conditions caused loss of one benzoyl group. So the monobenzoyl derivative 32 was 
prepared, essentially by the same reaction conditions as above, except that concentrated 
aqueous ammonia was added of instead of water to cleave both the trimethylsilyl group 
and one of the N6 benzoyl groups.
2.3 Synthesis of the donor
Initially it was thought that the trichloroacetimidate donor used in the synthesis of 
the minimal structure analogue ribophostin (discussed in chapter 3), would be ideal for 
coupling to an adenosine-based acceptor, but after several attempts using this 
glycosylation methodology with two differently protected adenosine acceptors (35 and 
40) only traces of product could be isolated. At first it was thought that the steric bulk of 
a monomethoxytrityl group at the 5’-position of the acceptor 35 was impeding the 
reaction, but attempts with acceptor 40, in which the 5'-postion was protected with a 
sterically smaller benzyl group also failed. The low reactivity of the acceptor was 
probably responsible for the absence of any reaction in either of these attempted 
glycosidations. A different coupling methodology was therefore sought.
After a thorough search of the literature, phosphite glycosidation methodology 
appeared the most promising for this particular coupling (reviewed 149). This
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glycosidation method was chosen for a number of reasons. First, a phosphite donor had 
been used successfully by Corey and W u150 with a ZnCl2-AgC1 0 4  promoter to 
glycosylate a sterically hindered alcohol that was part of an acid sensitive intermediate, 
in the total synthesis of paeoniflorin. They also noted that all other common 
glycosidation methods had failed to give the desired compound. This was encouraging 
for the present synthesis as it suggested that a phosphite donor could be used to 
glycosylate the relatively unreactive adenosine 3' secondary hydroxyl. Secondly, many 
model glycosidations using phosphite donors have been reported by Watanabe et 
a /.151,152 with good ar-stereoselectivity, and good yields. These authors have also 
reported the successful use of phosphite chemistry in the synthesis of a glycosyl 
phosphatidylinositol, 2,6 di-O-ar-D-mannopyranosylphosphatidyl-D-m^o-inositol.153 
Finally, the dimethyl phosphite donor needed for the glycosylation reactions is easily 
prepared in quantitative yield from the glucopyranose 46 which was already in hand as 




Figure 2.13: Conversion of 46 into a dimethyl phosphite
Conversion of 2,6-di-0-benzyl-3,4-di-0-/?-methoxybenzyl-D-glucopyranose (46) 
into its dimethyl phosphite (47) was achieved with 
bis(methoxy)(diethylamino)phosphine activated by tetrazole (Figure 2.13) in a similar 
manner to phosphitylation with bis(benzyloxy) (diisopropylamino)phosphine and 
tetrazole employed in the synthesis of phosphates. 'H NMR of the product indicated an 
anomeric mixture in a ratio of 1:1 as estimated from the integral ratio of the anomeric 
protons. The presence of an anomeric mixture of phosphites was confirmed by 31P NMR 
with two resonances of equal integral in the phosphite region at Sp 141.14 and 142.31.
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2.4 Glycosidation and deprotection
Glycosidation proved the most difficult step in this route. As mentioned 
previously it was quickly realized from preliminary experiments with 35 or 40 as 
glycosyl acceptor and a trichloroacetimidate glycosyl donor that this methodology was 
unsuitable, since after several attempts no product was obtained.
Meanwhile glycosylations in the synthesis of another minimal structure analogue 
which we named furanophostin (discussed in chapter 3) involving the phosphite donor 
47 indicated that a solvent mixture of dioxane/toluene gave improved solubility of the 
reactants and hence improved yields; accordingly this solvent mixture was used for all 
the subsequent glycosylations discussed below.
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Those glycosylations which furnished the desired product are entered in the table 
above. The first adenosine based acceptor to be investigated was A^^-dibenzoyl-S -O- 
benzyl-2 -0-/?-methoxybenzyl adenosine. Although the dibenzoyl derivative had been 
prepared to improve the acceptor solubility, it was found that this molecule was prone to 
loss of one of the benzoyl groups when exposed to the AgClCVZnCb promoter. This 
lead to a low isolated yield of glycosidation product and intolerance of higher 
equivalents of AgClCVZnCb (see entry 1 in Table 2.1).
Two other promoters reported for the activation of glycosyl phosphites resulting 
in or-stereoselective glycosylation were Ba(ClC>4)2,154 and TMSOTf.152 Unfortunately 
glycosylations attempted with either of these reagents failed to give any product.
Since A^^-dibenzoyl-S -O-benzyl-2 -O-p-methoxybenzyl adenosine was not an 
ideal acceptor, the mono-benzoyl derivative A^-benzoyl-S-O-benzyl-2-O-/?- 
methoxybenzyl adenosine was prepared. Glycosylation of this acceptor in the same 
conditions as those leading to 48 resulted in a reasonable, although still not acceptable, 
increase in yield (see entry 2 in Table 2.1).
The introduction of acyl groups is known to attenuate the reactivity of a glycosyl 
donor, and it was thought that a less reactive donor would be more compatible with the 
acceptor. In addition it was thought that an increase in promoter equivalents would 
compensate for any zinc chloride complexing with the acetate carbonyls. Therefore, a 
3,4-di-O-actetate phosphite glycosyl donor utilised in chapter 5 for the synthesis of a 
versatile disaccharide intermediate was employed. But again a disappointing yield was 
obtained with this combination of donor, acceptor and an increase in the promoter 
equivalents (see entry 3 in Table 2.1). However this coupled intermediate would be a 
reasonable starting point for the introduction of a 3",4"-bisphosphorothioate into an 
adenophostin A analogue since the 3",4"-di-0-acetate is orthogonal to the T-O-p- 





At this time the /?-methoxybenzylidene acetal was successfully cleaved to give 5 - 
0-benzyl-A/6-dimethoxytrityl-2 -0-/?-methoxyben2yl adenosine as discussed previously. 
The route to this adenosine acceptor was shorter and higher yielding than for the above 
acceptors, a fact which increased its suitability. The first glycosylation involving this 
acceptor gave a similar yield to those previously described (see entry 4 in Table 2.1), but 
increasing the promoter equivalents to 2.4/1.2 AgClOVZnCb led to a much improved 
yield of 53% (see entry 5 in Table 2.1).
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Figure 2.14: Glycosidation and deprotection
Compound 40 proved to be an extremely important intermediate, as it was also 
used to prepare derivatives of adenophostin A in which the glucose moiety was replaced 
by mannose and xylose equivalents, as discussed in later chapters. Thus these 
glycosylation conditions were used for the synthesis of the target compound 
adenophostin A. Of note is the complete a-selectivity in all these reactions, and the 
resulting downfield H-l" product resonances with small axial-equatorial coupling 








J = 3.4 Hz
Figure 2.15: 'H NMR spectrum of 53 indicating the a-anomeric configuration.
Deprotection of the /?-methoxybenzyl and dimethoxytrityl groups with 10% TFA 
in DCM, as described for the corresponding deprotection in the synthesis of 
furanophostin in chapter 3, led smoothly to the triol necessary for phosphorylation.




B n O HO54  R  = H
55  R  = P ( 0 ) ( 0 B n ) 2
Adenophostin A
Figure 2.16: Selective phosphorylation and deprotection of 54 to give adenophostin A
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The triol 54 was not protected at the N6 position, and even though this was 
achievable with transient protection and benzoylation, with subsequent deprotection it 
would have imposed two extra steps on the synthesis. Therefore a method for selective 
phosphorylation of the free hydroxyl groups was sought. In 1991155 and 1992156 
Letsinger reported the synthesis of oligodeoxynucleotides via base-unprotected 
phosphoramidite monomers where a mixture of pyridinium hydrochloride and aniline or 
imidazole was used as activator. Although not ideal this method would have been 
attempted were it not for a very recent publication detailing a more general method for 
the synthesis of oligodeoxynucleotides without nucleoside base protection.
Hayakawa and Kataoka157 reported that where a stoichiometric amount of 
imidazolium triflate was employed as phosphoramidite activator selective hydroxyl 
phosphitylation was achieved without base protection. It would seem that the reduction 
in reactivity from the routinely used tetrazole-phosphoramidite complex to the 
imidazolium-phosphoramidite complex is enough to differentiate between the 
nucleophilicity of the free ribosyl hydroxyls of 54 and the N6-position of the adenine 
base.
BnO,
CF3 SO 3 - + jj
P— OR BnO
R— OH
Figure 2.17: Proposed mechanism for phosphitylation involving imidazolium triflate
Initial protonation of the triflate salt of imidazole was necessary because free 
imidazole, unlike tetrazole, is not a strong enough acid to protonate the phosphoramidite
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reagent and form the diisopropylamine leaving group. However the resulting free 
imidazole conjugate base is then nucleophilic enough to displace the dialkylamine from 
the phosphorous atom to give the imidazolide intermediate. Selective phosphitylation 
ensues with loss of the imidazole moiety as shown in the proposed mechanism in Figure 
2.17.
So this approach was employed in an attempt to phosphitylate the adenophostin
A intermediate 54 without base-protection. Imidazolium triflate was easily prepared by
slowly adding trifluoromethanesulfonic acid to an equimolar amount of imidazole in
DCM. After dilution with diethyl ether the resulting white salt was collected by
filtration. Selective phosphitylation was then accomplished with a mixture of
bis(benzyloxy)(diisopropylamino)phosphine and imidazolium triflate in DCM. As may
be expected, monitoring the reaction by TLC indicated that phosphitylation with
imidazolium triflate instead of tetrazole was more sluggish. On complete conversion of
starting material into the trisphosphite the reaction mixture was cooled to -78°C before
being oxidised with MCPBA. The reaction was quenched at this temperature to avoid
 ^1any possible oxidation of the adenine base. P NMR spectrum of the purified product 
(55) confirmed the presence of three phosphate groups, with the !H-coupled spectrum 
exhibiting three sextets. In addition the presence of the free unphosphorylated N6- 
position NH2 was substantiated by the presence of a broad singlet in the !H NMR at 5a 
6.09 (Figure 2.18).
Deprotection of the fully protected adenophostin precursor 55 proved difficult, 
with the benzyl ethers proving particularly stable. Initial attempts with sodium and 
liquid ammonia were unsuccessful. Catalytic hydrogenation was also less than 
satisfactory. 55 Was treated separately with 10% palladium on carbon, palladium black 
and 20% palladium hydroxide, and while the former two catalysts were unsuccessful, the 
latter was very slow, with complete deprotection taking five days, and this was 







Figure 2.18: Part of the ’H NMR spectrum of 55 clearly indicating the free N6-amine of 
adenine and part of the 31P NMR (insert) indicating three protected phosphate groups.
Complete deprotection in high yield was finally achieved with catalytic transfer 
hydrogenation.158 A solution of 55 was refluxed in a mixture of methanol, water and 
cyclohexene with 20% palladium hydroxide for 2hours 30minutes. Following removal 
of the catalyst the crude product was purified on an M P1 AG ion exchange resin column, 
being eluted with a gradient of 0-100% 150mM TFA. Adenophostin A was isolated as 
the free acid and subsequently converted to the sodium salt. Quantification was 
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Figure 2.19: 400MHz !H NMR spectrum of the free acid of adenophostin A in D2O.
The !H NMR spectrum of adenophostin A shown in Figure 2.19 is in keeping 
with the published data.159,160 Although it is worth noting that the signals of some of the 
protons are not exactly the same as those found in the literature. This is probably due to 
differences in pH between this sample solution and those prepared by other groups, since 
the ]H NMR spectrum of adenophostin A shown in Figure 2.19 is of the free acid, and 
the published NMR data is of sodium salts.
This synthetic adenophostin A was compared with an authentic sample of natural 
adenophostin A by reverse-phase HPLC using an ODS column. The eluent was a 
gradient o f acetonitrile and phosphate buffer, containing 0.1% w/v of 
tetrabutylammoniumhydrogen sulphate, acting as an ion-pair reagent. The starting 
concentration was 10% acetonitrile/90% phosphate buffer and the gradient was run over 
20 minutes, finishing at 40% acetonitrile/60% phosphate buffer, with any eluting 
material being detected by a UV spectrometer set at 259 nm. The resulting traces are 

















Figure 2.20: Comparison of synthetic and natural adenophostin A by HPLC.
It is clear from the preceding figure that the synthetic adenophostin A has a 
similar retention time to that of the natural material. The sample of synthetic 
adenophostin A was shown to be 98% pure while the natural adenophostin A was 96% 
pure.
2.6 Biological results
The ability of a sample of the synthetic adenophostin A to release Ca2+ from 
permeabilised hepatocytes was compared with that of a sample of natural adenophostin 
A and the results are shown in Table 2.2. The method used by our collaborators was as 
follows: Permeabilised hepatocytes were loaded to steady state (5min at 37°C) with 
45Ca2+ in a cytosol-like medium (CLM: KC1, 140mM, NaCl, 20mM, 2mM MgCl2, ImM 
EGTA, 300pM CaCl2, 20mM Pipes, pH7.0) containing ATP (1.5mM), creatine 
phosphate (5mM) creatine phosphokinase (5units/ml) and FCCP (lOpM). After 5min, 
thapsigargin (1.25pM) was added to the cells to inhibit further Ca2+ uptake, 30s later the 
cells were added to appropriate concentrations of the agonists and after a further 60s the
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45Ca2+ contents of the stores were determined by rapid filtration. Concentration-response 
relationships were fitted to a four parameter logistic equation using Kaleidegraph 
software (Synergy Software, PA) from which the maximal response, half-maximally 




h % release n
Natural adenophostin A 9.2±1.7 2.99±0.32 49±3 3
Synthetic adenophostin A 9.6±1.0 2.46±0.19 50±1 3
Table 2.2: Ca + release from permeabilised hepatocytes
C 11 9 7 5
-log {[agonist], (M)}
Figure 2.21: Ca2+ mobilization evoked by natural and synthetic adenophostin A, and
Ins(l,4,5)P3.
The results (means ±sem, n = 3 or 4) show the concentration-dependent effects of 
Ins( 1,4,5)7*3 (black), natural (blue) or synthetic (red) adenophostin A on Ca2+ release
^ I
from the Ins(l,4,5)7*3-sensitive intracellular Ca stores of permeabilized rat 
hepatocytes.
^ I
It was clear from the Ca releasing activities of natural and synthetic 
adenophostin A presented in Table 2.2 and Figure 2.21 that our synthetic adenophostin A 
was equipotent with natural adenophostin A.
In an ongoing collaboration with Dr I. Bezprozvanny, University of Texas, it has 
been shown that this synthetic adenophostin A can interact with reconstituted cerebellar
61
Chapter two
Ins(l,4,5)P3 receptors in lipid bilayers in an unusual way, in conjunction with the 
observation of prolonged open-states for some receptors.
2.7 Potentiometric and NMR studies of adenophostin A
The ionisation of Ins(l,4,5)P3 at the Ins(l,4,5)P3 receptor is thought to be 
particularly influential in both its conformation and its interactions with specific residues 
of the binding pocket. Several NMR studies on myo-inositol phosphates have been 
reported by our group in collaboration with B. Spiess161'163 in which the conformation of 
an inositol phosphate in relation to its degree of protonation as a function of pH has been 
studied.
It was therefore thought that similar examination of adenophostin A would reveal 
whether or not the ionisation of adenophostin A at physiological pH was different to that 
of Ins(l,4,5)P3. Any differences in ionisation may potentially lead to a possible 
explanation for the exceptional activity of adenophostin A. Therefore, a sample of our 
synthetic adenophostin A was examined by B. Spiess using potentiometric and NMR 
titrations.
Adenophostin A carries, in addition to the protonatable nitrogen, three phosphate 
groups, each group being able to bind one proton for pH values ranging from 12 to 2.5. 
Thus, in the latter pH range, four macroscopic overall protonation constants quantify the 
protonation process. These constants cannot be attributed to a given protonation site, 
since most of them are less than two log units apart and therefore a given macroscopic 
protonation step involves two or even three different basic sites. An inframolecular 
approach, which aims at defining the intrinsic acid-base properties of each group requires 
the resolution of a more detailed protonation scheme as shown in Figure 2.22. In that 
figure, the first protonation steps, which refer to the three phosphate groups, have to be 
described by eight microspecies and twelve related micro-protonation constants, with the 
fourth equivalent of protons mainly binding to an adenine nitrogen.
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Figure 2.22: Protonation scheme for adenophostin A.
31P NMR can be used to study individual protonation, provided that the observed 
chemical shifts for the phosphorus resonances mainly depend on the electronic effects 
accompanying the variations in the protonation states. B. Spiess, using 31P NMR and 
potentiometric titrations, calculated the protonated fraction of the phosphate groups of 
adenophostin A in relation to pH and these are compared with the protonated fractions of 
Ins(l,4,5)P3 in Figure 2.22, w h e r e i s  the protonated fraction of a phosphate group in 
position i on adenophostin A and Ins(l,4,5)P3.
Consideration of the fraction of the protonated phosphates of adenophostin A at 
positions 2', 3” and 4” at nearly physiological pH (pH = 7.5) gave 5%, 61%, and 26% 
respectively. Remarkably, the protonated fractions for the equivalent phosphates of 
Ins(l,4,5)P3 were 8%, 57%, and 26% (vertical line in Figure 2.23). It was really 
surprising to observe such close values, knowing that minor structural variations in 
inositol phosphates can largely affect these percentages.
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Figure 2.23: Protonation fraction curves vs pH of adenophostin and Ins(l,4,5)P3. The 
curves in solid line correspond to the protonation fraction curves of Ins(l,4,5)P3 (P I , P4, 
P5). The curves in circles, squares and triangles correspond to the protonation fraction 
curves of adenophostin A (P2, P3, P4).
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Figure 2.24: The structures of Ins(l,4,5)P3 and adenophostin A.
We can imagine that the prime interactions of Ins(l,4,5)P3 with its binding pocket 
in the Ins(l,4,5)P3 receptor are made via the charged phosphate groups. These results 
have shown that the ionisation of the phosphate groups of Ins(l,4,5)P3 and adenophostin 
A is similar at nearly physiological pH, and therefore that their ionic interactions at the 
Ins(l,4,5)P3 receptor are presumably also similar. Thus, it may be concluded that the 
exceptional activity of adenophostin A cannot be explained by a difference in the 







3 Minimal structure analogues
3.1 Introduction
In between the discovery of adenophostin A and the beginning of this work a few 
analogues of adenophostin A were reported (see Figure 3.1). All of these analogues 
lacked the adenine base or a similar structure and were therefore termed minimal 
structure analogues. Moreover all were based on carbohydrates with the exception of 6- 
deoxy-6-hydroxymethyl-scy//o-inositol l,2,4-trisphosphate164(56) which was based on 
scyZ/o-inositol. 56 May be considered as an inositol based analogue of the adenophostin 
A glucose motif. If the glucopyranoside ring of adenophostin A is considered as 
analogous to the Ins(l,4,5)P3 cyclohexane ring then the adenophostin A 3",4" 
bisphosphate becomes equivalent to the 4,5 bisphosphate of Ins(l,4,5)P3. Therefore the 
position of adenophostin A most likely to correspond to the position 3-hydroxyl of 
Ins(l,4,5)P3 carries a sterically bulky hydroxymethyl group. 56 Was designed to explore 
the effect of introducing such a group into an Ins(l,4,5)P3-like structure. One report 
concludes that there is little tolerance at the Ins(l,4,5)P3 receptor for an increase in steric 
bulk at position 3 of Ins(l,4,5)P3. Investigation into alkylation at this position with a 
series of racemic 3-0-alkylated analogues165 found that increasing steric bulk of the 
equatorial 3-position produced analogues with progressively decreasing activity at the 
Ins(l,4,5)P3 receptor. However in contrast to this, D-3-C-trifluoro-methyl-wyo-inositol 
1,4,5-trisphosphate, which has an added axial 3-CF3-group, was almost equipotent to 
Ins(l,4,5)P3165 suggesting that there may be tolerance in the Ins(l,4,5)P3 receptor binding 
pocket for bulky axial substituents at the 3 position. Furthermore the Ins(l,4,5)P3 
analogue D-2,3-methoxymethylene-7wyo-inositol 1,4,5-trisphosphate has also been shown 
to be almost as active as Ins(l,4,5)P3 at the Ins(l,4,5)P3 receptor.166
Biological evaluation of racemic 56 in permeabilised rabbit platelets found that it
tyt
exhibited equal potency in Ca release to Ins(l,4,5)P3, and in binding assays in rat 
cerebellar membranes 56 was also found to be equipotent to Ins(l,4,5)P3. These findings 
demonstrate that modification of the 3-position of an analogue similar to Ins(l,4,5)P3 
with a hydrophilic hydroxymethyl group is well tolerated by the Ins(l,4,5)P3 receptor 
and this is in keeping with its similarity to the glucose 5 "-structure in adenophostin A. It 
is important to note here that 56 bears one other structural difference to Ins(l,4,5)P3, in
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that the 2-position is equatorial as opposed to axial. Although it has been demonstrated 
that the 2 position of Ins(l,4,5)P3 is relatively unimportant to the activity of 
Ins(l,4,5)P3.167 With this in mind it is better to compare the activity of 56 with scyllo- 
inositol 1,2,4 trisphosphate. Racemic 56 exhibits about four times greater potency and 
10-fold higher binding affinity than scyllo-Ins(l,2,4)P3 at the Ins(l,4,5)P3 receptor.168 
This finding means that a hydroxymethyl group at the position corresponding to position 
3 of Ins(l,4,5)P3 slightly increases Ca2+-mobilising potency and markedly increases 
affinity for the Ins(l,4,5)P3 receptor. It is possible that the equatorial 2-hydroxyl of 56 
allows accommodation of certain larger substituents at the 3-position, and in 
adenophostin A the analogous position is the relatively small glucopyranoside ring 
oxygen, so indeed the role of the 2- and 3-position substituents may be closely 
connected. In addition the acetate ester of the hydroxymethyl present in adenophostin B, 
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Figure 3.1: Minimal structure analogues of adenophostin A
The first carbohydrate based adenophostin A analogue, 2-hydroxyethyl a-D- 
glucopyranoside 2',3,4-trisphosphate [Gluc(2'3,4)P3, 57],168-171 in which the adenosine 
structure had been effectively removed, had an hydroxyethyl phosphate at the glucose 
anomeric position to mimic the 2' phosphate on the ribose ring of adenophostin A. Initial 
testing in rabbit platelets found Gluc(2'3,4)P3 to be a full agonist at the Ins(l,4,5)P3 
receptor with a potency ca. 10-fold lower than that of Ins(l,4,5)P3. These results were 
later confirmed by another group who carried out a more extensive biological evaluation 
of G1uc(2’3,4)P3 in SHSY5Y neuroblastoma cells.172’173 Molecular modeling studies on
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G1uc(2'3,4)P3 confirmed that the conformationally flexible hydroxyethyl phosphate was 
likely to adopt an extended conformation, therefore preventing the 2'-phosphate from 
accurately mimicking either the 1-phosphate of Ins(l,4,5)P3 or the 2'-phosphate of 
adenophostin A. Thus Gluc(2'3,4)P3 is a 100-fold weaker agonist at the Ins(l,4,5)P3 
receptor than adenophostin A. Although it may be possible that this is due just to the 
mobility of the ethylphosphate motif, it is more probable that the relatively low potency 
stems from a combination of a lack of the rigidity that is provided by the ribofuranoside 
ring and the lack of an adenine base structure.
Another study was later published outlining the synthesis and biological activity 
of a group of xylose analogues closely related to Gluc(2'3,4)P3.174 The xylose equivalent 
of G1uc(2'3,4)P3 (58), in which the 5-hydroxymethyl was absent, exhibited an EC50 value 
in permeabilised hepatocytes of 0.43 pM, about 10-fold weaker than Ins(l,4,5)P3. Other 
similar analogues in this series (59-61) where the aglycon was increased in length or the 
anomeric configuration inverted to ft  were all weaker than Gluc(2'3,4)P3 and its xylose 
equivalent. Unfortunately it is difficult to draw firm conclusions by comparison of these 
results as the tests were carried out in different cell models, although it is tempting to 
suggest that the 5"-hydroxymethyl of adenophostin may not be so crucial to its activity. 
This is supported by the finding that 3-deoxy-Ins(l,4,5)P3 is a relatively potent 
Ins(l,4,5)P3 agonist. Further consideration of this point is in chapter 4 where the 
biological results of'xylophostin' are discussed.
Following on from these initial syntheses it was decided that more rigid 
structures should be prepared lacking the adenine base.
3.2 Synthesis of Ribophostin
3.2.1 Introduction
The most intriguing feature of adenophostin A's structure is the adenine base, as 
nothing in the structure of Ins(l,4,5)P3 resembles it. This suggests that it plays an 
important role in the exceptional biological activity of adenophostin A, possibly by 
engaging with a nearby region of the Ins(l,4,5)P3 receptor and stabilising binding 
interactions, and/or optimising the position of the 2-phosphate at the binding site.
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Therefore, an analogue in which the adenine has been effectively deleted, leaving the 
ribose ring intact was an attractive target. We named this analogue "ribophostin" (62).
'Me
2-03po a - ^ '
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Figure 3.2: Retrosynthetic basis for the synthesis of ribophostin indicating the required 
glycosyl donor precursor and acceptor.
Disconnection of the adenophostin A structure with complete loss of the adenine 
base would be the most logical target, leaving a derivatised tetrahydrofuran ring as the 
required acceptor. Although plausible, it was decided that a synthetically simpler 
approach would be adopted where the adenine was replaced with OMe. The 
disaccharide 62 constructed from a D-glucopyranosyl donor and methyl-^-D- 
ribofuranoside acceptor was therefore designated as a suitable target. Work previously 
carried out be D. J. Jenkins provided the ideal route to the protected glucopyranose 
intermediate, and the acceptor was already in hand in our laboratory.
3.2.2 Synthesis of the donor
For the preparation of this adenophostin A analogue, imidate glycosylation 
methodology was adopted. Work carried out prior to this project by D. J. Jenkins170 
outlined a route to a selectively protected glucose intermediate amenable to conversion 
into the desired glucosyl donor. Thus 2,6-di-0-benzyl-3,4-di-0-p-methoxybenzyl-D- 
glucopyranose (46) was prepared on a large scale following the published procedures.170 
Briefly, Fischer glycosidation o f D-glucose with allyl alcohol in the presence of a strong
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cation-exchange resin yielded a mixture of allyl a -and y^-D-glucopyranoside products 
(64) in a ratio o f 7:3 as estimated from the integral ratio of the anomeric protons in the 
'H NMR spectrum. Direct benzylation of this mixture was then carried out by way of a 
bis-stannylene intermediate followed by stirring with neat benzyl bromide for three days 
at 80-90°C. After removal of benzyl bromide by column chromatography the desired 
allyl 2,6-di-O-benzyl-cr-D-glucopyranoside (65) was isolated by crystallisation from 
diisopropyl ether in 10% yield with melting point of 73-75°C (lit. 170 74—77°C). 
Although the yield was rather low, as expected from the literature, this is a convenient 
method to produce this intermediate on a large scale.
Conversion into allyl 2,6-di-O-benzyl-3,4-di-0-/?-methoxybenzyl-<z-D- 
glucopyranoside (67) with sodium hydride and p-methoxybenzyl bromide was easily 
achieved. This was followed by removal of the allyl aglycone by a two step method. 175 
First the allyl group was isomerised to the c/s-prop-1 -enyl glucopyranosides, and then 
this acid labile group was cleaved using acid hydrolysis to furnish the fully protected 
glucose intermediate (46) (melting point 117-120°C, lit. 170 120-131°C) ready for 
















Figure 3.3: Route to trichloroacetimidate 67a.
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46 Was then converted into its /^trichloroacetimidate. Of the two possible 
anomers this is the most difficult to prepare. Under reaction conditions reported by R. R. 
Schmidt and J. Michel176 for tetra-O-benzyl-D-glucopyranose the kinetic product (J3- 
anomer) is formed first. Thus the presence of a relatively mild base, in this case 
potassium bicarbonate, results in the formation of the /?-anomer, but this is accompanied 
by slow conversion into the a-anomer, which is the thermodynamic product. Therefore 
the reaction was monitored closely by TLC and quenched when the optimum conversion 
to the yff-anomer was observed, before the formation of too much of the a-anomer. Flash 
chromatography yielded the desired 2,6-di-0-benzyl-3,4-di-0-p-methoxybenzyl-/?-D- 
glucopyranosyl trichloroacetimidate (67) in only moderate yield (48%), accompanied by 
a notable amount of the or-anomer. Configurations of the two anomers were easily 
assigned on the basis of their NMR spectra. The axial H-l of the yff-anomer exhibited 
a typically large coupling constant J  8.3 Hz and was upfield ( S h  5.78) of the equatorial 
H-l of the a-anomer, 8h 6.51, J  3.3 Hz. The trichloroacetimidate NH proton was also 
clear in the spectra for both anomers.
After repeated attempts at the preparation of this glycosyl donor the yield could 
not be improved and since plenty of the starting glucopyranose had been using the large 
scale procedure described above, the yield of glycosyl donor was accepted and the 
synthesis continued.
3.2.3 Synthesis of the acceptor
A route to an appropriate acceptor, methyl 2-0-allyl-5-0-benzyl /?-D-
171ribofuranoside has recently appeared in the literature. However a co-worker, D. J. 
Jenkins, prepared the corresponding 2-0-p-methoxybenzyl ether (63) by a shorter route 
in five steps from D-ribose as shown in Figure 3.4. Briefly, D-ribose was converted to 
the known methyl /2-D-ribofuranoside which was reacted with 1.05 equivalents of p- 
methoxybenzaldehyde dimethyl acetal to yield the 2,3-0-p-methoxybenzylidene 
derivative. 5-0-Benzylation and subsequent reductive cleavage of the p- 
methoxybenzylidene with either LiAlH4-AlCl3 in refluxing THF or DIBAL-H in DCM 
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Figure 3.4: Route to glycosyl acceptor 63.
Reagents and conditions: i) p-methoxybenzylidene dimethyl acetal (1.05 equiv.), 
PTSA, DMF, 70 °C; ii) NaH, BnBr, DMF; iii) DIBAL-H (2.5 equiv.), CH2C12, -78 °C.
3.2.4 Glycosidation and deprotection
With suitable imidate glycosyl donor and acceptor in hand the glycosidation was 
carried out under conditions established as those that generally favour a- 
stereoselectivity, 177 that is at room temperature in diethyl ether in the presence of 
catalytic TMSOTf. The reaction proceeded smoothly to give predominantly the a-D- 
glucopyranosyl isomer (yield of mixture 54%), and the H-l' signal in the NMR 
spectrum confirmed the formation of the a-coupled product with a typically small axial- 
equatorial coupling constant of J  3.4 Hz. The /?-D-glucopyranosyl isomer constituted ca. 
20% of the isolated product as judged by !H NMR integrals and unfortunately, it was not 
possible to remove this undesired product at this point. It was decided to proceed with 
the deprotection of the p-methoxybenzyl groups to give the desired triol ready for 
phosphorylation, in the hope that the anomeric mixture of triols could be separated.
In the synthesis of Ins(l,4 ,5 )P3 analoguesp-methoxybenzyl groups are often used 
to mask the hydroxyls designated for phosphorylation towards the end of a synthetic 
route, because they are easily removed in the presence of other protecting groups such as 
benzyl ethers. This approach has been adopted here also. Oxidative cleavage of p- 
methoxybenzyl ethers is the most frequent method of deprotection and can be achieved 
with either DDQ or eerie ammonium nitrate. At this time DDQ was considered the best 
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Figure 3.5: Synthetic route to ribophostin (62).
Once treated with DDQ in wet dichloromethane the resulting or-D-glucopyranosyl 
triol (73) could be separated from its /?-isomer by flash chromatography leaving the pure 
triol for phosphorylation.
Since this work was carried out details of a method of p-methoxybenzyl cleavage 
using catalytic amounts of DDQ have appeared in the literature. 178 FeCh used for the 
oxidation of hydroquinones to quinones was used to oxidise the by-product dichloro 
dicyano hydroquinone (DDHQ) back to DDQ. Reducing the amount of DDQ in a 
reaction overcomes the two main disadvantages of its use, first the by-product DDHQ is 
often difficult to get rid of, and second DDQ is a relatively expensive and toxic reagent.
3.2.5 Phosphorylation and Deprotection
The triol 73 was phosphitylated in the usual way with bis(benzyloxy) 
(diisopropylamino)phosphine and tetrazole to give a trisphosphite intermediate. 
Oxidation with MCPBA at reduced temperature resulted in the fully protected 
trisphosphate (74) in good yield after purification. 31P NMR confirmed the presence of 




Figure 3.6: Part o f the ‘H-‘H COSY NMR spectrum of 74 in CDCI3 .
The final deprotection was achieved by hydrogenation over a palladium catalyst. 
Purification of the product by ion exchange chromatography afforded the 
triethylammonium salt of 62. Strangely, this salt was not soluble in water (not even 
partially), and for quantification purposes aqueous solubility was essential. Therefore it 
was converted into the freely water soluble potassium salt by addition of 0.1 M aqueous 
potassium hydroxide. The volume added was calculated based on the *H NMR spectrum 
in which a ratio of triethylammonium ions : disaccharide of 3.5:1 was observed. Thus 
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Figure 3.7: Part of the *H NMR spectrum of the triethylammonium salt of ribophostin in 
CD3OD.
3.3 Biological results
Compound EC50 h n
(nM)
Ins(l,4,5)P3 153.13±11.08 2.2510.20 7
Ribophostin 213.3517.41 2.4910.18 3
Table 3.1: Unidirectional 4 5Ca2+ efflux in permeabilised hepatocytes. The EC50  
values and Hill coefficients (h) were separately determined for n independent
1 cnexperiments by fitting results to a logistic equation. Results are shown as means ± 
S.E.M.
Biological evaluation of ribophostin by a collaborator using the method described
for adenophostin A indicated that it was a full agonist at the Ins(l,4 ,5 )P3 receptor with a
* 2^* * potency for releasing intracellular Ca from permeabilised hepatocytes almost the same
as Ins(l,4 ,5 )P3 (Table 3.1). Ribophostin was also shown in equilibrium binding studies
with hepatic membranes to completely displace specific [3H]Ins(l,4 ,5 )P3 binding with
equal potency to Ins(l,4 ,5 )P3 (Table 3.2). Figure 3.8 depicts the specific
[3HIns(l,4 ,5 )P3] binding to rat hepatic membranes in the presence of the indicated
concentrations of adenophostin A (□) or ribophostin (□).
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Compound K d h
(nM)
Ins(l,4,5)P3 8.65±0.89 0.96±0.04
I I  Ribophostin 8.42±2.5 0.89±0.10
I I  Adenophostin A 0.87±0.20 1.28±0.37
Table 3.2: The K<± values were determined from equilibrium competition binding 
experiments with [3H]Ins(l,4 ,5 )P3 in the presence o f and ribophostin or Ins(l,4 ,5 )P3 in 
hepatic membranes. Results are shown as means ± S.E.M.
1 0 0 -












Figure 3.8: Specific [3H Ins(l,4 ,5 )P3 ] binding to rat hepatic membranes is shown in the 
presence of the indicated concentrations of adenophostin A (■) or ribophostin (A).
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3.4 Synthesis of furanophostin
3.4.1 Introduction
It was clear from molecular modelling studies that the rather mobile 
hydroxyethylphosphate of Gluc(2 ',3 ,4 )P3 (57) did not achieve good positioning of the 2'- 
phosphate at the Ins(l,4 ,5 )P3 receptor binding site. It was therefore decided that a more 
rigid structure would be prepared to investigate how this might affect binding to the 
Ins(l,4 ,5 )P3 receptor. We were also interested in pruning the structure of ribophostin to 
find out if the 4f-hydroxymethyl group was necessary for its Ins(l,4 ,5 )P3-like activity, 
and if the anomeric O-methyl group was detrimental to binding in any way. Thus we 
developed a synthesis of [(35',47?)-3-hydroxytetrahydrofuran-4-yl] a-D-glucopyranoside 
3,3',4-trisphosphate (furanophostin), an analogue that lacks both the O-methyl and 4'- 
hydroxymethyl moieties of ribophostin, but retains the rigidity of a ribofuranose ring.
.OBn
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Figure 3.9: Synthetic route to furanophostin.
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3.4.2 Synthesis of the donor
At the time this synthesis was undertaken we thought that phosphite 
glycosidation methodology would be preferable to the use of trichloroacetimidates, since 
the glycosyl phosphite donor was much easier to prepare in quantitative yield and the 
reported or-stereoselectivity for glycosidations with phosphite donors has been shown to 
be comparable to those using trichloroacetimidate donors151 (also see chapter 2 ). 
Therefore 2,6-di-0-benzyl-3,4-di-O-/?-methoxybenzyl-D-glucopyranose was converted 
into its dimethyl phosphite as described in the synthesis of adenophostin A.
3.4.3 Synthesis of the acceptor
This acceptor (75) was prepared by A. M. Riley. Although the structure is simple 
the synthesis required optical resolution of an enantiomeric intermediate, and the 
conversion of one enantiomer into a compound for which the absolute configuration was 
already known. The route followed is outlined in Figure 3.10.
P M B O  0 ( - ) C a m p hH O  OH H O  O P M B  
(±)"81
( - )C a m p h  O  O P M B
HO O P M B PM B O  O H
H - 75
( - )C a m p h  =
(+)-75
H O  O B n  
H -84
Figure 3.10: Synthetic route to glycosyl acceptor (+)-75.
Reagents and conditions: i) a) /?-methoxybenzylidene dimethyl acetal (1.05 
equiv.), PTSA, DMF, 70 °C; b) DIBAL-H (2.5 equiv.), CH2C12, -78 °C; 90 % yield for 
two steps; ii) (-)-(S)-camphanic chloride, pyridine, 0 °C to rt, 82 (80 % yield), 83 (82 % 
yield); iii) NaOH, MeOH, reflux, 94-97 %; iv) a) NaH, BnBr, DMF; b) CF3COOH, 
CH2C12; 87 % yield for two steps.
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3.4.4 Glycosidation and deprotection
An initial attempt at glycosidation with donor (47) and acceptor (75) used 
conditions reported by Y. Watanabe et <2 / . 151 They detailed glycosidation conditions for 
phosphite donors where cr-stereoselectivity is highly favoured, i.e. at room temperature 
in diethyl ether with zinc chloride (1.2 equivalents) and silver perchlorate (2.4 
equivalents) as promoters and in the presence of 4A molecular sieves. Observation of 
some clumping together of the molecular sieves in the reaction mixture after addition of 
the promoters seemed to suggest a low solubility of either the donor or acceptor (or both) 
in the reaction conditions, and subsequently the glycosidation gave disappointing results, 
with a low yield of an inseparable mixture of a- and ^-coupled products. It was 
concluded that solubility of reactants was probably the key factor impeding a smooth 
reaction, thus another reaction solvent was sought.
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A recent publication of iodonium-ion mediated glycosidation of thioglycosides 
in solvent mixtures with similar dipole moments and dielectric constants to diethyl ether 
found that a mixture of toluene/1,4-dioxane showed the greatest promise. Much higher 
a-selectivities with this solvent mixture were reported than with conventional 
glycosylation solvents, and a ratio of 1:4 toluene:dioxane was found to give the best 
results. This solvent mixture was therefore used in the place of diethyl ether in the 
phosphite coupling. The reaction mixture exhibited no signs o f low solubility o f the 
reactants and yielded solely the a-coupled product (76) in 76% yield. The 'H NMR 
spectrum exhibited the characteristic resonance of a deshielded equatorial anomeric 
proton with small coupling constant (<5h 5.18, J  3.4 Hz), typical of or-coupled sugars 
(Figure 3.11).
Although deprotection of the p-methoxybenzyl groups of 76 in the synthesis of 
ribophostin was achieved successfully the yield was only moderate. New reaction 
conditions that cleave p-methoxybenzyl ethers have appeared recently in the literature,
1 O ') 1 O ')notably iodine in methanol, magnesium bromide diethyl etherate-methyl sulfide and 
trifluoroacetic acid in dichloromethane.184 The latter conditions were chosen for the 
deprotection of 76 as they have been reported to selectively cleave p-methoxybenzyl 
ethers in the presence of multiple glycosidic linkages. The treatment of 76 with 10% 
trifluoroacetic acid in dichloromethane proved very effective and resulted in the desired 
triol (77) in high yield (84%).
3.4.5 Phosphorylation and Deprotection
Figure 3.12: ’H-coupled 31P NMR spectrum of 78.
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77 Was phosphitylated in the usual way with bis(benzyloxy) 
(diisopropylamino)phosphine activated with tetrazole to give a trisphosphite 
intermediate. This was oxidised with MCPBA to give the fully protected intermediate 
(78) in high yield. 31P NMR confirmed the presence of three phosphate groups, shown in 
Figure 3.12.
Catalytic hydrogenation with palladium on carbon in a mixture of water and 
methanol, followed by purification with ion exchange chromatography gave the 
completely deprotected target compound 79, which was quantified by the Briggs 
phosphate assay.
3.5 Biological results
The biological testing by a collaborator with the same method used for 
adenophostin A indicated that furanophostin behaves as a full agonist, with potency in 
Ca2+ release assays in permeabilised hepatocytes similar to those of Ins(l,4 ,5 )P3 and 
ribophostin.
Maximally effective concentrations (10 pM) of either Ins(l,4 ,5 )P3 or 
furanophostin released the same fraction of the intracellular Ca2+ stores, 29 ± 6  % and 29 
± 1 % respectively. A similar response, release of 28 ± 2 % of the actively sequestered 
Ca2+, was evoked by the simultaneous addition of maximal concentration of both 
agonists. The concentration of furanophostin required to cause half-maximal Ca2+ 
release (EC50) was only 1.7-fold higher than that for Ins(l,4 ,5 )P3 , and the responses to 




Ins(l,4,5)P3 194±30 2.08±0.22 3
Furanophostin 329±48 2.18±0.46 5
Table 3.3. 4 5Ca2+ release data for Ins(l,4 ,5 )P3 and furanophostin. The EC50 values 
and Hill coefficients (h) were separately determined for n independent experiments by 
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Figure 3.13: 45Ca2+ release from permeabilised hepatocytes by Ins(l,4,5)P3 ( • )  and 7 
(O). For each experiment, the 45Ca2+ released in response to each concentration of 
agonist was determined and the concentration-effect relationship was then fitted to a 
logistic equation180 from which the maximal response was determined. The results 
(means ± S.E.M. of 3-5 independent determinations) are shown as percentages of that 
maximal response.
3.6 Further minimal structure analogues
Several other minimal structure analogues have been reported since this work
1 Of. 1 o /
was commenced, including another synthesis of furanophostin. ’ This synthesis was 
accompanied by biological testing data for binding to porcine cerebella, indicating an 
IC50 value of 25nM, which is comparable to the affinity of Ins(l,4 ,5 )P3 itself in this assay
i
(IC50 19nM), thus confirming our Ca release results that furanophostin is almost 
equipotent to Ins(l,4,5)P3. Shuto et al. also reported the synthesis and biological testing 
of some related compounds shown in Figure 3.14. Of particular interest is 85, which has 
a structure midway between furanophostin and ribophostin: it contains a hydroxymethyl 
group analogous to the ribophostin 4-hydroxymethyl, but like furanophostin lacks the 1- 
0-methyl group. 85 Has an IC50 very similar to furanophostin, indicating that the 4- 
hydroxymethyl motif does not increase affinity for the Ins(l,4,5)P3 receptor towards that 
of adenophostin A, and neither does it seem necessary for Ins(l,4,5)P3-like activity.
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79 R1 = R2 = H Furanophostin
85 R1 = H, R2 = CH2OH
62 R1 = OMe, R2 = CH2OH, Ribophostin
Figure 3.14: Structures of three minimal structure analogues retaining the ribose five- 
membered ring.
Three further disaccharide adenophostin A analogues have also been reported, 
(Figure 3.15) based on «,a'-trehalose and sucrose, both of which are readily available
i cnnaturally occurring starting materials. It was found that simple selective protection 
furnished intermediates suitable for phosphorylation to make target polyphosphates, all 
of which contained the same glucose-based structure as adenophostin A and placed the 
third phosphate on a second ring in a more rigid conformation that Gluc(2',3,4)P3. 
Although molecular modeling indicated that the positioning of the third phosphate may 
not have been ideal, these were easily accessible analogues avoiding the need for 
glycosidation coupling reactions.
OH ■OHO H
H O H OHO,
OH O P O -8 7
O H O P O . O P O -HO
HO H O
Figure 3.15: Disaaccharide polyphosphates
The effects of these analogues, ribophostin and Gluc(2’,3,4)P3 on [3H]Ins(l,4,5)P3 
binding and 45Ca2+ mobilisation from rat hepatocytes which predominantly express type
i fin2 Ins(l,4,5)P3 receptors were recently compared. Sucrose 3,4,3'-trisphosphate 
[Sucr(3,4,3')P3] (86) was found to be 25-fold less potent in Ca2+ release than ribophostin, 
which is surprising as it is structurally quite similar to ribophostin. It was suggested that 
this was caused by one or all of the following factors: i). Steric hindrance from one or 
both of the hydroxymethyl groups on the fructofuranosyl ring. ii). Overlapping anomeric
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effects about the glycosidic linkage, not present in ribophostin, influence the 
conformation about the glycosidic linkage, iii). The presence of a quaternary furanosyl 
anomeric center may lead to increased flexibility about the fructofuranosyl linkage.
Of the two tf,a’-trehalose based analogues, the unsymmetrical or,a’-trehalose 
2,4,3',4'-tetrakisphosphate [Trehal(2,4,3’,4')P4 (87)], gave the best results with a potency 
10-fold lower than Ins(l,4,5)P3, suggesting that the positioning of the 2'-phosphate group 
must be better than either o f the 3' or 4’-phosphates of 88 (assuming that one glucose 
bisphosphate residue of 88 interacts with the bisphosphate recognition site and the other 
is left to interact with the accessory phosphate recognition site). It was also reasoned 
that the alteration in the substitution pattern on one glucose residue may influence the 
conformation about the glycosidic linkage.
Two further inositol based adenophostin A analogues (89 and 90) have been 
reported very recently187 (Figure 3.16) in an attempt to optimise the positioning of the 
non-vicinal phosphate group at the Ins(l,4,5)P3 receptor and explore the possibility that 
correct positioning of this phosphate may engender adenophostin-like activity without 
the need for an adenosine structure. In both analogues this phosphate is positioned away 
from the inositol ring in a in a conformationally restrained manner. We are awaiting the 
biological evaluation of these compounds and therefore cannot yet comment on their 
structure-activity relationships.
Figure 3.16: Bicyclic analogues based upon adenophostin A.
Finally several clustered disaccharide polyphosphate analogues (91, 92 and 93) 
have been prepared188 (Figure 3.17) in an effort to exploit the tetrameric nature of the 
Ins(l,4,5)P3 receptor which has been shown to have four independent ligand binding 
sites. Although the biological evaluation of these analogues has not yet been reported it 
is unlikely that they will exhibited enhanced activity relative to ribophostin as the linking




Figure 3.17: Clustered disaccharide polyphosphate analogues of adenophostin A.
3.7 Summary
It is clear from the results published so far that the conformational restraint of the 
non-vicinal phosphate group analogous to the 2'-phosphate of adenophostin A is 
necessary for activity similar to Ins(l,4,5)P3, since Gluc(2',3,4)P3 is approximately 10- 
fold less potent than Ins(l,4,5)P3. The more rigid five-membered ring common to 
ribophostin and furanophostin probably delivers their 2- and 3'-phosphates respectively 
to an optimal position for Ins( 1,4,5)P3-like activity. Although their activities were not 
compared directly in the same biological assay, comparison of binding results for 
ribophostin and 85 do indicate that while the 1-0-methyl of ribophostin does not seem to 
hinder activity, neither is it necessary for Ins(l,4,5)P3-like activity. Similarly 
comparison of 85 and furanophostin indicates that the hydroxymethyl group is not 
essential for Ins(l,4,5)P3-like activity, but it may yet be shown to play a role in the 
activity of adenophostin A because the interaction of adenophostin A with the receptor 
binding site must in some way be different to these minimal structure analogues.
Thus, furanophostin probably approaches the minimal structure for potent 
agonism in a simple carbohydrate-based polyphosphate mimic of adenophostin A. But 
from results published so far we can also conclude that the adenine component of the 
adenophostins plays a pivotal role in their activity presumably by interacting with a 
nearby binding pocket o f the Ins(l,4,5)P3 receptor and optimising binding interactions, 







4 Sugar modified analogues
4.1 Introduction
The belief that the activity of the adenophostins stems from the phosphorylated 
glucose moiety is supported by the inactivity of 2'-AMP at releasing Ca2+ from 
intracellular stores of permeabilised platelets. This is given further credence by the 
ability of minimal structure analogues based on glucose, and lacking adenosine, to 
release Ca2+180 (see chapter 3). In addition the structure of the glucose moiety of 
adenophostin A most closely resembles that of Ins(l,4,5)P3, and therefore some changes 
in the structure of Ins(l,4,5)P3 and the subsequent effect on activity may be useful in 






Figure 4.1: Representation of the two possible binding orientations of Ins(l,3,4,6)P4, A 
and B, at the Ins(l,4,5)P3-binding site. (lD-numberings o f the inositol ring are shown).
Biological evaluation of many synthetic Ins(l,4,5)P3 analogues modified at one 
or several of the functional groups around the ring has brought greater understanding of 
the contribution they make to the activity of Ins(l,4,5)P3. In particular the investigation 
into the binding orientation of the meso compound myoinositol-1,3,4,6- 
tetrakisphosphate [Ins(l,3,4,6)P4, 94] and related molecules has brought an appreciation 




The finding that Ins(l,3,4,6)P4 was capable of releasing Ca2+ from the 
intracellular stores of permeabilised rabbit platelets, but was 40-fold less potent than 
Ins(l,4,5)P3190 led to a rationalisation of its activity with two different binding 
orientations. This required the vicinal D -1,6-bisphosphate of Ins( 1,3,4,6)P4 to mimic the 
Ins(l,4,5)P3 D-4,5-bisphosphate, and placed the axial 2-hydroxyl of Ins(l,3,4,6)P4 in a 
position equivalent to the 3 or 6-position of Ins(l,4,5)P3, (see Figure 4.2).
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Figure 4.2: Representation of L-Ins(l,3,4)P3 and D-Ins( 1,4,6)P3 to show the inverted 6 
and 3-hydroxyls in a binding orientation similar to Ins(l,4,5)P3.
It was therefore hypothesised that D-wyo-inositol-l,4,6-trisphosphate [ d - 
Ins(l,4,6)P3, 96] and D-myo-inositol-l,3,6-trisphosphate [D-Ins(l,3,6)P3, 95], analogues 
in which the 3 or 6-hydroxyl had been inverted respectively, would possess Ca2+ 
releasing activity. Though they were strictly analogues of scy//o-Ins(l,4,5)P3 (because 
the pseudo 2-hydroxyl was equatorial rather than axial), this was considered to be of 
little consequence because DL-scy//o-Ins(l,2,4)P3191 and DL-2-deoxy-Ins(l,4,5)P3167 have 
been shown to be only approximately 2.5-fold weaker than Ins(l,4,5)P3 in biological 
activity. (A c/nro-inositol based analogue o f Ins(l,4,5)P3, L-c/uro-inositol 2,3,5- 
trisphosphate was previously synthesised. This is an analogue of Ins(l,4,5)P3 in which 
the 3-hydroxyl was inverted and the 2-hydroxyl remained axial with potency 
approximately 10-fold lower than Ins(l,4,5)P3 in permeabilised SH-SY5Y cells192).
Hence the total synthesis and biological evaluation of D-Ins(l,4,6)P3 and D- 
Ins(l,3,6)P3 [alternative nomenclature: L-Ins(l,3,4)P3] showed that these analogues were 
indeed active,190 with D-Ins(l,4,6)P3 (in which the 3-hydroxyl was axial) being only 2-3- 
fold less potent than Ins(l,4,5)P3, and L-Ins(l,3,4)P3 (in which the 6-hydroxyl was axial)
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being 12-fold less potent than Ins(l,4,5)P3. Furthermore, Ins(l,4,5)P3 analogues 
previously reported in the literature where the hydroxyls at positions 3 and 6 were
^ I
deleted have been biologically evaluated for Ca release. The results indicated that 
although both were active, the absence of the 6-hydroxyl resulted in a greater loss of 
activity193 than the absence of the 3-hydroxyl.194
Comparison of the structure o f these Ins(l,4,5)P3 analogues modified at the 3 and 
6-positions with the adenophostin A glucopyranose ring structure quickly brings to light 
the possibility of modification at the analogous positions in adenophostin A (Figure 4.3). 
Since the 3",4"-bisphosphate and the adjacent 2"-hydroxyl of adenophostin A possess 
identical relative stereochemistry to the 4,5-bisphosphate and adjacent 6-hydroxyl of 
Ins(l,4,5)P3 it follows that the 2" and 5” positions of adenophostin A may be considered 
analogous to the 6 and 3 positions of Ins(l,4,5)P3 respectively. Therefore, with the 
above discussion in mind it is possible to speculate on the effect of modification of the 2” 
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Figure 4.3: Comparison of Ins(l,4,5)P3 analogues modified at positions 3 and 6 with that 
of adenophostin A.
Working within the constraints of readily available monosaccharide starting 
materials, two sugar modified adenophostin A analogue targets were selected (see Figure 
4.4). The first was based on mannose, which has an axial hydroxyl at its 2-position. 
This epimerisation with respect to adenophostin A is equivalent to having an axial 
phosphate at the 6-position of Ins(l,4,5)P3. Therefore D-Ins(l,3,6)P3 [L-Ins(l,3,4)P3] 
may be thought of as the closest Ins(l,4,5)P3 analogue counterpart of the mannose
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analogue of adenophostin A, although the mannose analogue has a hydroxymethyl group 
in a position equivalent to the 3-hydroxyl of Ins(l,4,5)P3. Bearing this in mind, the 
activity of a mannose adenophostin A analogue might be expected to be considerably 
lower than that of adenophostin A
93 Xylophostin97 Mannophostin NH 2
,PO-
O P 0 3‘
HO
Figure 4.4: The structures of mannophostin and xylophostin.
It was decided that a second sugar analogue would be based on xylose, because a 
sugar with an inverted hydroxyl at position 6 was not readily accessible. Such an 
adenophostin A analogue lacks the 5"-hydroxymethyl, the position corresponding to the 
Ins(l,4,5)P3 3-hydroxyl. As outlined above 3-modified analogues of Ins(l,4,5)P3 have 
already been made with both 3-deoxy Ins(l,4,5)P3 and D-Ins(l,4,6)P3 being slightly 
weaker than Ins(l,4,5)P3. It might be predicted that the xylose based adenophostin A 
analogue would have slightly lower activity than adenophostin A itself, but, be more 
active than Ins(l,4,5)P3. It is also interesting to note that 3-deoxy Ins(l,4,5)P3 appears to 
be a type II partial agonist" (see also chapter one) and the phosphorothioates of D- 
Ins(l,4,6)P3 and D-Ins(l,3,6)P3 have also been defined as type I partial agonists. 
Therefore the xylophostin and mannophostin equivalents, with their (presumably) 
enhanced affinity for the receptor, may also exhibit interesting partial agonist activity.
A convergent approach to the synthesis to these molecules was adopted, using the 
adenosine acceptor described in chapter 2 for the synthesis of adenophostin A and 
suitably protected mannose and xylose donors.
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4.2 Synthesis of Mannophostin













102 R = H
103  R =  PMB
Figure 4.5: Route to fully protected D-mannopyranose 104.
Reagents and conditions: i) AllOH, acetyl chloride, reflux; ii)
MeC(OMe)2C(OMe)2Me, CSA, MeOH, (MeO)3CH, reflux; iii) NaH, BnBr, DMF; iv) 
95% aq. TFA-DCM (1:1); v) NaH, PMBC1, DMF; vi) PdCl2, MeOH.
The fully protected D-mannopyranose suitable for conversion to the mannose 
phosphite donor was prepared by a colleague (A. M. Riley) as shown in Figure 4.5. 
Although intermediate 101 with the butane diacetal (BDA) still in place may appear to 
be a suitable precursor to a mannose-based donor it has been reported that protection 
with a BDA group has a considerable deactivating effect. It was suggested that this 
effect may be due to the rigidity of such protection hindering the flattening of the sugar 
ring which occurs during oxonium ion formation.195 Therefore, the BDA group was
91
Chapter four
removed and replaced with /?-methoxybenzyl ethers. Conversion into the dimethyl 
phosphite was achieved by treatment of 104 with tetrazole and
bis(methoxy)(diethylamino)phosphine in DCM. The 31P and *H NMR spectra of the 
phosphitylated product (105) indicated that the a-anomer had almost exclusively been 
formed. The characteristically deshielded anomeric proton of the ar-anomer observed at 
8u 5.52 exhibited both a small equatorial-equatorial coupling to H-2 (J  1.8 Hz) and a 
large coupling to the phosphite phosphorus atom ( J h -p 8.2 Hz). Furthermore, the slightly 
more upheld 31P signal from the tf-anomer was observed in the 3IP NMR spectrum 
(Figure 4.6). The a-configuration at this position is preferentially formed as there are 
unfavourable electrostatic interactions between the axial 2-position and the equatorial J3- 
anomer 1- position. In addition the a-anomeric effect favours the ^-configuration at the 
anomeric position.
1411 4 1 .71 4 1 .81 4 1 .91 4 1 .91 4 1 .11 4 1 .21 4 1 .3




Figure 4.7: Conversion of 104 into a dimethyl phosphite.
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4.2.2 Glycosidation and deprotection
The adenosine donor prepared for the synthesis of adenophostin A was coupled 
to the mannose phosphite donor with zinc chloride and silver perchlorate as promoters in 
a similar fashion to that used in the synthesis of adenophostin A. The reaction went 
smoothly in 8 hours to furnish the fully protected intermediate 106 in 61% yield. This 
isolated product was found to be solely the or-coupled compound by examination of the 
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106  R = PM B, R-|= DMTr
107  R = Rt = H
Figure 4.9: Glycosidation and deprotection
Cleavage of the all the acid-labile protecting groups was achieved with 10% TFA 
in DCM. The equivalent reaction in the synthesis of adenophostin A only took 1.75 
hours, while complete deprotection for the mannose-based intermediate took 5 hours. 
Monitoring of the reaction by TLC indicated that cleavage of the DMTr group was 
quickly complete, and that it was probably one of the p-methoxybenzyl groups that was 
more refractory to the reaction conditions. It is most likely that the /?-methoxybenzyl 
group concerned was that at the 2'-position, and that the or-D-mannopyranoside affected 
the conformation of the ribofuranose ring in such a way as to increase the ^-stacking 
interaction between the phenyl ring of the 2'-0-/?-methoxybenzyl group and the adenine 
base.
The resulting triol (107) was found to be barely soluble in most of the common 
organic solvents and so the NMR spectra were accumulated from a sample in deuterated 
DMF. The absence of the acid-labile protecting groups was obvious from the 'H NMR 
spectrum where the aromatic region was occupied by signals from the three remaining 
benzyl groups. In addition the signal from H-l" was still present at Su 5.37, indicating 




4.2.3 Phosphorylation and Deprotection
The triol was phosphorylated using the same phosphitylating reagents described 
for the phosphitylation of the corresponding adenophostin A triol. Again there was no 
need for protection of the N6-position prior to phosphitylation. Subsequent oxidation 
with MCPBA furnished the fully protected trisphosphate, identified by the three sextets 
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Figure 4.11: Part of the 1H-1H COSY of 108 indicating the free N6 position.
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Complete deprotection was achieved with catalytic transfer hydrogenation 
conditions. Thus treatment with 20% palladium hydroxide on carbon in a mixture of 
cyclohexane, methanol and water for 10 hours gave the free acid of the desired mannose
o I i
analogue of adenophostin A 97 (mannophostin). Unfortunately the P and H NMR 
spectra clearly showed a minor impurity, probably the migration product of ring-opening 
of a cyclic intermediate. Formation of such an intermediate is favoured by the cis- 
relationship of positions 2 and 3 on the mannose ring. Thus the reaction was repeated for 
a shorter length of time (2.5 hours), whereupon the j lP and lH NMR spectra of the 
product purified by ion exchange indicated pure 97 in good yield. Finally the free acid 
was converted into its sodium salt by elution through a sodium ion exchange column, 
and quantified by both UV and Briggs total phosphate assay, which were in agreement.
Figure 4.12: Cyclic phosphate intermediate responsible for 
phosphate migration.
A sample of mannophostin was examined by HPLC using the same reverse phase 
column and method as those used in the analysis o f the adenophostin A samples in 














Mannophostin was tested by a collaborator, with the same method used to test 
adenophostin A, for Ca2+ mobilisation in permeabilised hepatocytes and the results are 
shown in Table 4.1 with results for Ins(l,4 ,5 )P3 and adenophostin A. The activity of 
mannophostin was clearly weaker than both that of adenophostin A and Ins(l,4 ,5 )P3 .
EC50 (nM) h Maximal 
response %
n
Mannophostin 180±16 2.85±0.55 49±3 8
Ins(l,4,5)P3 119±8 2.69±0.55 55±3 15
Adenophostin A 14±2 1.99±0.18 51±6 6
Table 4.1. 4 5Ca2+ release data for Ins(l,4 ,5 )P3 , adenophostin A and mannophostin. 
The EC50 values and Hill coefficients (h) were separately determined for n independent 




4.4 Synthesis of xylophostin
4.4.1 Synthesis of the donor
Although the required regioselectively protected D-xylopyranose 115 had already
o o
been prepared and reported by a colleague (Figure 4.14), the overall yield was 
restricted to less than 46% from allyl a-D-xylopyranoside by the unavoidable formation 
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Figure 4.14: Literature route to fully protected D-xylopyranose 115 developed by our 
group.
A different route was therefore investigated. Even though this proposed route 
was longer it was hoped that the overall yield would be higher and require less time- 
consuming purification by chromatography. Thus Fischer glycosidation by a slight 
modification of the method described by Jenkins & Potter88gave the allyl glycoside (109) 
as a fluffy white crystals in 41% yield over three crops. It was found that the reaction
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mixture could be satisfactorily neutralised by addition of solid NaHCOs, avoiding the 
need for more expensive Amberlite ER-45 (OH ) resin. Furthermore adding diisopropyl 
ether to the crystallisation mixture immediately before filtration facilitated the isolation 
of the crystalline product and consequently the yield was significantly improved from 
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113 R = H
114 R = PMB
Figure 4.15: Alternative route to fully protected D-xylopyranose 115.
A modification of a selective pivaloylation method described in the literature196 
was used to selectively acylate the 2-hydroxyl of 109. This particular report was 
concerned with regioselective acylation of a selection of carbohydrates, and although 
they did not actually attempt the reaction with a xylopyranoside treatment of methyl a-D- 
glucopyranoside was shown to give the 2,6-di-O-pivaloyl derivative in high yield (83%). 
Consequently, since the 5-hydroxymethyl is absent in xylose it was thought that there 
would be regioselectivity for the 2-hydroxyl in an analogous reaction. Treatment of 109 
with pivaloyl chloride at -20°C in pyridine did indeed give one major product, although 
other minor products were shown to be present by TLC. Since a colleague (H. 
Rosenberg) carried out this reaction at a similar time and identified the major product to
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be the 2-O-pivaloyl derivative from the ^ - 'H  COSY NMR spectrum (which indicated a 
typically deshielded acylated doublet of doublets at Sh 4.61 with coupling constants J  3.8 
Hz and 10.0 Hz, corresponding to H-2), the crude material obtained from the reaction 
was carried forward to the next step.
The protection of the remaining /ra«s-diequatorial hydroxyl groups at positions 3 
and 4 was achieved by treating the crude residue with 2-methoxypropene and catalytic 
/?TSA in dry THF to give one major product (117), which after purification was 
identified as the 3,4-O-isopropylidene derivative.197
Conversion into the known allyl 2-O-benzyl-a-D-xylopyranoside was then 
straightforward, with each intermediate being isolated for identification and yield 
purposes. The 2-O-pivaloyl was saponified by heating at reflux with NaOH pellets in 
methanol. The resulting free 2-hydroxyl was alkylated with benzyl bromide and sodium 
hydride in DMF, and the 3,4-O-isopropylidene easily removed by treatment of 119 with 
10% 1M aqueous HC1 in methanol. As these three steps were all found to be clean and 
high yielding reactions it was decided that the route up to 113 was suitable for large scale 
synthesis with just one purification of 113 by flash chromatography. Therefore the five 
steps from D-xylose to 113 were carried out on a 20g scale resulting in an overall yield of 
60%. This was considered a significant improvement on the yield reported for the 
literature route from the same starting material to 113 of 39%.
The introduction o f /7-methoxybenzyl ethers at positions 3 and 4 was 
accomplished by treatment of 113 with sodium hydride and /?-methoxybenzyl chloride in 
DMF at room temperature. The literature method for this step remarks that heating of 
the reaction mixture was necessary to give a good yield. It was therefore decided that the 
effect of two equivalents of each reagent per hydroxyl should be explored in an effort to 
increase the yield and avoid heating the reaction. This approach was successful and the 
fully protected intermediate (114) was isolated in 84% yield (literature 74%).
PMBO PMBO
PMBO PMBO
BnO ° P ( ° M e )2
Figure 4.16: Conversion of 115 into a dimethyl phosphite.
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The allyl group at the anomeric position was cleaved with palladium chloride in 
methanol198 to give the desired xylopyranose (115) in 90% yield as a 7:3 cc.p anomeric 
mixture as judged from the !H NMR spectrum. This method represents a more 
convenient and higher yielding cleavage of the allyl glycoside than that reported in the 
literature. Finally 115 was converted into the phosphite donor (120) with tetrazole and 
bis(methoxy)(diethylamino) phosphine in DCM. The 3IP and *H NMR spectra of the 
phosphitylated product indicated a 2:3 a. f t  anomeric mixture as judged from the !H and 
31P NMR spectra.
4.4.2 Glycosidation and deprotection
The adenosine based acceptor 40 was glycosylated with the xylopyranoside 
phosphite donor 115 in the presence of zinc chloride and silver perchlorate in a similar 
manner as that previously described in the synthesis of adenophostin A. TLC of the 
reaction mixture indicated the formation of a single product, but ’H NMR of the isolated 
material indicated that both a  and p  anomeric products (12lab) had formed in a 1:1 
anomeric mixture (46%), with the signals for H-T of the two anomers being immediately 
noticeable at ^  6.13 and Sh 6.22. This anomeric mixture was found to be inseparable at 
this point and so it was treated with 10% TFA in DCM. The resulting two products 
(122ab) were easily separated by TLC, and were isolated after repeated purification by 
flash column chromatography.
N(H)DMTr
BnO  O P (O M e)2
115
PM BO '







121ab R = PM B, R-|= DMTr 
122ab r  =  Rt =  H
Figure 4.17: Glycosidation and deprotection.
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*H NMR of these two triol anomers confirmed the configurations at the two 
anomeric centers. The more deshielded equatorial H-l" of the a-anomer (122a) was 
found to resonate at Sh 5.17 with a small coupling constant of J  3.8 Hz while the more 
shielded axial H-l" for the y^-anomer (122b) resonated at Su 4.46 with a larger coupling 
constant of J  7.9 Hz.
4.4.3 Phosphorylation and Deprotection
The a-coupled triol (122a) was successfully phosphitylated with imidazolium 
triflate and bis(benzyloxy)(diisopropylamino)phosphine in DCM without prior protection 
of the N6 position. Oxidation with MCPBA gave, after purification, the fully protected 
xylose analogue intermediate 123.
BnO.
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HOHO 1 2 2 a  R = H
1 2 3  R = P(0)(0Bn)2 9 8  Xylophostin
Figure 4.19: Selective phosphorylation and deprotection of 122a to give xylophostin
Complete cleavage of all the benzyl protecting groups of 123 was achieved with 
catalytic transfer hydrogenation, by treatment of 123 with 20 % palladium hydroxide on 
carbon in a mixture of cyclohexene, methanol and water. Purification by ion exchange 
chromatography with a 0-100 % gradient of 150 mM TFA as eluent to gave the xylose- 
based adenophostin A analogue xylophostin in good yield. Deprotection of 123 was 
confirmed by the 'H NMR spectrum which showed an absence of benzyl protons, and 
the presence of a peak at m/z 638 of the negative ion FAB mass spectrum corresponding 
to (M -l)' of xylophostin.
The isolated free acid was converted into its sodium salt by elution through a 
sodium ion exchange column and finally quantified by UV and Briggs phosphate assay, 
both of which were in agreement.
A sample of xylophostin was also examined by HPLC with the same conditions 
and column used for the analysis of adenophostin A and the resulting trace is shown 
below in Figure 4.20.
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Xylophostin was tested by a collaborator for Ca2+ mobilisation in permeabilised 
hepatocytes with the method used in chapter 2 for adenophostin A. The results are 
shown in Table 4.2 with those for Ins(l,4 ,5 )P3 and adenophostin A. Xylophostin was 
found to be 2-fold weaker the adenophostin A in Ca2+ mobilisation from permeabilised 
hepatocytes
EC50 (nM) h Maximal 
response %
n
Xylophostin 28±8 2.50±0.77 52±4 8
Ins(l,4,5)P3 119±8 2.69±0.55 55±3 15
Adenophostin A 14±2 1.99±0.18 51±6 6
Table 4.2. 4 5Ca2+ release data for Ins(l,4 ,5 )P3 , adenophostin A and xylophostin. 
The EC50 values and Hill coefficients (h) were separately determined for n independent 
experiments by fitting results to a logistic equation. Results are shown as means ± 
S.E.M.
4.6 Summary
The biological data for mannophostin and xylophostin show that a change in the 
2M-position of adenophostin A, has a far greater effect on its Ca2+ releasing ability 
compared with a change at the 5"-position. Previous discussion considered the current 
understanding on the alteration of the Ins(l,4 ,5 )P3 structure at positions 6  and 3, with the 
conclusion that modification at position 6  of Ins(l,4 ,5 )P3 has a more profound effect on 
its activity compared with modification at position 3. The Ca2+ releasing abilities of 
mannophostin and xylophostin therefore provide evidence for a binding orientation at the 
Ins(l,4 ,5 )P3 receptor, in which the 2"-hydroxyl and 5 "-hydroxymethyl of adenophostin A 
mimic the 6 -hydroxyl and 3-hydroxyl of Ins(l,4 ,5 )P3 respectively. Moreover, a more 
detailed comparison of the EC50 values given here for xylophostin and adenophostin A 
indicated that the deletion of the adenophostin A motif equivalent to the Ins(l,4 ,5 )P3 3- 
hydroxyl resulted in a 2-fold drop in activity. A similar drop in activity was observed
104
Chapter four
between 3-deoxy Ins(l,4,5)P3 and Ins(l,4,5)P3 in permeabilised SH-SY5Y cells, and 
between D-Ins(l,4,6)P3 (96) (which has an axial pseudo 3-hydroxyl) and Ins(l,4,5)P3 in 
permeabilised platelets. Comparison of the EC50 values for mannophostin, in which the 
position equivalent to the 6-hydroxyl of Ins(l,4,5)P3 had been inverted, and 
adenophostin A found there was a 12-fold drop in activity. Interestingly, this was 
analogous to the 12-fold difference in activity between L-Ins(l,3,4)P3 (95) (which has an 
axial pseudo 6-hydroxyl), discussed in section 4.1, and Ins(l,4,5)P3 when tested in 
permeabilised platelets. These observations therefore suggest that the introduction of the 
adenophostin A 2'-AMP motif to a monosaccharide version of an Ins(l,4,5)P3 analogue 
improves the potency in a manner which correlates to the activity this Ins(l,4,5)P3 
analogue. With this in mind it may be possible to design sugar modified analogues 
containing the 2-AMP motif for which the activity may be more accurately predicted.
In addition it is interesting that the deletion of the 5 "-position of adenophostin A, 
found in xylophostin, and the resulting reduction in activity supports the findings from 
earlier studies (discussed in chapter 3), that suggested that the activities of Gluc(2'3,4)P3 
(58) and its xylose equivalent were of a similar order.
Further biological investigation into the binding properties of mannophostin and 
xylophostin at the Ins(l,4,5)P3 receptor is required as they might be partial agonists. 
Examination of the properties of the Ins(l,4,5)P3 analogue analogous to xylophostin, 3- 
deoxy-myo-inositol 1,4,5-trisphosphate, led to the finding that it is a type II partial 
agonist"(see chapter 1). It can therefore be reasoned that xylophostin might be a partial 
agonists with amplified affinity for the Ins(l,4,5)P3 receptor.
Moreover the synthesis of trisphosphorothioates of two Ins(l,4,5)P3 analogues 
modified at the 3 and 6 positions has led to the synthesis of two type I partial agonists, 
DL-Ins(l,3,4)PS3 and DL-Ins(l,4,6)PS3. It is therefore possible that phosphorothioate 
analogues of mannophostin and xylophostin might also be type I partial agonists, but 







5 Base modified analogues
5.1 Introduction
As previously discussed in chapter 3 the biological activity of the minimal 
structure analogues synthesized so far has not exceeded that of Ins(l,4,5)P3. It would 
seem that activity in the realm of the adenophostins at least requires the adenine base or a 
similar motif. In an endeavour to ascertain the features of the adenine base crucial for 
adenophostin A-like activity the synthesis of two base modified analogues was planned 
based on purine and imidazole. It is clear that purine represents only a small 
modification of the adenine base with the absence of the N6 amino group. The imidazole 
analogue, meanwhile, represented a much more drastically pruned analogue of 
adenophostin A.
The chosen disconnection of these base modified analogues indicates a common 
disaccharide intermediate (124) to which each base may be added see Figure 5.1. This 
was found to be the most logical approach since regioselective protection of each 








Figure 5.1: Retrosynthetic basis for the synthesis of base modified analogues indicating 
the required di saccharide precursor
A recent synthesis of adenophostin A 160 adopted this disaccharide approach and 
detailed the synthesis of such an intermediate. Although this is the highest yielding
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synthesis reported in the literature so far for adenophostin A, some of the disaccharide 
protecting group strategy involved more than one protection and deprotection for several 
functional groups. Since this was not ideal another protecting group strategy was sought. 
After a search of the literature a synthesis for the two target base modified adenophostin 
A analogues from a versatile disaccharide intermediate was designed with a single 
protection and deprotection step for all but the ribose 1,2-diol. Benzyl ethers were 
chosen to mask those positions that needed to be protected during phosphorylation, and 
the more labile acetate group was chosen to protect positions where phosphorylation was 
required. Acetate protection was also crucial to the Vorbriiggen condensation, since it is 
the presence of acyl groups at the 1- and 2-posittions of the disaccharide which controls 
the regioselectivity of the condensation. Thus the glycosyl donor and acceptor were 
prepared from known intermediates with this protecting group strategy in mind, and then 
coupled together using phosphite glycosidation methodology give a disaccharide 
intermediate.
5.2 Synthesis of a versatile disaccharide intermediate
5.2.1 Synthesis of the acceptor
The desired acceptor was easily prepared from commercially available 1,2-0- 
isopropylidene-or-D-xylofuranose (125).199 Selective alkylation of the 5-hydroxyl was 
achieved by two different methods. The first method was investigated by a colleague (D. 
J. Jenkins), and involved the regioselective ring opening of a 3,5-O-dibutylstannylene 
derivative with benzyl bromide to yield the 5-O-benzyl ether in one step. A 78% yield of 
benzylated products was isolated containing 90% of the desired 5-O-benzyl regioisomer 
(128) as indicated by NMR. This method has since been reported independently by 
another group.200
The other method involved the selective ring opening of a 3,5-O-benzylidene 
acetal. Treatment of 1,2-O-isopropylidene- or-D-xylofuranose with benzaldehyde 
dimethyl acetal in the presence of catalytic /?TSA at 70°C with continuous removal of 
liberated methanol gave the desired acetal (126) as a single diastereoisomer in 89% yield, 
with the lH NMR spectrum showing a singlet at Sa 5.45 corresponding to the 
benzylidene CH. Regiospecific cleavage of this acetal was achieved in 68% yield with a
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mixture of 1 .OM sodium cyanoborohydride in THF and 1.0 M hydrochloric acid in ether 
to yield the desired 5-O-benzyl ether. These reagents were chosen since they are known 
to cleave benzylidene acetals at the most hindered oxygen,201 the selectivity being due to 
the small electrophilic proton favouring protonation at 0-3 rather than 0-5. The 
cleavage product structure was verified by acetylation. *H NMR of the acetate derivative 
indicated a deshielded signal at 8h 5.25, corresponding to H-3. The combined yield for 
this two step alkylation of the 5-hydroxyl however was 60%, thus the higher yielding 






Figure 5.2: Synthesis of glycosyl acceptor 130.
Inversion of the 3-hydroxyl to give the ribofuranoside acceptor (130) was 
achieved by oxidation of this position with acetic anhydride and DMSO and reduction of 
the 3-ulose intermediate with NaBH4 200(and references therein).
5.2.2 Synthesis of the donor
The free 3 and 4 positions of 65 meant it was an ideal starting material for the 
synthesis o f the glycosyl donor. Treatment of 65 with acetic anhydride in pyridine gave 
the diacetate in quantitative yield. The acetylated positions gave rise to two deshielded 
triplets with large diaxial coupling constants {J 9.8 Hz), corresponding to H-3 and H-4 in 
the *H NMR spectrum.
The conditions used for the cleavage of the allyl glycoside of 66 were not suitable 
for the analogous reaction with 131 since treatment with the potassium /-butoxide would 
have cleaved the acetate protecting groups. A milder method was however found
10Rinvolving PdC^. Under these conditions 131 was smoothly converted into the
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regioselectively protected glucopyranose 132. Finally phosphitylation in the manner 
described in chapter 2 gave the phosphite donor 133 in a 1:1 anomeric mixture as judged 
by 'H and 3IP NMR.




133 BnO OP(OMe)2 132
Figure 5.3: Route to glycosyl donor 133.
5.2.3 Disaccharide synthesis
Donor 133 and acceptor 130 were coupled together in a similar fashion to that 
described in the synthesis of furanophostin to give the desired disaccharide in 81% yield. 
In this case however, the reaction time was extended because of the deactivating effects 
of the donor 3,4-di-O-acetate protecting groups which are known to decrease the 
reactivity o f a donor.195
BnO'
130
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Figure 5.4: Route to versatile disaccharide intermediate 124.
Of note is the high regiospecificity of this glycosylation, the ^-coupled anomer 
being the sole isolated product in high yield. The cr-conflguration about the new 
glycosidic bond was easily identifiable from the *H NMR spectrum, which presented a
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deshielded doublet at 5.20 with a characteristically small coupling constant of J  3.9 
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Figure 5.5: Part of the H NMR spectrum of 124.
Cleavage of the isopropylidene acetal was accomplished by heating 134 at reflux 
for a short time in a mixture of acetic acid and water containing ethylene glycol.160 The 
1,2-di-O-acetate (124) was then prepared by treatment with acetic anhydride, in order to 
meet the Vorbriiggen condensation criteria of acyl groups at these positions.
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5.3 Synthesis of purinophostin
The first base modified analogue synthesized involved the effective deletion of 
N6 to leave the purine base. It was thought that this amine group may enhance the 
interaction of the adenophostins with the Ins(l,4,5)P3 receptor by acting as a hydrogen 
bond donor, and that its absence may result in a drop in activity.
5.3.1 Hilbert Johnson-Vorbruggen condensation and deprotection
Synthesis of nucleosides via the reaction of silylated heterocyclic bases with 
peracetylated sugars in the presence of Friedel-Crafts catalysts is now well established. 
The use of TMSOTf as the catalyst was first described by Vorbriiggen et al. in 1981.202 
Previously SnCL* had been used, but it was difficult to remove in the work up. TMSOTf 
was found to be a better catalyst because it was easily removed in the work up and gave 
higher yields.
In a subsequent paper Vorbriiggen and Hofle203 reported an investigation into the 
mechanism of nucleoside formation with TMSOTf as catalyst. They found that 
TMSOTf converted the 1,2-di-O-acyl ribofuranoside into an electrophilic 1,2- 
acyloxonium salt and it also formed a a-complex with the silylated base. These two 
intermediates then reacted together to form the nucleoside. With this discussion in mind 
the prerequisite for the 1,2-di-O-acteate of disaccharide 124 becomes apparent.
Before the condensation of 124 with purine was attempted a model reaction was 
carried out to confirm that the nucleosidic bond would be formed at the desired purine 
N9-position. It is known that treatment of 2',3',5'-tri-0-acetyl adenosine with «-pentyl 
nitrite gives 2',3',5'-tri-0-acetyl 9-/?-D-ribofuranosidopurine (142) for which full 
characterization data have been published.204 It was reasoned that condensation of
1,2,3,5-tetra-O-acetyl-D-ribofuranose and silylated purine in the presence of TMSOTf 
should give a product identical to 142. The isolated product from this reaction did
1 13indeed give H and C NMR spectra in agreement with those from 2',3',5'-tri-0-acetyl 
adenosine treated with w-pentyl nitrite. In addition the fully deprotected product from 
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Figure 5.8: Route to purinophostin (140).
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After the success of the model Vorbriiggen condensation reaction the 
condensation of purine with disaccharide 124 was attempted. TLC during the course of 
the reaction saw the formation of two products. Initially the lower spot was the major 
one, but over time the higher spot began to predominate. Extended reaction times did 
not however see complete conversion to the upper spot. The reaction was carried out 
successfully with both catalytic and stoichiometric amounts of TMSOTf with no 
significant difference in proportions of the major and minor products. Catalytic 
TMSOTf was slower though, taking 24 hours for complete reaction of starting material 
and equilibration of products.
The major product was identified as the 9-/2-D-ribofuranosidopurine nucleoside 
derivative (137). The characteristic pattern of purine ring-carbon signals found in the 
13C NMR of 2',3',5'-tri-0-acetyl 9-/2-D-ribofiiranosidopurine was clearly exhibited by the 
13C NMR spectrum of 137, while the 'H NMR of 137 exhibited a deshielded doublet at 
Sh 6.30 corresponding to H-l'. Unfortunately the identification of the regioisomer 






Figure 5.9: H NMR spectrum of 137.
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Cleavage of the acetate esters was straightforward. Fully protected intermediate 
137 was stirred in a mixture of concentrated aqueous ammonia and methanol in a sealed 
flask overnight to give the triol 138 required for phosphorylation.
5.3.2 Phosphorylation and deprotection
Triol 138 was phosphitylated with a pre-formed complex between tetrazole and 
bis(benzyloxy)(diisopropylamino)phosphine in DCM. The resulting trisphosphite was 
oxidised with MCPBA to the trisphosphate (139). The ‘H-coupled 3IP NMR spectrum of 
the purified product exhibited three overlapping sextets corresponding to the three 
dibenzyloxy phosphate groups.
Deprotection of 139 to give the purine analogue of adenophostin A was achieved 
with catalytic transfer hydrogenation in a similar manner to the deprotection of the 
adenophostin A precursor. Complete deprotection did however take 17 hours compared 
to the 2 hours needed to deprotect the corresponding adenophostin A precursor, and this 
probably lowered the yield. The crude product was purified on MP1 AG ion exchange 
resin, and eluted with a 0-100% gradient of 150mM aqueous TFA. Great care was 
required during evaporation of the eluent as depurination was found to occur if the water 
bath temperature was not kept below 20°C. ]H NMR of the clear glassy product 
indicated complete loss of all the benzyl protecting groups, and 3IP NMR exhibited three 
resonances from the three deprotected phosphates. The isolated free acid was finally 
converted into the sodium salt by eluting through a short column of sodium exchange 
resin. Quantification was carried out with the Briggs phosphate assay and by UV, both 
of which were in agreement. A sample of purinophostin was examined by HPLC and the 
resulting HPLC trace is shown below in Figure 5.10.
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Biological testing o f purinophostin for Ca2+ mobilisation in permeabilised 
hepatocytes was carried out by a collaborator using the method described in chapter 2 . 
The results are shown in Table 5.1. Purinophostin was found to be essentially equipotent 
with adenophostin A.
EC50 (nM) h Maximal 
response %
n
Purinophostin 18±1 2.04±0.24 52±3 10
Ins(l,4,5)P3 119±8 2.69±0.55 55±3 15
Adenophostin A 14±2 1.99±0.18 51±6 6
Table 5.1. 4 5Ca2+ release data for Ins(l,4 ,5 )P3 , adenophostin A and purinophostin. 
The EC50 values and Hill coefficients (Ji) were separately determined for n independent 




5.5 Synthesis of imidophostin
The second base modified analogue constituted the deletion of the adenine six 
membered ring to leave the imidazole moiety. It is known that the position of the base at 
the nucleosidic bond can adopt two main orientations relative to the sugar moiety, called 
syn and anti (Figure 5.11).
NH- NHanti syn
HO OH HO OH
Figure 5.11: Syn and anti conformations of adenosine.
Often the syn conformation in adenosine is stabilized by a Os-N 3 intramolecular 
hydrogen bond. In an imidazole analogue there is no opportunity for such an interaction 
to take place and so the conformation about its nucleosidic bond may be completely 
different to that of the adenophostins. These considerations may also have some bearing 
on the ring puckering of the ribose ring and thus the positioning of the 2'-phosphate 
group. In addition N 1 is often a hydrogen bond acceptor; such an interaction with the 
Ins(l,4,5)P3 receptor may contribute to the adenophostins enhanced binding affinity. 
The absence of N 1, and indeed the pyrimidine ring in the imidazole analogue may affect 
binding to the receptor.
5.5.1 Hilbert Johnson-Vorbruggen condensation and deprotection
To the author’s knowledge there is only one reported synthesis of N-(J3-d- 
ribofuranosyl)imidazole in the literature,205 although other groups must have prepared it 
because they have described its crystal structure,206 circular dichroism207 and molecular
n A O
orbitals. The method employed to prepare A^-(/?-D-ribofuranosyl)imidazole is similar 
to that used in the synthesis of purinophostin (the silyl Hilbert Johnson-Vorbruggen 
method), and involves TMSOTf catalysed condensation of V-trimethylsilylimidazole and
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l,2,3,5-tetra-0-acetyl-D-ribofuranose. The formation of ./V-(/?-D-ribofuranosyl) imidazole 
was also accompanied by the formation of the C2 symmetrical bis-glycosylated 
compound in significant amounts, although a reduction in the amount of imidazole 
reagent used minimalised this.
The successful preparation of A-(/?-D-ribofuranosyl)imidazole by this method 
meant that the preparation of an imidazole analogue of adenophostin A was easily 
accessible by condensation of disaccharide 124 already in hand with N- 
trimethylsilylimidazole (144).
Bni OAC
1 4 4 AcO-
BmBnO'
Bni BnO'Bni BnO'
AcO' BniOAc BnO'AcO- ORBnOO A cBnO AcO'
OAC1 2 4 1 4 5  R = A c BnO
1 4 7  R = H 1 4 6
HO' BnO'
O P 0 3“1 4 9  HO 1 4 8  BnO
Figure 5.12: Route to imidophostin (149).
Thus 124 and A-trimethylsilylimidazole were heated at reflux in 1,2- 
dichloroethane with TMSOTf for a total of 24 hours. The mono-glycosylated compound 
was the major product (145)(57%) and the bis-glycosylated compound the minor (20%) 
(146). Efforts to reduce the formation of bis-glycosylated compound met with little 
success. A reduction in the equivalents of A-trimethylsilylimidazole used lead to 
incomplete reaction of the starting material with bis-glycosylated compound still being 
formed.
Identification of the major product as the mono-glycosylated compound from the 
NMR spectrum was based on the loss of symmetry in the imidazole ring, and the 
integral of each imidazole ring proton signal being one. H-4 and H-5 were distinctly 
separate signals at Sh 7.14 and 7.08 respectively while H-2 resonated at 7.82. The 13C
118
Chapter five
NMR spectrum reiterated this pattern with a marked difference between the signal shifts 
for C-4 and C-5 116.84, C-5, and Sc 129.52, C-4). In addition the peak at m/z 759 of
the positive ion FAB mass spectrum corresponded to (M+H)+ of the mono-glycosylated 
product.
The structure o f the bis-glycosylated product was identified in a similar way. 
Both the !H and 13C NMR spectra exhibited only two signals for the imidazole ring 
protons. The *H NMR was especially distinctive with one broad singlet for H-4 and H-5 
at ^  7.51 integrating for two protons and a highly deshielded broad singlet at Sh 9.37 for 
H-2 integrating for one proton. Furthermore the rest of the *H NMR spectrum signals all 
integrated for twice the number of protons seen in the mono-glycosylated 'H NMR 
spectrum. Finally the positive ion FAB mass spectrum for this compound exhibited a 
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Figure 5.13: Part of the ’H-'H COSY NMR spectrum of the triol 147.
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As with the corresponding purinophostin intermediate, cleavage of the acetate 
esters of 145 was achieved by stirring in a mixture of concentrated aqueous ammonia 
and methanol in a sealed flask overnight. Purification of the product gave the desired 
triol 147 ready for phosphorylation.
5.5.2 Phosphorylation and deprotection
Phosphitylation of 147 with tetrazole and bis(benzyloxy)(diisopropylamino)
phosphine in DCM went smoothly to give the trisphosphite which was oxidised to the
1  ^1trisphosphate with MCPBA. The H-coupled P NMR spectrum exhibited three 
characteristic sextets corresponding to the three protected phosphate groups.
Again complete deprotection was achieved with catalytic transfer hydrogenation. 
148 Was heated at reflux in a mixture of water, methanol and cyclohexene with 20% 
palladium hydroxide on carbon for 10 hours. After removal of the catalyst by filtration 
the crude product was purified by ion exchange chromatography with a gradient of 0- 
100% 150 mM aqueous TFA. The fractions containing product (149) were identified by 
a qualitative Briggs test and those found to contain phosphate were concentrated to a 
clear glassy solid. ]H NMR spectroscopy indicated complete loss of all the benzyl 
protecting groups and as expected no imidazole ring reduction. This was in agreement 
with the ^-coupled 31P NMR spectrum, which exhibited three doublets. Quantification 
was only carried out by the Briggs phosphate assay since this analogue had little UV 
activity. The isolated free acid was then finally converted into its sodium salt by eluting 




EC50 (nM) h Maximal 
response %
n
Imidophostin 108±20 2.51±0.64 5713 7
Ins(l,4,5)P3 119±8 2.69±0.55 5513 15
Adenophostin A 14±2 1.9910.18 5116 6
Table 5.2. 45Ca2+ release data for Ins( 1,4,5)P3, adenophostin A and imidophostin. 
The EC50 values and Hill coefficients (h) were separately determined for n independent
1 onexperiments by fitting results to a logistic equation. Results are shown as means ± 
S.E.M.
Imidophostin was biologically tested for Ca2+ mobilisation in permeabilised 
hepatocytes by a collaborator according to the method described for adenophostin A in 
chapter 2. The results shown in Table 5.2 indicate that imidophostin was only 
marginally more active than Ins(l,4,5)P3.







Figure 5.14: Further base modified analogues
The disaccharide 124 was considered an ideal intermediate for the synthesis of 
base modifies analogue of adenophostin A, and as such it was used in our laboratory by
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Professor S. Shuto in the synthesis of 150-152. These analogues were designed to 
investigate the effect of replacing adenine with other aromatic base substitutes, with a 
view to elucidating the key properties of adenine which contribute to the outstanding 
activity of adenophostin A.
Substitution of adenine for uracil was achieved using standard Vorbriiggen 
methodology, and the resulting adenophostin A analogue was named uridophostin. 
When tested for Ca2+ release from permeabilised hepatocytes uridophostin exhibited an 
EC50 of 34 nM, while adenophostin A tested gave an EC50 of 9.6 nM recently. The 3- 
fold difference in the activities of adenophostin A and uridophostin would suggest that 
the type of interaction between the adenine of adenophostin A and the imidazole of 
imidophostin with residues of the Ins(l,4,5)P3 receptor differs only slightly. It is clear 
from comparison of the structures of adenine and uracil that the positions available for 
hydrogen bonding are spatially quite different, and so it is plausible that the main 
interaction of this part of the molecule with the receptor relies on aromatic character 
rather than any hydrogen bonding, with hydrogen bonding playing a more accessory 
role. This conclusion is supported by the results from the benzimidazole and 4-methyl 
anisole analogues, which gave EC50 values of 47 nM and 48 nM respectively. Both of 
these analogues possess base substitutes which lack the ability to form hydrogen bonds
1 1in the same way as the N and N -positions of adenine.
Furthermore it is feasible that the marginally lower potency of these analogues 
compared with adenophostin A may have arisen from differences in binding 
conformation at the receptor. As mentioned earlier, hydrogen bonding between N3 of the 
adenine ring and the 5-hydroxyl is possible in adenophostin A; in the above base 
modified analogues such an interaction is impossible.
Finally the condensation of the disaccharide intermediate 124 with 4- 
methylanisole gave some or-product. This material was used to make the a-4-methyl
*yi
anisole analogue of adenophostin A. The ability of this analogue to mobilise Ca was 
almost 30-fold lower (EC50 1372nM) than the analogous /^linked analogue. Thus it is 
clear that the conformation about the ribofuranoside anomeric position is extremely 




The similar Ca2+ mobilising properties of purinophostin and adenophostin A 
suggest that the N6 amine of adenophostin A does not play a significant part in its 
binding at the Ins(l,4,5)P3 receptor. However the weaker activity of imidophostin 
indicates clearly that the imidazole ring is not enough for adenophostin A-like activity. 
Perhaps the imidazole of imidophostin is not large enough to reach fully the binding 
pocket occupied by the adenine of adenophostin A. Or it may be that the imidazole 
moiety is not be able to engender the same hydrophobic interactions with the receptor 
that are possible with the adenine of adenophostin A. In addition the absence of N of 
adenine in imidophostin means that there is no hydrogen bond acceptor to stabilise its 
conformation through hydrogen bonding with the 5'-hydroxyl. Although weaker than 
adenophostin A, imidophostin is however somewhat more active than both ribophostin 
and furanophostin, this suggests that the either the imidazole moiety alters the 
conformation of the molecule resulting in a more optimal binding conformation, or it 
directly enhances binding at the Ins(l,4,5)P3 receptor to give increased activity.
It is also possible that the imidazole moiety was protonated at the pH at which the 
biological evaluation took place, since imidazole has a pKa of 6.92. Hence the activity 
of imidophostin needs to be examined at a range of pH values to investigate the effect of 
its ionisation on its ability to release Ca2+.
Thus the biological results of purinophostin, imidophostin and the analogues 
synthesised by Professor S. Shuto suggest that the interaction of the adenine base of 
adenophostin A with the Ins(l,4,5)P3 receptor is probably a hydrophobic one, and that 









6 Recent background and general conclusions
6.1 Recent background
6.1.1 Further adenophostin A analogues modified at either the ribose or 
glucose moieties
After this work was commenced the synthesis of adenophostin A and several 
other adenophostin A analogues were published by van Straten et a / 160 209 210 jn addition 
the biological properties of some of these analogues (153-157) were reported recently.211 
These adenophostin A analogues shown in Figure 6.1 were modified at the ribose and 
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Figure 6.1: Adenophostin A analogues modified at either the ribose or glucose moieties.
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The ability of these analogues to release Ca2+ from the intracellular stores of 
permeabilised hepatocytes was investigated. Analogues 155 and 157 were found to be 
inactive at concentrations of >100 jiM. Their inactivity however, was to be expected, 
since neither possessed the structural motif assumed to be necessary for activity at the 
Ins(l,4,5)P3 receptor. Namely, a vicinal bisphosphate with the same relative 
stereochemistry as Ins(l,4,5)P3, a neighbouring hydroxyl corresponding to the 6- 
hydroxyl of Ins(l,4,5)P3 and a third suitably positioned phosphate. In particular, the 
disruption of the glucose-related ring in analogue 155 probably allowed too much 
conformational mobility around the bisphosphate and neighbouring hydroxyl. While the 
position of the third phosphate of analogue 157 is clearly not analogous to that of 
adenophostin A or Ins(l,4,5)P3.
The third phosphate at the 2’-position of adenophostin A has been demonstrated 
to be crucial to its binding at the Ins(l,4,5)P3 receptor, since its deletion resulted in a 
~2000-fold reduction in affinity for the receptor159 relative to adenophostin A. This loss 
in activity was paralleled by the activity of analogue 156, which exhibited >3000-fold 
decrease in affinity for the Ins(l,4,5)P3 receptor compared with adenophostin A. Thus it 
may be concluded that the mobility of analogue 156, resulting from the loss of C-2' of 
the ribose ring, in conjunction with the loss of the 2'-phosphate further decreases the 
ability of 156 to bind to the Ins(l,4,5)P3 receptor.
Analogue 154 was found to be 100-fold weaker than Ins(l,4,5)P3 in both Ca2+ 
release and binding to the receptor. This was surprising since it does not possess a 
vicinal bisphosphate. The most probable explanation for the activity of this analogue 
was that a protecting group migrated during a prephosphorylation stage of its synthesis. 
<1% Contamination of 154 with adenophostin would account for its observed activity.
The analogue named acyclophostin exhibited unusual activity. It bound to 
hepatic membranes with appreciably higher affinity than Ins(l,4,5)P3, yet it was 
marginally less potent in causing Ca2+ mobilisation. All the other analogues investigated 
along with acyclophostin had similar ECso/^d ratios, whereas the ratio for acyclophostin 
was significantly higher. Such characteristics led to the suggestion that acyclophostin 
was a partial agonist. Further investigation demonstrated that acyclophostin was in fact a 
pH dependent partial agonist, it was found to be a partial agonist at high pH (8.3) and a 
full agonist at pH 7. It was speculated that the pH dependent efficacy of acyclophostin 
was either the result of a conformational change related to the pKa of the 2'-phosphate
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and the lack of conformational restriction from a furanoside ring, or that acyclophostin 
may differ from Ins(l,4,5)P3 in the residues involved in its binding and Ca2+ release at 
the Ins(l,4,5)P3 receptor.
6.1.2 An investigation into the solution conformation of adenophostin A
Using a combination of molecular mechanics calculations and NMR Hotoda et 
al. have suggested a putative conformation for adenophostin A at the Ins(l,4,5)P3 
receptor binding site. Their suggested conformation accounts for NOE data observed 
between H-8 and H-l', and between H-8 and H-2'. They propose that their model 
indicates the possibility that the relative position of the 2-phosphate group of 
adenophostin A is optimal for the recognition by the Ins(l,4,5)P3 receptor. They found 
that the ribose ring of adenophostin A prefers the C2'-endo form, while the ribose ring of 
ribophostin gave the C3'-endo form. The Cl'-endo form results in a more extended 
conformation for adenophostin A, and a greater distance between the bisphosphate and 
the single phosphate on the ribose ring compared with ribophostin. Furthermore the N- 
glycosyl linkage was found to be in the syn orientation.
These findings are consistent with the results of the work in this thesis; i.e. that 
the adenine of adenophostin A induces a conformation in the molecule that results in 
optimal binding at the Ins(l,4,5)P3 receptor, and/or the adenine moiety directly interacts 
with the Ins(l,4,5)P3 receptor in close vicinity to the Ins(l,4,5)P3 binding pocket.
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6.2 Summary of the work in this thesis
6.2.1 Synthetic work
An efficient route to the synthesis of adenophostin A has been devised and 
completed. The regioselective protection of adenosine to give 5 -O-benzyl-JV6- 
dimethoxytrityl-2-O-p-methoxybenzyl adenosine (40) included a new selective 
dimethoxytritylation of the adenine N6 position and a key regioselective reduction of a p- 
methoxybenzylidene acetal. Glycosidation of 40 with a fully protected glucosyl 
phosphite followed by cleavage of all the acid sensitive groups gave the desired triol 
ready for phosphitylation. Phosphitylation was achieved in the presence of a free Im­
position by a recently reported method involving imidazolium triflate. The resulting 
trisphosphite was oxidised to the trisphosphate with MCPBA and final debenzylation 
was accomplished by catalytic hydrogenation to give adenophostin A. The synthesis of 
two sugar modified analogues, mannophostin and xylophostin, was achieved using the 
preceding strategy and glycosidation with either a mannose or xylose phosphite.
A concise route to the minimal structure analogue ribophostin, was devised and 
completed using trichloroacetimidate glycosidation methodology. While the synthesis of 
another minimal structure analogue was achieved using phosphite glycosidation 
methodology.
An efficient route to the synthesis of a versatile disaccharide intermediate (124) 
from a regioselectively protected ribofuranose glycosyl acceptor and a glucosyl 
phosphite donor and was completed. Vorbriiggen condensation of this intermediate with 
purine and imidazole led to the synthesis of two base modified analogues of 
adenophostin A, purinophostin and imidophostin.
6.2.2 Structure-activity relationship work
Along with the synthesis of adenophostin A, the syntheses of six adenophostin A 
analogues have been presented in this thesis. Their biological evaluation in direct 
comparison with our synthetic adenophostin A and Ins(l,4,5)P3 has allowed several 
important conclusions to be drawn concerning the structure-activity relationships of 
adenophostin A at the Ins(l,4,5)P3 receptor. These are summarised in Figure 6.2.
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Figure 6.2: The properties of some of the structural features o f adenophostin A involved 
in activity at the Ins(l,4,5)P3 receptor.
From the structure-activity information in Figure 6.2 it is possible to propose a 
binding model for adenophostin A at the Ins(l,4,5)P3 receptor. The 3",4"-bisphosphate, 
adjacent equatorial 2"-hydroxyl, and well positioned accessory 2-phosphate of 
adenophostin A comprise the basic structural motif that elicits similar activity to that of 
Ins(l,4,5)P3, and thus probably binds in a similar way to the analogous motif of 
Ins(l,4,5)P3. But for activity to approach that of adenophostin A the adenine base (or a 
similar structure) is vital. The interaction of this adenine base with the Ins(l,4,5)P3 
receptor is most likely a hydrophobic one, and probably has two main functions, either to 
optimise the conformation of adenophostin A at the Ins(l,4,5)P3 receptor, and/or a direct 
interaction with nearby residues of the Ins(l,4,5)P3 receptor to improve binding.
By taking into account the recent reports in the literature for adenophostin A 
analogues, and combining these with the conclusions from section 6.2 it was possible to 
further summarise some of the features of the structure of adenophostin A responsible for
6.3 Overall summary of the structure-activity 
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Figure 6.3: Summary of the structure-activity relationships of adenophostin A at the 
Ins(l,4,5)P3 receptor.
6.4 Future directions
We now have a better understanding of the structural features of adenophostin A 
that contribute to its exceptional activity, but an extension of this work in an effort to 
refine these ideas is desirable. Further investigation into the properties of the base 
moiety that are required for adenophostin A-like activity, using base modified analogues 
derived from the versatile disaccharide intermediate 124 would lead to a better 
understanding of the effect of the base moiety on binding interactions. In particular the 
investigation of conformational restriction about the nucleosidic bond would be 
interesting. Such an understanding, could then lead to a more informed approach to the 
design of analogues modified at the glucose portion of the adenophostin A structure, and 








7 Experimental and References 
Experimental
7.1 General information
Thin layer chromatography (TLC) was performed on percolated plates (Merck 
TLC aluminium sheet silica 60 F2 5 4 A1I: no.5554); the compounds were detected by 
dipping in phosphomolybdic acid in ethanol followed by heating. Flash chromatography 
refers to the procedure developed by Still et al.,2U and was carried out using Sorbsil C60 
silica gel.
!H and 13C NMR were recorded on either JEOL GX270 or EX 400 or Varian
Mercury 400 spectrometers. Chemical shifts were measured in part per million (ppm)
1relative to internal tetramethylsilane or D2O. P NMR spectra were also recorded on 
JEOL GX270 or 400 spectrometers and 31P NMR NMR chemical shifts were measured 
in ppm relative to external 85% H3 PO4 . J  values are given in Hz and the following 
abbreviation are used: s, singlet; d, doublet; dd, doublet of doublets*; ddd, doublet of 
doublet of doublets*; t, triplet; q, quartet; m, multiplet; br, broad; exch., exchanged with. 
Proton assignments were established with 2D COSY experiments, and the number of 
protons attached to carbon atoms was established by DEPT experiments.
Melting points were determined using a Reichert-Jung Therm Galen Kofler block 
and are uncorrected.
Microanalysis was carried out at the University of Bath Microanalysis Service.
Low resolution mass spectra were recorded at the University of Bath Mass 
Spectrometry Service using +ve and -ve fast atom bombardment (FAB) with m- 
nitrobenzyl alcohol as the matrix. High resolution accurate mass spectra were recorded 
at the University of Bath Mass Spectrometry Service.




Optical rotations were measured at ambient temperature using an Optical Activity
Ltd AA-10 polarimeter in a cell volume of 1cm3 or 5cm3 and specific rotation are given 
1 ^ 1in 10' deg cm g" . Ion exchange chromatography was performed on an LKB-Pharmacia 
Medium Pressure Ion-Exchange Chromatograph using either Sepharose Q fast flow resin 
and gradients of triethylammonium bicarbonate as eluent, or MP1 AG ion exchange resin 
and a gradient of 150mM TFA as eluent.
HPLC analysis was carried out on a Dynamax model SD-200 with reverse phase 
column: APEX ODS II 5// S/N 7121103. A gradient of 0.05M phosphate buffer 
containing 0 .1% tetrabutylammoniumhydrogen sulphate, and acetonitrile was used as 
eluent at 1.5mL/min, with a UV detector set at 259 nm.
Synthetic phosphates were assayed by adaptations of the Briggs phosphate test179 
as follows. For the qualitative test, 200mm3 aliquots of the ion exchange column 
fractions were pipetted into a test tube and the solutions were evaporated to dryness at 
200°C. For drops of concentrated sulphuric acid were added to each tube, which was 
then heated in an oven at 200°C for 90min. The tubes were cooled to room temperature 
(rt), and water (250mm ) was added with shaking to dissolve. To each tube were added 
500mm3 of a solution of ammonium molybdate (2.5g) in water (20 cm3) and 
concentrated sulphuric acid (8 cm3), followed by 250mm3 of a solution of quinol 
(lOOmg) in water (20cm3) and one drop of concentrated sulphuric acid, then finally 
250cm3 of a solution of sodium sulphite (4g) in water (20cm3). Each tube was heated at 
the boiling point (bp) of the mixture for 10 s. A blue colour indicated the presence of 
inorganic phosphate.
For the quantitative assay the mixtures treated as above were transferred to 
volumetric flasks and made up to 10cm with water. The UV absorbances at 340nm 
were recorded using 3cm quartz cells. Concentration was calculated from a standard 
curve compiled from UV absorbance values of known concentrations of KH2 PO4  treated 
as above and measured at 340nm.
Chemicals were purchased from Aldrich, Fluka, Lancaster and Sigma chemical 
companies.
Acetonitrile and DCM were distilled over calcium hydride and stored over 4A 
molecular sieves. A^V-dimethylformamide (DMF) was dried over barium oxide, distilled 
under reduced pressure and stored over 4A molecular sieves. Pyridine was dried over 
potassium hydroxide pellets, distilled and then stored over potassium hydroxide pellets.
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Tetrahydrofuran (THF) was dried by passing through activated alumina to expel 
peroxide radicals followed by distillation from sodium in the presence of benzophenone 




7.2 Synthesis of adenophostin
7.2.1 2-O-p-Methoxybenzyl adenosine (30)
To a suspension of dry adenosine (10.02g, 0.038mol) in dry DMF (300cm3) was 
added sodium hydride (1.95g of a 60%w/w dispersion in mineral oil, 0.049mol). This 
suspension was stirred at room temperature for 45 min, after which time p- 
methoxybenzyl chloride (6.23cm , 0.045mol) was added over 60 min. Stirring continued 
for 48 h, when TLC (DCM/methanol 9:1) indicated no further conversion of starting 
material (Rf 0.11) to product (Rf 0.26). Water (40cm3) was added, and stirring was 
continued for 10 min. The resulting yellow solution was concentrated to an oil and 
subjected to flash chromatography, (being preadsorbed to silica, for application to the 
column; eluent ethyl acetate then ethyl acetate/ethanol 4:1). To give crude product. 
Crystallisation from ethanol/water gave pure title compound (4.67g, 32%). 
mp 153°C ( water/ethanol) (lit.123155-156°C); *H NMR (400 MHz; d* DMSO) Sn 3.55 
(1H, m, H-5 A), 3.65 (1H, m, H-5B), 3.67 (3H, s, OCH3), 4.02 (1H, m, H-4 ), 4.33 (1H, 
dd, obscured by OCH2Ar, H-3), 4.35, 4.56 (2H, AB, 7ab 11.7, OCtf2Ar), 4.52 (1H, dd, J
5.7, J  5.6, H-2), 5.32 (1H, d, J  5.4, D20  exch., 3-OH), 5.51 (1H, t, 76.8, D20  exch., 5- 
OH), 6.02 (1H, d, 76.3, H -l), 6.70 (2H, m, H-3 and H-5 of PMB ring), 7.04 (2H, m, H-2 
and H-6 of PMB ring), 7.36 (2H, s, D20  exch., NH2), 8.07, 8.30 (2H, 2s, H-2, H-8); 13C 
NMR (100.4 MHz; <k DMSO) 5C 54.95 (q, OC/73), 61.56 (t, C-5), 68.98 (d, C-3), 70.72 
(t, OCH2Ar), 79.73 (d, C-2'), 86.30(d, C-4), 86.65(d, C -l), 113.33 (d, C-3 and C-5 of 
PMB ring), 119.40 (s, C-5), 129.06 (d, C-2 and C-6 of PMB ring), 129.62 (s, C-l of 
PMB ring), 139.74 (d, C-8), 148.83 (s, C-4), 152.30 (d, C-2), 156.14 (s, C-6), 158.67 (s, 
C-4 of PMB ring).
7.2.2 A/^Benzoyl^’-O-p-methoxybenzyl adenosine (31)
To a solution of 30 (1.15g, 2.97mmol) in dry pyridine (15cm ) was added 
benzoyl chloride (1.85cm , 15.76mmol). The resultant rose-coloured solution was
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stirred at 0°C for 3 h, when TLC (ethyl acetate) indicated conversion to an intermediate 
(Rf 0.71). The reaction was quenched with iced water (20cm ) and extracted with DCM 
(3 x 50cm ). The combined organic extracts were washed with 50cm each of water and 
saturated aqueous NaHCC>3 solution, dried (MgSC>4), filtered and concentrated. The 
resulting yellow solid was redissolved in ethanol (30cm3) and pyridine (20cm3), and this
7
solution was treated with a mixture of 1M aqueous NaOH solution (40cm ) and ethanol 
(20cm3). The mixture was stirred for 3 min at room temperature and was then 
concentrated. Methanol (200cm ) was added to the remaining solid, and carbon dioxide 
was bubbled through this solution, whereupon a white precipitate formed. The solvent
7
was evaporated in vacuo, water was added (100cm ) and evaporated in vacuo. The 
resulting solid was extracted with DCM (3 x 100cm ). The organic extracts were filtered 
and concentrated. Crystallisation from hot methanol gave the title compound (0.96g, 
66%).
mp 156°C (methanol) (lit.123 186-187°C); 'H NMR (400 MHz; d« DMSO) 4  3.56-3.72 
(2H, m, H-5 A, H-5'b), 3.68 (3H, s, OCH3), 4.05 (1H, ddd, J  3.7 Hz, 7.1, H-4), 4.39 (1H, 
dd, J4 .9 , 8.3, H-3 ), 4.44, 4.63 (2H, AB, 11.7, OC/fcAr), 4.60 (1H, dd, obscured by 
OCtf2Ar, H-2 ), 5.20 (1H, t, J  5.6, D20  exch., 5 -OH), 5.39 (1H, d, J  5.4, D20  exch., 3'- 
OH), 6.19 (1H, d, J 6 .4 , H -l), 6.75 (2H, m, H-3 and H-5 of PMB ring), 7.10 (2H, m, H-2 
and H-6 of PMB ring), 7.56 (2H, m, H-3 and H-5 of Bz ring), 7.65 (1 H, m, H-4 of Bz 
ring), 8.06 (2H, m, H-2 and H-6 of Bz ring), 8.67, 8.71 (2H, 2s, H-2 and H-8), 11.23 
(1H, br. s, D20  exch., flNC=0); 13C NMR (100.4 MHz; d« DMSO) Sc 54.97 (q, OCH3),
61.21 (t, C-5 ), 68.83 (d, C-3 ), 70.85 (t, OCH2Ar), 79.92 (d, C-2 ), 86.08 (d, C-4 ), 86.46 
(d, C-l ), 113.44 (d, C-3 and C-5 of PMB ring), 125 84 (s, C-5), 128.51 (d, C-2 and C-6 
of PMB ring), 129.13 (d, C-3, C-4 and C-5 of Bz ring), 129.62 (s, C-l of PMB ring),
132.49 (d, C-2 and C-6 of Bz ring), 133.37 (s, C-l of Bz ring), 143.01 (d, C-8), 150.44 
(s, C-4), 151.51 (d, C-2), 151.90 (s, C-6), 158.70 (s, C-4 of PMB ring), 165.67 (s, 
COPh).




31 (0.78g, 1.60mmol) In DMF (15cm3) was cooled to -5°C and sodium hydride 
(0.08g of a 60%w/w dispersion in mineral oil, 1.91 mmol) was added. After stirring for 50 
min at -5°C, benzyl bromide was added dropwise. The reaction mixture was left stirring 
at -5°C for a further 6.5 h before being quenched with water (10cm3). Concentration of 
the reaction mixture gave a yellow oil which was preadsorbed to silica and then 
subjected to flash chromatography (eluent ethyl acetate/hexane 1:1, then 4:1, then ethyl 
acetate/ethanol 9:1) to yield a minor product 33 (0.21g, 30%), and a major product 34 
(0.6 lg, 66%).
Data for 33 which was tentatively identified as A^-benzoyl-V1-benzyl-2-0-p-
methoxybenzyl adenosine : Rf 0.34 (ethyl acetate); (Found: (M+H)+, 582.236. Calc for 
C32H31N5O6 [M+H]+: 582.235); *H NMR (400 MHz; d* DMSO) Sn 3.50, 3.58 (2H, m, 
simplifies to ABX on D2O exch., 2Jab 12.2, V ax  = 3J b x  3.7, H-5'a, H-5'b), 3.64 (3H, s, 
OCH3), 3.98 (1H, m, H-4'), 4.24-4.26 (2H, m, H-3’, OC£/HAr), 4.40-4.47 (2H, m, H-2', 
OCH/fAr), 5.07 (1H, dd, J  5.4, D20  exch., 5’-OH), 5.33 (1H, d, J  5.4, D20  exch., 3'- 
OH), 5.50 (2H, s, NCi/2Ar), 6.05 (1H, d, J5.9, H-l'), 6.67 (2H, m, H-3 and H-5 of PMB
ring), 6.98 (2H, m, H-2 and H-6 of PMB ring), 7.16-7.43 (10H, m, ArCH), 8.54 (2H, s,
H-2, H-8); 13C NMR (100.4 MHz; CDC13) & 51.29 (t, NCH2Ar), 55.05 (q, OCH3), 62.92 
(t, C-5'), 70.45 (d, C-3’), 70.45 (d, C-3’), 72.52 (t, OCH2Ar), 78.90 (d, C-2’), 87.72 (d, C- 
4'), 89.03 (d, C-l'), 113.61 (d, C-3 and C-5 of PMB ring), 127.18, 127.36, 127.80,
128.01, 128.28, 128.65, 129.45, 130.89 (8d and 2s, ArCH, C-l of PMB ring, C-5), 
135.83 (s, C-l of Bz ring), 137.35 (s, C-l of Bn ring), 143.14 (d, C-8), 150.90 (d and s, 
C-2 and C-4), 154.69 (s, C-6), 159.42 (s, C-4 of PMB ring), 172.13 (s, COPh); UV 
(CHCI3) Xmax 254 nm; m/z (FAB+) 582 [(M+l)+, 100%].
Data for 34 which was tentatively identified as A/6-benzoyl-A/6-benzyl-2-O-/?-
methoxybenzyl adenosine: Rf 0.15 (ethyl acetate); (Found: (M+H)+, 582.236. Calc for 
C32H3iN50 6 [M+H]+: 582.235); *H NMR (400 MHz; de DMSO) Sn 3.51, 3.58 (2H, m, 
simplifies to ABX on D2O exch., 2Jab, 12.2, 3Jax 3.9, 3Jbx 3.7, H-5'a, H-5’b), 3.64 (3H, s, 
OCH3), 3.97-3.99 (1H, m, H-4'), 4.25-4.27 (1H, m, H-3'), 4.32-4.37 (2H, m, H-2’, 
OCtfHAr), 4.55 (1H, AB, Jab 11.9, OCHtfAr), 5.04 (1H, dd, J5 .9 , D20  exch., 5'-OH),
5.32 (1H, d, J5 .4  D20  exch., 3'-OH), 5.31, 5.35 (2H, AB Jab 15.0, NC//2Ar), 5.90 (1H, 
d, J6.1, H-l'), 6.69-6.71 (2H, m, H-3 and H-5 of PMB ring), 7.01-7.04 (2H, H-2 and H- 
6 of PMB ring), 7.23-7.46 (8H, m, ArCH), 7.58-7.60 (2H, m, ArCH), 8.04, 8.56 (2H,
137
Chapter seven
2s, H-2, H-8); 13C NMR (100.4 MHz; CDC13) Sc 52.05 (t, NCH2Ar), 55.41 (q, OCH3), 
62.89 (t, C-5'), 70.12 (d, C-3'), 72.53 (t, OCH2Ar), 79.52 (d, C-2'), 87.47 (d, C-4'), 88.72 
(d, C-l'), 113.92 (d, C-3 and C-5 of PMB ring), 123.65 (s, C-5), 128.02, 128.33, 128.47,
129.02, 129.63, 129.79, 132.00 (7d and s, ArCH and C-l of PMB ring), 134.97, 135.41 
(2s, C-l of Bz ring, C-l of Bn ring), 139.92 (d, C-8), 143.45, 145.79 (2s, C-4, C-6), 
146.58 (d, C-2), 159.62 (s, C-4 of PMB ring), 176.99 (s, COPh); UV (CHC13) Xmax 284 
nm, 257 nm; m/z (FAB+) 582 [(M+l)+, 100%].
7.2.4 A^-Benzoyl^'-O-p-methoxybenzyl-S -O-monomethoxytrityl 
adenosine (35)
31 (1.56g, 3.18mmol) Was concentrated repeatedly (four times) from dry 
pyridine (10cm3) and redissolved in dry pyridine (25cm3). Monomethoxytrityl chloride 
(1.47g, 4.77mmol), and diisopropylamine (2.22cm , 12.71 mmol) were added to this 
solution, and stirring was continued overnight at 50°C, after which time TLC (ethyl 
acetate/ethanol 20:1) indicated no further conversion of starting material to product (Rf 
0.65). 20cm3 Each of 5% aqueous NaHC03 solution and methanol were added to 
quench the reaction. The aqueous layer was extracted with DCM (3 x 75cm ) and the 
organic layers were combined and concentrated to a dark yellow oil. This oil was 
subjected to flash chromatography (eluent ethyl acetate/hexane 4:1) to give the title 
compound as a clear yellow oil (2.29g, 94%).
[a h  +1-57 (c 5.1, CHCU); (Found: (M+H)+, 764.310. Calc for C45H42N5O7 (M+H)+: 
764.308); 'H NMR (400 MHz; d<; DMSO) 3.26 (2H, d, 74.4, H-5A, H-5'B), 3.69, 3.73 
(6H, 2s, 2 x OCH3), 4.17 (1 H, ddd, 7 4 .6,9.0, H-4 ), 4.47-4.52 (2H, m, H-3', OCHHAr),
4.66 (1H, AB, 711.7, OCHHAr), 4.73 (1H, dd,75.1, 5.1, H-2), 5.40 (1H, d, 75.9, D20  
exch., 3 -OH), 6.21 (1H, d, 7  4.9, H-l ), 6.76-6.78 (2H, m, H-3 and H-5 of p-OCH3 
phenyl ring), 6.84-6.87 (2H, m, H-3 and H-5 of/?-OCH3 phenyl ring), 7.13-7.37 (14H, 
m, ArCH), 7.53-7.57 (2H, m, H-3 and H-5 of Bz ring), 7.63-7.67 (1H, m, H-l of Bz 
ring), 8.06 (2H, m, H-2 and H-6 of Bz ring), 8.53, 8.60 (2H, 2s, H-2 and H-8), 11.22 
(1H, br. s, D20  exch., 77NC=0); 13C NMR (100.4 MHz; d* DMSO) Sc 54.95, 55.01 (2q, 
OCH3), 63.55 (t, C-5 ), 69.09 (d, C-3 ), 71.01 (t, OC/J2Ar), 79.08 (d, C-2 ), 83.87 (d, C-
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4), 85.77 (s, MMTr Cq), 86.44 (d, C-l ), 113.16, 113.46 (2d, C-3 and C-5 of/?-OCH3 
phenyl rings), 125.87 (s, C-5), 126.84, 127.81, 127.92, 128.45, 128.49, 129.18 (6d, 
ArCH), 129.62 (s, C-l of PMB ring), 130.01, 132.44 (2d, ArCH), 133.34 (s, C-l of Bz 
ring), 134.87 (s, C-l of MMTr /?-OCH3 phenyl ring), 143.25 (d, C-8), 144.09, 144.25 (2s, 
2 x C-l of MMTr phenyl rings), 150.40 (s, C-4), 151.51 (d, C-2), 151.86 (s, C-6), 
158.15, 158.74 (2s, C-4 of p-OCH3 phenyl rings), 165.61 (s, COPh); m/z (FAB+) 764 
[(M+H)+, 20%], 273 (100).
7.2.5 2,3-O-Benzylidene adenosine (159)
Method A
A suspension of zinc chloride (7.00g, 50mmol) in benzaldehyde (35cm3) was 
stirred at 5°C for 30 min. Adenosine (2.50g, 9.00mmol) was added and the mixture was 
stirred in the dark for 7 days at 5°C. The resulting viscous cream-coloured suspension 
was poured into 500cm3 of chilled water and this mixture was extracted with ethyl 
acetate (3 x 200cm3). The combined organic extracts were dried (MgS04), filtered and 
concentrated. Diisopropyl ether (50cm3) was added to this mixture of product and 
benzaldehyde which was then refrigerated overnight. The product was collected by 
filtration to give the endo isomer (3.07g, 92%).
*H NMR (270 MHz; d* DMSO) <5k 3.52-3.63 (2H, m, H-5'A, H-5'B), 4.37-4.41 (1H, m, 
H-4'), 5.10 (1H, dd, J  2.3, 6.5, H-3'), 5.30 (1H, dd, J  5.4, D20  exch., 5'-OH), 5.52 (1H, 
dd, J  2.8, 6.5, H-2'), 6.03 (1H, s, benzylidene CH), 6.31 (1H, d, 72.9, H-l'), 7.41-7.60 
(5H, m, ArCH), 8.18-8.40 (2H, 2s, H-2, H-8).
Method B
A suspension of zinc chloride (7.00g, 50mmol) in benzaldehyde (35cm3) was 
stirred at 5°C for 30 min, before adding adenosine (2.50g, 9.00mmol). This mixture was 
stirred for 16 h in the dark and then for 1 h at 100°C. An identical work-up to Method A 
gave 2.10g (63%) of the title compound which was shown by !H NMR to be a 2:3 ratio 
of endo : exo diastereoisomers.
*H NMR (270 MHz; 6* DMSO) Sn 3.57-3.63 (2H, m, H-5'A, H-5'B), 4.30-4.32 (0.6H, m, 
H-4'exo), 4.39-4.40 (0.4H, m, H-4'emto), 5.09-5.12 (1H, m, H-3'), 5.19 (0.6H, dd, J  5.4,
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D2O exch., S'-OH^o), 5.31 (0.4H, dd, J 5.4, D2O exch., 5-OHem/0), 5.48-5.53 (1H, m, H- 
2'), 6.03 (0.4H, s, benzylidene CHend0), 6.26 (0.6H, s, benzylidene CHexo), 6.30-6.31 (1H, 
m, H-l), 7.42-7.56 (5H, m, ArCH), 8.19, 8.40 (2H, 2s, H-2, H-8).
7.2.6 2',3-O-p-Methoxybenzylidene adenosine (36)
Method A
A suspension of zinc chloride (70g, 0.50mol) in /7-methoxybenzaldehyde 
(350cm3) was stirred for 30 min. Adenosine (25.0g, 0.09mol) was added and the mixture 
was stirred for 18 h. The resulting viscous cream-coloured suspension was divided into 
two. Each half was poured into 400cm3 of chilled water and this mixture was extracted 
with chloroform (400cm , 300cm , 200cm ). The combined organic extracts were 
washed with water (300cm3), dried (MgSCU), filtered and concentrated. The suspensions 
from each half, containing product and p-methoxybenzaldehyde, were recombined and 
left at 4°C overnight. Precipitated product was recovered by filtration (13.8g, endo 
isomer by !H NMR), and remaining product left in the /7-methoxybenzaldehyde filtrate 
was precipitated by addition of diisopropyl ether (300cm ), and the refrigeration (lO.Og 
mixture of endo and exo isomers, 2:1 endo : exo, as indicated by the integrals of the p- 
methoxybenzylidene CHs in the ]H NMR). Combined yield (23.80g, 66%).
Rf 0.26 (ethyl acetate/ethanol, 9:1)
Data for endo diastereoisomer: mp 215-217°C (ethanol) (lit.133 198-200°C); (Found: C, 
55.90; H, 4.87; N 18.10. Calc for CigH^NjOs: C, 56.08; H, 4.97; N, 18.18%); !H NMR 
(400 MHz; cU DMSO) Sn 3.65-3.63 (2H, m which simplifies on D2O exch., H-5 a, H- 
5 b ) ,  3.77 (3H, s, OCH3), 4.35^1.39 (1H, m, H-4 ), 5.06 (1H, dd, J  2.2, 6 .6, H-3 ), 5.28 
(1H, t, J  5.4, D20  exch., 5-OH), 5.47 (1H, dd, J  2.9, 6.3, H-2 ), 5.96 (1H, s, p- 
methoxybenzylidene CH), 6.30 (1H, d, J  2.9, H-l ), 6.99 (2H, m, H-3 and H-5 of p- 
methoxybenzylidene phenyl ring), 7.38 (2H, s, D2O exch., NH2), 7.50 (2H, m, H-2 and 
H-6 ofp-methoxybenzylidene phenyl ring), 8.17, 8.38 (2H, 2s, H-2 and H-8); 13C NMR 
(100.4 MHz; d* DMSO) Sc 55.83 (q, OCH3), 62.05 (t, C-5 ), 83.12 (d, C-3'), 84.32 (d, C-
2 ), 86.79 (d, C-4), 90.30 (d, C-l'), 107.29 (d,/7-methoxybenzylidene CH), 114.44 (d, C-
3 and C-5 of/?-methoxybenzylidene phenyl ring), 119.38 (s, C-5), 128.44 (s, C-l of p- 
methoxybenzylidene phenyl ring), 129.24 (d, C-2 and C-6 of p-methoxybenzylidene
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phenyl ring), 140.67 (d, C-8), 149.34 (s, C-4), 153.36 (d, C-2), 156.36 (s, C-6), 161.02 
(s, C-4 of £>-methoxybenzylidene phenyl ring); m/z (FAB*) 386 [(M+l)+, 100%].
Method B
A mixture of p-methoxybenzaldehyde (400cm), adenosine (20.0g, 0.07mol), 
triethyl orthoformate (100cm3) and dry /?TSA (40.3g, 0.26mol) was stirred at 35-40°C 
for 4 h, after which time the resulting purple solution was poured into 0.3M aqueous 
NaHC03 solution (1000cm3) and stirred vigorously for 15 min. Ethyl acetate (300cm3) 
was added and the resulting organic layer was set aside. The aqueous layer was 
extracted with more ethyl acetate (300cm3) and the combined organic layers were 
washed with brine (200cm ), dried (MgS04), filtered and concentrated. Diisopropyl 
ether (400cm ) was added and the suspension was kept at 4°C for 48 h. The product was 
isolated as a white powder (26.01g as a mixture of endo and exo isomers, 2:3 endo : exo, 
by JH NMR, 90%).
Data for mixture of diastereoisomers: !H NMR (400 MHz; d$ DMSO) Sh 3.57-3.62 (2H, 
m, H-5 a, H-5 B), 3.77 (1.8H, s, OCH3ew), 3.79 (1.2H, s, OCH3endoX 4.26-4.31 (0.6H, m, 
H-4'exo), 4.37-4.40 (0.4 H, m, H-4'endo\  5.05-5.10 (1H, m, H-3 ), 5.16 (0.6H, t, J  5.6, 
D2O exch., 5 -OHeco), 5.29 (0.4H, t, 7  5.6, D2O exch., 5 -OH^o), 5.45-5.49 (1H, m, H-
2 ), 5.97 (0.4H, s ,/7-methoxybenzyhdene CHend0), 6.19 (0.6H, s,/?-methoxybenzylidene 
Gtfexo), 6.28 (0.6H, d, 72.9, H -l’«,), 6.30 (0.4H, d, 72.9, H - l '^ ) ,  6.95-7.02 (2H, m, H-
3 and H-5 of /?-methoxybenzylidene phenyl ring), 7.39-7.52 (4H, m, H-2 and H-6 of p- 
methoxybenzylidene ring, D2O exch., NH2), 8.18, 8.39 (2H, 2s, H-2, H-8); 13C NMR 
(100.4 MHz; d<> DMSO) Sc 55.21 (q, OCH3), 61.57 (t, C-5'), 80.47, 82.81, 84.45 (3d, C- 
4', C-3', C-2’ all exo\ 82.59, 83.67, 86.30 (3d, C-4', C-3’, C-2' all endo), 87.98 (d, C- 
1 exo), 89.55 (d, C-1 endo), 102.87 (d, p-methoxybenzylidene CH^), 106.56 (d, p- 
methoxybenzylidene CHe„^ 0), 113.66 (d, C-3 and C-5 of p-methoxybenzylidene phenyl 
ringexo), 113.79 (d, C-3 and C-5 of/?-methoxybenzylidene phenyl ringed), 119.14 (s, C-
5), 128.07 (s, C-l o f/7-methoxybenzylidene phenyl ring), 128.51, (d, C-2 and C-6 o fp- 
methoxybenzylidene phenyl ring), 139.72 (d, C-8ex0), 139.88 (d, C-8em/0), 148.81 (s, C- 
4), 152.68 (d, C-2), 156.18 (s, C-6), 160.26 (s, C-4 of p-methoxybenzylidene phenyl 
ringexo), 160.38 (s, C-4 of/?-methoxybenzylidene phenyl ringed).
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7.2.7 A^-Dimethoxytrityl^^-O-p-methoxybenzylidene adenosine (37)
36 (3.83g, 8.78mmol) Was repeatedly concentrated from dry pyridine (3 x 
20cm), and resuspended in dry pyridine (50cm). After addition of 
chlorotrimethylsilane (2.79cm , 21.95mmol) the starting material dissolved. Stirring was 
continued for 2 h before dimethoxytrityl chloride (7.83g, 21.95mmol) was added. The 
resultant orange mixture was stirred overnight. The mixture was cooled to 0°C and the 
reaction was quenched by addition of water (5cm ). The cooling bath was removed and 
after 10 min concentrated aqueous ammonia (20cm ) was added. Stirring was continued 
for a further 30 min, then the solution was partitioned between 5% aqueous NaHCC>3 
solution (150cm3) and DCM (150cm3). The aqueous layer was extracted with DCM (2 x 
50cm3) and the combined organic layers were dried (MgS04), filtered and concentrated 
to leave a dark orange oil that was subjected to flash chromatography (eluent ethyl 
acetate/hexane 3:2) to give the title compound as a pale cream foam (6.60g, 97%).
Rf 0.29 (ethyl acetate/hexane 3:2)
Data for endo diastereoisomer: (Found: M*, 687.267. Calc for C39H37N5O7 M+: 687.269); 
*H NMR (400 MHz; de DMSO) Sn 3.49-3.61 (2H, m, H-5A, H-5B), 3.71 (6H, s, 2 x 
OCH3 of DMTr), 3.78 (3H, s, OCH3 of p-methoxybenzylidene), 4.35-4.39 (1H, m, H- 
4 ), 5.03 (1H, dd, J  2.3, 6.5, H-3 ), 5.22 (1H, t, J  6.6, D20  exch., 5 -OH), 5.48 (1H, dd, J
2.8, 6.5, H-2), 5.95 (1H, s, p-methoxybenzylidene CH), 6.30 (1H, d, J  2.8, H-l'), 
6.82-6.86 (4H, m, ArCH), 6.98-7.01 (2H, m, ArCH), 7.19-7.29 (9H, m, ArCH), 7.48 
(1H, br. s, D20  exch., NH), 7.51-7.96 (2H, m, ArCH), 8.32, 8.48 (2H, 2s, H-2, H-8); 13C 
NMR (100.4 MHz; de DMSO) Sc 55.36 (q, 2 x OCH3), 55.58 (q, OCH3), 61.76 (t, C-5 ),
69.93 (s, DMTr Cq), 82.84, 84.01, 86.70 (3d, C-4’, C-3', C-2 ), 90.01 (d, C-l ), 106.95 (d, 
/ 7-methoxybenzylidene CH), 113.35, 114.15 (2d, C-3 and C-5 of /7-OCH3 phenyl rings),
120.97 (s, C-5), 126.86, 128.07,128.34,128.71, 128.91, 130.12 (5d, ArCH, and s, C-l of 
p-methoxybenzylidene phenyl ring), 137.52 (s, C-l of DMTr J9-OCH3 phenyl rings), 
140.85 (d, C-8), 145.57 (s, C-l of DMTr phenyl ring), 148.31 (s, C-4), 151.79 (d, C-2),
153.97 (s, C-6), 158.04 (s, C-4 of DMTr /7-OCH3 phenyl rings), 160.75 (s, C-4 of p- 
methoxybenzylidene phenyl ring); m/z (FAB+) 688 [(M+H)+, 26%], 303 (100).
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Data for mixture of diastereoisomers, endo : exo 2:3: 'H NMR (270 MHz; CDCI3) 8h 
3.77-3.84 (1H, m, H-5'a«*, H -5'a^ *), 3.77 (6H, s, 2 x OCH3 of DMTr), 3.80 (3H, s, 
OCH3 ofp-methoxybenzylidene), 3.94-4.00 (1H, m, H-5 b ) ,  4.53 (0.4H, m, H-4e ^ ) ,  4.68 
(0.6H, m, H-4'endo\  5.16-5.18 (1H, m, H-3 ), 5.26-5.35 (1H, m, H-2 ), 5.98 (0.4H, d, J  
4.95, H-l endo), 6.00-6.02 (1H, m, jp-methoxybenzylidene CHend0i H-l ^o), 6.25 (0.6H, s, 
/7-methoxybenzylidene CHexo), 6.77-7.02 (7H, m, ArCH), 7.21-7.50 (10H, m, ArCH), 
7.76, 7.83 (1H, 2s, H-2 or H-8), 8.01, 8.02 (1H, 2s, H-2 or H-8); 13C NMR (100.4 MHz; 
CDClj) Sc 55.59 (q, OCH3), 63.41 (t, C-5 '„„), 63.72 (t, C -5 '^ ) , 71.12 (s, DMTr Cq), 
80.52, 84.21, 86.43 (3d, C-2', C-3', C-4' all endo), 83.07, 84.01, 85.91 (3d, C-2', C-3', C- 
4 all exo), 92.26 (d, C -\ex0), 94.47 (d, C-1 endo), 104.93 (d, p-methoxybenzylidene 
CHexo), 107.85 (d,/?-methoxybenzylidene CHe„^ 0), 113.41, 114.15 (2d, C-3 and C-5 ofp- 
OCH3 phenyl rings), 122.43 (s, C-5**,), 122.56 (s, C-5endo\  127.12, 127.97, 128.14, 
128.28, 128.83, 128.93, 130.27 (6d, ArCH, and s, C-l of /?-methoxybenzylidene phenyl 
ring), 137.30 (s, C-l of DMTr p-OCH3 phenyl rings), 139.49, (d, C-8^ )  139.81 (d, C- 
8endo), 145.28 (s, C-l of DMTr phenyl ring), 147.31 (s, C-4endo)> 147.45 (s, C-4ex0), 
152.02 (d, C-2endo\  152.20 (d, C-2**,), 154.73 (s, C-6ex0), 154.76 (s, C-6endo), 158.46 (s, 
C-4 of DMTr /7-OCH3 phenyl rings), 160.79 (s, C-4end0 of /7-methoxybenzylidene phenyl 
ring), 161.00 (s, C - 4 o f  /7-methoxybenzylidene phenyl ring).
7.2.8 S-O-Benzyl-A^-dimethoxytrityl^.S-O-p-methoxybenzylidene 
adenosine (38)
Potassium Hydroxide 85% (14.57g, 220.69mmol) and benzyl chloride (3.05cm3, 
26.48mmol) were consecutively added to 37 (6,06g, 8.83mmol) in benzene (85cm3) and 
dioxane (41cm ). The reaction mixture was refluxed for 20 min, cooled and partitioned 
between ether (200cm3) and iced water (150cm3). The ethereal layer was washed with 
water (2 x 75cm ), and the combined aqueous layers were extracted with ether (100cm ). 
The combined ethereal layers were dried (MgSCU), filtered and concentrated and the 
remaining yellow oil subjected to flash chromatography (eluent ethyl acetate/hexane 1:1) 
to yield the title compound as a pale cream foam (6.53g, 95%).
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Data for endo diastereoisomer: (Found: C, 70.80; H, 5.53; N, 8.85. Calc for C46H43N5O7: 
C, 71.03; H, 5.57; N, 9.00%); ‘H NMR (400 MHz; CDCI3) A  3.68-3.72 (2H, m, H-5'A, 
H-5'b), 3.77 (6H, s, 2 x OCH3 of DMTr), 3.82 (3H, s, OCH3 of /?-methoxybenzylidene), 
4.46, 4.49 (2H, AB, Jab 12.2, OCH2Ai ), 4.65 (1H, ddd, J  2.4, H-4'), 5.04 (1H, dd, 72.4,
6.4, H-3'), 5.51 (1H, dd, J  2.2, 6.6, H-2’), 5.95 (1H, s ,/7-methoxybenzylidene CH), 6.27 
(1H, d, J  2.5, H-l'), 6.78-6.94 (7H, m, ArCH), 7.20-7.48 (15H, m, ArCH), 7.96, 8.05 
(2H, 2s, H-2, H-8); 13C NMR (100.4 MHz; CDCI3) <5fc 55.21 (q, 2 x OCH3), 55.34 (q, 
OCH3), 70.10 (t, C-5 ), 70.64 (s, DMTr Cq), 73.45 (t, OCH2Ar), 82.79, 84.86, 85.57 (3d, 
C-2 , C-3 , C-4 ), 90.89 (C-l ), 107.66, (d,/>-methoxybenzylidene CH), 113.13, 113.89 
(2d, C-3 and C-5 of /7-OCH3 phenyl rings), 121.32 (s, C-5), 126.81, 127.72, 127.78, 
127.89, 128.14, 128.31, 128.47, 128.78, 130.10 (8d, ArCH, and s, C-l of p- 
methoxybenzylidene phenyl ring), 137.31 (s, C-l of Bn ring), 137.45 (s, C-l of DMTr p- 
OCH3 phenyl rings), 138.81 (d, C-8), 145.43 (s, C-l of DMTr phenyl ring), 148.39 (s, C- 
4), 152.47 (d, C-2), 154.15 (s, C-6), 158.26 (s, C-4 of DMTr /?-OCH3 phenyl rings), 
160.88 (s, C-4 of /?-methoxybenzylidene phenyl ring); m/z (FAB+) 688 [(M+H)+, 26%], 
303 (100).
Data for mixture of diastereoisomers, endo : exo 2:3: ]H NMR (400 MHz; CDCI3 ) Sn 
3.67 (0.4H, 0.5 ABX, 27ab 13.9, 37ax 4.2, H-5 Aendo), 3.68-3.72 (1.6H, m, U-5'Aexo, H- 
5’b), 3.77, 3.81, 3.82 (6H, s, 2 x OCH3 of DMTr), 3.81, 3.82 (3H, 2s, OCH3 of p- 
methoxybenzylidene), 4.46 (0.4H, AB, Jab 12.2, OC//HAre„j0), 4.48-4.54 (2.2H, m, 
OCH2Arexo, OCH7/Aremfo, H-4'^), 4.65 (0.4H, ddd, 72.4, H -4 '^ ) , 5.04 (0.4H, dd, 72.4,
6.4, H-3'endo), 5.13 (0.6H, dd, J 3.7, 6.1, H-3'^), 5.45 (0.6H, dd, 72.9, 6.4, H-2'^), 5.51 
(0.4H, dd, 72.2, 6 .6, H-2'em/0), 5.95 (0.4H, s, p-methoxybenzylidene CHend0), 6.13 (0.6H, 
s, p-methoxybenzylidene CHexo), 6.21 (0.6H, d, 72.4, \i-Yexo), 6.27 (0.4H, d, 7, 2.5, H- 
I'endo), 6.78-6.94 (7H, m, ArCH), 7.20-7.48 (15H, m, ArCH), 7.03, 7.95 (1H, 2s, H-2 or 
H-8), 7.96, 8.05 (1H, 2s, H-2 or H-8); 13C NMR (100.4 MHz; CDC13) & 55.21 (q, 2 x 
OCH3), 55.34 (q, OCH3), 70.10 (t, C-5 ), 70.64 (s, DMTr Cq), 73.45 (t, OCH2Ar), 81.33,
84.00, 84.27 (3d, C-2‘, C-3‘, C-4' all exo), 82.79, 84.86, 85.57 (3d, C-2’, C-3', C-4' all 
endo), 89.98 (d, C-l ec„), 90.89 (d, C-l endo\ 104.26 (d, p-methoxybenzylidene CHexo), 
107.66, (d, p-methoxybenzylidene C H ^0),113.13, 113.89 (2d, C-3 and C-5 of /7-OCH3 
phenyl rings), 121.32 (s, C-5), 126.81, 127.72, 127.78, 127.89, 128.14, 128.31, 128.47,
128.78, 130.10 (8d, ArCH, and s, C-l of77-methoxybenzylidene phenyl ring), 137.31 (s,
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C-l of Bn ring), 137.45 (s, C-l of DMTr/?-OCH3 phenyl rings), 138.81 (d, C-8), 145.43 
(s, C-l of DMTr phenyl ring), 148.39 (s, C-4), 152.47 (d, C-2), 154.15 (s, C-6), 158.26 
(s, C-4 of DMTr /7-OCH3 phenyl rings), 160.88 (s, C-4 of p-methoxybenzylidene phenyl 
ring).
7.2.9 S-O-Acetyl-S'-O-benzyl-A^-dimethoxytrityl^'-O-p-methoxybenzyl 
adenosine (42) and 2-O-acetyl-5-O-benzyl-A/0-dimethoxytrityl-3-O-p- 
methoxybenzyl adenosine (41)
38 (l.OOg, 1.29mmol) In DCM (6cm3) was cooled to -78°C and 1M DIBAL-H in 
DCM (6.5cm , 6.50mmol) was added dropwise. The reaction mixture was allowed to 
warm slowly to -25°C over 2 h, after which time TLC (ethyl acetate/pentane 1:1) 
indicated conversion to two close-running products Rf 0.51 (minor product) and 0.39 
(major product). The reaction mixture was again cooled to -78°C and quenched with 
ethyl acetate (5cm3) at -78°C. Ether (100cm3) was added and the cooling bath was 
removed. Ice-cold 1M NaOH solution was added until there were two clear layers, the 
resulting aqueous layer was discarded. The organic layer was washed with water 
(75cm3), dried (MgSCLt), filtered and concentrated to a yellow oil that was directly 
acetylated by dissolving in pyridine (10cm ) and acetic anhydride (5cm ) and leaving to 
stir overnight. The reaction mixture was concentrated, and then concentrated repeatedly 
from toluene. The residue was subjected to flash chromatography (eluent ethyl acetate 
/hexane 2:3, then 1:1, then 3:2). Initial fractions contained pure 3-0-acety 1-5-O-benzyl- 
A6-dimethoxytrityl-2 ,0 -p-methoxybenzyl adenosine, while further fractions contained a 
mixture of the two regioisomers. The material in these fractions was repeatedly 
recolumned in order to completely separate the two regioisomers. Yield of 3 -0-acetyl- 
5 -0-benzyl-JV6-dimethoxytrityl-2 -O-p-methoxybenzyl adenosine (0.58g, 55% over two 
steps). Yield of 2 -0-acetyl-5 -O-benzyl-A/6-dimethoxytrityl-3 -O-p-methoxybenzyl 
adenosine (0.39g, 38% over 2 steps).
Data for 3 -0-acetyl-5-0-benzyl-A6-dimethoxytrityl-2-0 -/7-methoxybenzyl adenosine 
(42): Rf 0.35 (chloroform/acetone 19:1); (Found: C, 70.00; H, 5.80; N, 8.49. Calc for 
C48H47N5O8: C, 70.14; H, 5.76; N, 8.52%); NMR (400 MHz; CDCI3) Sh 2.14 (3H, s,
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CH3CO), 3.67 (1H, Vab 10.7, Vax 3.1, H-5'A), 3.74-3.79 (1H, m, H-5 B, obscured by 
OCH3), 3.75 (3H, s, OCH3), 3.76 (6H, s, 2 x OCH3), 4.34-4.39 (2H, AB, Jab 12.0, 
OCZ/HAr, overlapping with H-4 ), 4.50 (1H, AB, /ab 12.0, OCHtfAr), 4.54, 4.58 (2H, 
AB, Jab 11.7, OCi/2Ar), 4.68 (1H, dd, /  5.3, 6.4, H-2 ), 5.43 (1H, dd, /2 .8 , 5.1, H-3 ), 
6.12 (1H, d, /6 .7 , H-l ), 6.66-6.69 (2H, m, ArCH), 6.79-6.83 (4H, m, ArCH), 6.88 (1H, 
br.s, D20  exch., NH), 6.95-6.99 (2H, m, ArCH), 7.22-7.38 (14H, m, ArCH), 7.77, 8.06 
(2H, s, H-2, H-8); 13C NMR (100.4 MHz; CDC13) Sc 21.36 (q, CH3CO), 55.59 (q, 3 x 
OCH3), 69.96 (t, C-5 ), 70.96 (s, DMTr Cq), 72.14, 79.01, 82.44 (3d, C-2’, C-3', C-4 ), 
72.86, 74.06 (2t, 2 x OCH2Ar), 86.38 (d, C-l ), 113.36, 113.95 (2d, C-3 and C-5 oip-  
OCH3 phenyl rings),121.20 (s, C-5), 127.00, 128.01, 128.08, 128.23, 128.82, 129.02, 
129.73, 130.32 (7d, ArCH, and s, C-l of PMB ring), 137.49 (s, C-l of Bn ring), 137.68 
(s, C-l ofDMTrp-OCH3 phenyl rings), 138.23 (d, C-8), 145.65 (s, C-l of DMTr phenyl 
ring), 149.05 (s, C-4), 152.60 (d, C-2), 154.19 (s, C-6), 158.38 (s, C-4 of DMTr p-OCH3 
phenyl rings), 159.60 (s, C-4 of PMB ring), 170.39 (s, CH3CO); m/z (FAB+) 822 
[(M+H)+, 30%], 303 (100), 91 (17).
Data for 2 -O-acetyl-5 -0-benzyl-A6-dimethoxytrityl-3-O-p-methoxybenzyl adenosine 
(41): Rf 0.30 (chloroform/acetone 19:1); *H NMR (400 MHz; CDC13) Sa 3.54 (1H, 0.5 
ABX, 2Jab 10.7, Vax 3.9, H-5 A), 3.77-3.79 (1H, m, H-5 B, obscured by OCH3), 3.77 
(3H, s, OCH3), 3.78 (6H, s, 2 x OCH3), 4.22-4.24 (1H, m, H-4 ), 4.34 (1H, AB, /ab 10.7, 
OC/THAr), 4.46-4.58 (4H, m, 3 x OCHtfAr, H-3 ), 5.72 (1H, dd, /  2.9, 4.9, H-2 ), 6.17 
(1H, dd, /2 .9 , H-l ), 6.78-6.87 (9H, m, ArCH, D20  exch., NH), 7.17-7.35 (14H, m, 
ArCH), 8.05, 8.07 (2H, 2s, H-2, H-8); 13C NMR (100.4 MHz; CDC13) Sc 20.81 (q, 
CH3CO), 55.23 (q, 3 x OCH3), 68.40 (t, C-5 ), 70.61 (s, DMTr Cq), 72.89, 73.39 (2t, 2 x 
OCH2Ar), 74.41, 75.33, 81.55 (3d, C-2', C-3', C-4'), 87.09 (d, C-l ), 113.15, 113.84 (2d, 
C-3 and C-5 ofp-OCH3 phenyl rings), 126.81 (s, C-5), 127.72, 127.87, 128.51, 128.78, 
129.30, 129.86, 130.10 (6d, ArCH, and s, C-l of PMB ring), 137.43 (s, C-l of Bn ring),
137.53 (s, C-l of DMTrp-OCHs phenyl rings), 138.57 (d, C-8), 145.11 (s, C-l of DMTr 
phenyl ring), 148.00 (s, C-4), 152.49 (d, C-2), 153.66 (s, C-6), 158.26 (s, C-4 of DMTr 
P-OCH3 phenyl rings), 159.66 (s, C-4 of PMB ring), 169.91 (s, CH3CO).
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7.2.10 5 -0-Benzyl-/\/6-dimethoxytrityl-2 -0-p-methoxybenzyl adenosine 
(40)
A solution of 42 (3.85g, 4.69mmol), in methanol (60cm3) chloroform (30cm3) 
and concentrated ammonia (15cm ) was stirred in a sealed flask for 48 h. The solvents 
were removed under reduced pressure and the residue repeatedly concentrated from 
chloroform and then subjected to flash chromatography (eluent ethyl acetate /hexane 3:2) 
to yield the title compound as a white foam in quantitative yield (3.65g).
Rf 0.39 (ethyl acetate/hexane 1:1); Found: C, 70.60; H, 5.86; N, 8.91. Calc for 
C46H45N5O7: C, 70.84; H, 5.82; N, 8.98%; !H NMR (400 MHz; CDC13) <5k 3.66 (1H, 0.5 
ABX, 2Jab 10.8, Vax 3.5, H-5 A), 3.77 (3H, s, OCH3), 3.78-3.82 (1H, 0.5ABX obscured 
by OCH3, VBx 2 .6, H-5 B), 3.78 (6H, s, 2 x OCH3), 4.18-4.21 (1H, m, H-4 ), 4.34 (1H, 
dd, 75.0, H-3 ), 4.47 (1H, dd, 74.7, H-2 ), 4.56, 4.60 (2H, AB, 7ab 12.0, OCH2Ai \  4.57,
4.66 (2H, AB, /ab 11-7, OCtf2Ar), 6.16 (1H, d, /4 .1 , H-l ), 6.71-6.84 (7H, m, ArCH),
6.93 (1H, br. s, D20  exch., NH), 7.11-7.38 (15H, m, ArCH), 7.97, 8.07 (2H, 2s, H-2, H- 
8); 13C NMR (100.4 MHz; CDC13) Sc 55.59 (q, 3 x OCH3), 69.69 (t, C-5 ), 70.33, 81.24, 
84.20 (3d, C-2', C-3', C-4 ), 70.96 (s, DMTr Cq), 72.97, 73.90 (2t, 2 x OCH2Ar), 87.03 
(d, C-l ), 113.35, 114.18 (2d, C-3 and C-5 of/?-OCH3 phenyl rings), 121.30 (s, C-5),
127.00, 127.94, 128.06, 128.13, 128.77, 128.82, 129.02, 130.33 (7d, ArCH, and s, C-l of 
PMB ring), 137.67 (s, C-l of DMTr p-OCU3 phenyl rings), 137.72 (s, C-l of Bn ring),
138.53 (d, C-8), 145.63 (s, C-l of DMTr phenyl ring), 148.62 (s, C-4), 152.49 (d, C-2), 
154.19 (s, C-6), 158.38 (s, C-4 of DMTr /7-OCH3 phenyl rings), 159.82 (s, C-4 of PMB 
ring); m/z (FAB-") 780 [(M+H)+, 32%], 303 (100), 91 (21).
7.2.11 5-O-Benzyl adenosine (43)
38 (3.46g, 4.45mmol) In 80% aqueous acetic acid (170cm3) was heated at 100°C 
for 45 min. After cooling the acetic acid was evaporated under reduced pressure and the 
residue repeatedly concentrated from toluene to a yellow solid which was dissolved in 
minimum of methanol. Ether was added and the mixture left at -20°C over-night. The 
title compound was isolated as a white powder by filtration (1.35g, 85%).
147
Chapter seven
(Found: M+, 358.152. Calc for C17H20N5O4 (M+H)+: 358.151); 'H NMR (270 MHz; d6 
DMSO) <5h 3.64, 3.75 (2H, ABX, 2J A b ,  10.6, Vax 5.0, VBX 3.6, H-5'a, H-5’b), 4.08 (1H, 
ddd, J  4.0, 4.2, H-41), 4.22 (1H, ddd, J  4.9, 9.4, H-3'), 4.53 (2H, s, OCH2Ai), 4.60 (1H, 
dd, J  5.3, 10.8, H-2’), 5.31 (1H, d, J5 .3 , -OH), 5.54 (1H, d, y  6.1, -OH), 5.92 (1H, d, J
5.3, H -l1), 7.26-7.37 (5H, m, ArCH), 8.15, 8.27 (2H, 2s, H-2, H-8); 13C NMR (100.4 
MHz; d« DMSO) * 7 0 .1 0  (t, C-5'), 70.57, 73.52, 83.25 (3d, C-2', C-3', C-4'), 72.42 (t, 
OCH2Ar), 87.45 (d, C-l'), 118.95 (s, C-5), 127.52, 128.31 (2d, ArCH), 138.20 (s, C-l of 
Bn ring), 139.55 (d, C-8), 149.34 (s, C-4), 151.79 (d, C-2), 155.35 (s, C-6); m/z (FAB+) 
358 [(M+H)+, 100%], 91 (37).
7.2.12 p-Methoxybenzyl bromide148 (160)
A solution of p-methoxybenzyl alcohol (48g, 0.35mol) in ether (75cm3) was 
added slowly to a solution of 48%HBr (80g) in ether (75cm ). After addition the mixture 
was stirred for a further 30 min and then quenched with an excess of solid NaHCC>3 
(27g). The resulting two layers were separated and the aqueous layer extracted with 
ether (2 x 50cm3). The ethereal extracts were combined with the organic layer, washed 
with water (100cm3), dried (MgSCU), filtered and concentrated to a clear liquid. The 
crude product was distilled [bp 109°C (1mm); lit.148 92-95°C (0.02mm)] to give a 
colourless liquid that was stored over dry K2 CO3 .
7.2.13 5 -0-Benzyl-2 -0-p-methoxybenzyl adenosine (44)
43 (258mg, 0.72mmol) In DMF (13cm3) was cooled to -20°C and sodium 
hydride (38mg of a 60%w/w dispersion in mineral oil, 0.94mmol) was added. After 
stirring for one h at -20°C to -12°C / 7-methoxybenzyl bromide in DMF (5cm ) was added 
dropwise over 2 h 30 min. The reaction mixture was left stirring for a further 2 h at - 
20°C before being quenched with water (2cm ). Concentration of the reaction mixture 
gave a clear oil that was preadsorbed to silica and then subjected to flash 




Rf 0.38 (ethyl acetate/ethanol 39:1); (Found: M+, 478.209. Calc for C25H28N5O5 (M+H)+: 
478.209); !H NMR (270 MHz; CDC13) <5h 3.69, 3.83 (2H, ABX, 27ab 10.7, 37ax 3.2, 37BX
2.8, H-5'a, H-5'b), 3.76 (3H, s, OCH3), 4.23-4.27 (1H, m, H-4'), 4.39 (1H, dd, 7  4.8, H- 
3'), 4.44 (1H, dd, 7  4.7, H-2'), 4.53-4.65 (4H, m, 2 x OCi^Ar), 6.13 (2H, br. s, D20  
exch., NH2), 6.20 (1H, d, 7  4.0, H -l’), 6.70-6.73 (2H, m, H-3 and H-5 of PMB ring), 
7.07-7.10 (2H, m, H-2 and H-6 of PMB ring), 7.29-7.36 (5H, m, ArCH), 7.99, 8.24 (2H, 
2s, H-2, H-8); 13C NMR (67.9 MHz; CDC13) Sc 55.01 (q, OCH3), 69.17 (t, C-5’), 69.93, 
80.91, 83.93 (3d, C-2', C-3', C-4’), 72.31, 73.45 (2t, 2 x OCH2Ar), 86.54 (d, C-l’), 113.62 
(d, C-3 and C-5 of PMB ring), 119.43 (s, C-5), 127.55, 127.60, 127.78, 128.33, 128.38, 
129.56 (6d, ArCH), 128.44 (s, C-l of PMB ring), 137.39 (s, C-l of Bn ring), 138.66 (d, 
C-8), 149.28 (s, C-4), 152.75 (d, C-2), 155.23 (s, C-6), 159.35 (s, C-4 of PMB ring); m/z 
(FAB*) 478 [(M+H)+, 100%], 121 (88).
A sample of 5 -O-benzyl-2 -0 -/?-methoxybenzyl adenosine was converted to its 
A/6,3 -O-diacetate with acetic anhydride and pyridine in the usual way.
‘H NMR (270 MHz; CDCI3) <5h 2.16, 2.18 (6H, 2s, 2 x CH3CO), 3.67-3.74 (1H, m, H- 
5'a, obscured by OCH3), 3.73 (3H, s, OCH3), 3.78 (1H, 0.5 ABX, 27ab 10.4, Vax 2.9, H- 
5'b), 4.31, 4.84 (2H, AB, 7ab 11.9, OCJ72Ar), 4.36-4.39 (1H, m, H-4'), 4.57 (2H, s, 
OC/f2Ar), 4.64 (1H, dd, 7  5.1, 6.8, H-2'), 5.46 (1H, dd, 7  5.1, 2.4, H-3’), 6.13 (1H, d, 7
6.6, H-l'), 6.19 (1H, br. s, D20  exch., NH), 6.58-6.61 (2H, m, H-3 and H-5 of PMB 
ring), 6.88-6.91 (2H, m, H-2 and H-6 of PMB ring), 7.29-7.39 (5H, m, ArCH), 7.78,
8.32 (2H, 2s, H-2, H-8).
7.2.14 A^-Benzoyl-S'-O-benzyl^-O-p-methoxybenzyl adenosine (32)
After being repeatedly concentrated from dry pyridine 44 (413mg, 0.87mmol) 
was redissolved in dry pyridine (5cm3) and chlorotrimethylsilane (0.27cm3, 2.16mmol)
<5
was added. This mixture was stirred for one h before benzoyl chloride (0.50cm , 
4.33mmol) was added. Stirring was continued for a further 2 h, and then the mixture was
- j
cooled to 0°C and the reaction quenched by addition of water (1cm ). After 5 min 
concentrated aqueous ammonia (2cm3) was added and the reaction mixture was allowed
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to warm to room temperature over 30 min. Subsequent concentration of the reaction 
mixture was followed by partitioning of the residue between DCM (50cm3) and saturated 
aqueous NaHCC>3 solution (30cm ). The organic layer was dried (MgSO/i), filtered and 
concentrated and the resulting yellow oil subjected to flash chromatography (eluent ethyl 
acetate/hexane 9:1) to yield the title compound as a clear oil (323mg, 64%).
Rf 0.60 (ethyl acetate/hexane 9:1); (Found: M+, 582.236. Calc for C32H32N5O6 (M+H)+: 
582.235); *H NMR (400 MHz; CDC13) &  3.12 (1H, br. s, D20  exch., 3'-OH), 3.66, 3.83 
(2H, ABX, Vab 10.7, Vax 2.9, 2JBX 2.4, H-5’A, H-5'B), 3.73 (3H, s, OCH3), 4.24-4.26 
(1H, m, H-4'), 4.37 (1H, dd, J  4.4, H-3'), 4.47 (1H, dd, 74.4, H-2'), 4.54-4.63 (4H, m, 2 
x OCi/2Ar), 6.24 (1H, d, 7  4.4, H-l'), 6.67-6.71 (2H, m, H-3 and H-5 of PMB ring), 
7.05-7.07 (2H, m, H-2 and H-6 of PMB ring), 7.22-7.39 (5H, m, ArCH), 7.50-7.53 
(2H, m, H-3 and H-5 of Bz ring), 7.57-7.61 (1H, m, H-4 of Bz ring), 8.03-8.04 (2H, m, 
H-2 and H-6 of Bz ring), 8.22, 8.77 (2H, 2s, H-2, H-8), 9.22 (1H, br. s, D20  exch., NH); 
13C NMR (67.9 MHz; CDC13) Sc 55.24 (q, OCH3), 69.33 (t, C-5'), 70.14, 81.14, 84.30 
(3d, C-2', C-3', C-4'), 72.81, 73.68 (2t, 2 x OCH2Ar), 86.91 (d, C-l), 113.86 (d, C-3 and 
C-5 of PMB ring), 123.14 (s, C-5), 127.80, 127.89, 128.02, 128.61, 128.83, 129.81, 
132.74 (7d, ArCH), 128.36 (s, C-l of PMB ring), 133.78 (s, C-l of Bz ring), 137.41 (s, 
C-l of Bn ring), 141.45 (d, C-8), 149.36 (s, C-4), 151.37 (s, C-6), 152.54 (d, C-2),
159.66 (s, C-4), 164.72 (s, COPh); m/z (FAB+) 582 [(M+H)+, 100%], 240 (40).
7.2.15 A^.A^-Dibenzoyl-S'-O-benzyl^'-O-p-methoxybenzyl adenosine 
(45)
After being repeatedly concentrated from dry pyridine 44 (428mg, 0.90mmol) 
was redissolved in pyridine (7cm3) and chlorotrimethylsilane (0.28cm3, 2.24mmol)
- j
added. This mixture was stirred for one h then benzoyl chloride (0.52cm , 4.49mmol) 
was added and stirring was continued for a further 2 h. The reaction was quenched by 
cooling the mixture to 0°C and the addition of water (1cm ). The mixture was stirred for 
a further 30 min at room temperature and then was concentrated and the residue 
partitioned between DCM (75cm3) and saturated aqueous NaHCC>3 solution (50cm3). 
The organic layer was dried (MgSCU), filtered and concentrated and the resulting yellow
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oil was subjected to flash chromatography (eluent ethyl acetate/hexane 3:2) to yield the 
title compound as a clear oil (539mg, 88%).
Rf 0.40 (ethyl acetate/hexane 3:2); (Found: M+, 686.261. Calc for C39H36N5O7 (M+H)+: 
686.261); *H NMR (270 MHz; CDC13) <5k 3.61 (1H, 0.5 ABX, Vab 10.8, Vax 3.1, H- 
5'a), 3.74-3.79 (1H, m, H-5'B, obscured by OCH3), 3.75 (3H, s, OCH3), 4.19-4.21 (1H, 
m, H-4’), 4.32 (1H, dd, .74.9, H-3'), 4.45-4.65 (5H, m, H-2', 2 x OCi/2Ar), 6.24 (1H, d, J
4.2, H-l'), 6.77-6.80 (2H, m, H-3 and H-5 of PMB ring), 7.06-7.10 (2H, m, H-2 and H- 
6 of ring), 7.23-7.37 (9H, m, ArCH), 7.44-7.50 (2H, m, H-4 of Bz rings), 7.84-7.87 
(4H, m, H-2 and H-6 of Bz rings), 8.33, 8.61 (2H, 2s, H-2, H-8); m/z (FAB+) 686 
[(M+H)+, 100%], 91 (52).
7.2.16 A/6,A/6-Dibenzoyl-2,,>5,,6"-tri-0-benzyl-3,-0-<ar-D-glucopyranosyl- 
2 ,3 ,,,4"-tri-0-p-methoxybenzyl adenosine (48)
47 (201mg, 0.29mmol) And 45 (lOOmg, 0.15mmol) in dioxane (2.25cm3) and 
toluene (0.75cm3) were stirred with 4A molecular sieves (approx. 150mg) for 1.75 h, and 
then dry zinc chloride (34mg, 0.25mmol) and silver perchlorate (104mg, 0.50mmol) 
were added. The flask was wrapped in foil and stirring was continued for 44 h. Solid 
NaHCC>3 (200mg) and water (2cm3) were added and the reaction mixture was diluted 
with ethyl acetate (5cm3), after stirring for a further 15 min the mixture was filtered 
through a celite pad, and the residue was well washed with ethyl acetate. The filtrate was 
washed with brine (20cm3) and saturated aqueous NaHCC>3 solution (20cm3), dried 
(MgSC>4), filtered and concentrated. The residue was subjected to flash chromatography 
(eluent ethyl acetate/hexane 7:3) to yield the title compound as a clear oil (29mg, 16%). 
Rf 0.56 (ethyl acetate/toluene 1:4); (Found: M+, 1268.520. Calc for C75H73N5O14 
(M+H)+: 1268.523); *H NMR (400 MHz; CDC13) <5k 3.51-3.53 (1H, m, H-5'A), 
3.57-3.81 (6H, m, H-2', H-4', H-5'B, H-5", H-6'A, H-6"B), 3.68, 3.78, 3.79 (9H, 3s, 
OCH3), 3.98 (1H, dd, J  9.3, H-3"), 4.36-4.58 (10H, m, 4 x OC772Ar, H-3', H-4’), 
4.65-4.78 (4H, m, 3 x OCH/ZAr, H-2'), 4.89 (1H, AB, Jab 10.3, OCH/ZAr), 5.24 (1H, d, 
J  3.4, H-l"), 6.30 (1H, d, J  5.9, H-l'), 6.66- 6.68 (2H, m, H-3 and H-5 of PMB ring),
6.80-6.68 (4H, m, ArCH), 6.95-6.97 (2H, m, ArCH), 7.04-7.06 (2H, m, ArCH), 
7.21-7.37 (21H, m, ArCH), 7.46-7.50 (2H, m, H-4 of Bz ring), 7.85-7.88 (4H, m, H-3
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and H-5 of Bz ring), 8.24, 8.55 (2H, 2s, H-2, H-8); m/z (FAB+) 1268 [(M+H)+, 12%], 
121 (100).
7.2.17 A^-benzoyl-Z'.S'.e'-tri-O-benzyl-S'-O-a-D-glucopyranosyl"
2 ,3,,,4"-tri-0-p-methoxybenzyl adenosine (49)
47 (290mg, 0.42mmol) And 32 (122mg, 0.21mmol) in dioxane (2.25cm3) and 
toluene (0.75cm3) were stirred with 4A molecular sieves (approx. 150mg) for 1.75 h, and 
then dry zinc chloride (34mg, 0.25mmol) and silver perchlorate (104mg, 0.50mmol) 
were added. The flask was wrapped in foil and stirring was continued for 20 h. Solid 
NaHCC>3 (200mg) and water (2cm3) were added and the reaction mixture was diluted 
with ethyl acetate (5cm ), and was stirred for a further 15 min the mixture was filtered 
through a Celite pad, and the residue was well washed with ethyl acetate. The filtrate 
was washed with brine (20cm ) and saturated aqueous NaHCC>3 solution (20cm ), dried 
(MgSC>4), filtered and concentrated. The residue was subjected to flash chromatography 
(eluent ethyl acetate/hexane 7:3) to yield the title compound as a clear oil (70mg, 29%). 
Rf 0.38 (toluene/ethyl acetate 3:2); (Found: M+, 1164.505. Calc for C69H72N4O13 
(M+H)+: 1164.509); *H NMR (270 MHz; CDC13) <5k 3.56-3.79 (7H, m, H-2', H-4', H- 
5'a, H-5'b, H-5", H-6"a, H-6"b), 3.66, 3.78, 3.79 (9H, 3s, 3 x OCH3), 4.00 (1H, dd, J 9.1, 
H-3"), 4.36-4.60 (10H, m, 4 x OC/f2Ar, H-3', H-4'), 4.72-4.80 (4H, m, 3 x OC//HAr, 
H-2'), 4.91 (1H, AB, Jab 10.4, OCi/HAr), 5.31 (1H, d, J3 .7 , H-l"), 6.30 (1H, d, J  5.5, 
H-l'), 6.55-6.58 (2H, m, H-3 and H-5 of PMB ring), 6.80-7.08 (8H, m, ArCH), 
7.20-7.32 (21H, m, ArCH), 7.51-7.60 (3H, m, H-3, H-4 and H-5 of Bz ring), 8.03-8.06 
(2H, m, H-2 and H-6 of Bz ring), 8.12, 8.76 (2H, 2s, H-2, H-8), 9.21 (1H, br. s, D20  





133 (182mg, 0.34mmol) and 32 (lOOmg, 0.17mmol) in dioxane (2.25cm3) and 
toluene (0.75cm3) were stirred with 4A molecular sieves (approx. 150mg) for 1.75 h, and 
then dry zinc chloride (56mg, 0.41mmol) and silver perchlorate (171mg, 0.83mmol) 
were added. The flask was wrapped in foil and stirring was continued for 26 h. Solid 
NaHCC>3 (200mg) and water (2cm ) were added and the reaction mixture was diluted
•y
with ethyl acetate (5cm ) and stirred for a further 15 min. The mixture was filtered 
through a Celite pad, and the residue was well washed with ethyl acetate. The filtrate 
was washed with brine (20cm3) and saturated aqueous NaHCC>3 solution (20cm3), dried 
(MgSC>4), filtered and concentrated. The residue was subjected to flash chromatography 
(eluent ethyl acetate/hexane 7:3) to yield the title compound as a clear oil (50mg, 29%). 
Rf 0.57 (toluene/ethyl acetate 1:1); (Found: M*, 1008.397. Calc for C56H58N5O13 
(M+H)+: 1008.403); lH NMR (400 MHz; CDC13) Sn 1.91, 2.01 (6H, 2s, 2 x CH3CO), 
3.35-3.41 (2H, m, H-6"A, H-6"B), 3.61 (1H, dd, J  10.0, H-2"), 3.68-3.73 (1H, m, H-5'A, 
obscured by OCH3), 3.68 (3H, s, OCH3), 3.80 (1H, 0.5 ABX, Vab 10.5, VBX 4.2, H-5'B), 
3.87-3.91 (1H, m, H-5"), 4.35-4.66 (8H, m, H-3’, H-4', 3 x OCH2Ar), 4.77 (1H, dd, J
5.1, H-2'), 5.08 (1H, dd, J 9.8, H-4"), 5.30 (1H, d, J3 .4 , J3.4, H-l"), 5.47 (lH,dd, /9 .8 , 
H-3"), 6.24 (1H, d, J  5.9, H-l'), 6.59-6.61 (2H, m, H-3 and H-5 of PMB ring), 6.95-6.97 
(2H, m, H-2 and H-6 of PMB ring), 7.20-7.34 (15H, m, ArCH), 7.50-7.62 (3H, m, H-3, 
H-4 and H-5 of Bz ring), 8.03-8.05 (2H, m, H-2 and H-6 of Bz ring), 8.11, 8.73 (2H, 2s, 




To a mixture of 46 (2.00g, 3.33mmol) and tetrazole (0.35g, 5.00mmol) in DCM 
(20cm3) was added bis(methoxy)(diethylamino)phosphine (0.72cm3, 4.33mmol). After 
stirring for 20 min TLC (ethyl acetate/hexane 1:3) indicated complete conversion to
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product (Rf 0.66). The reaction mixture was partitioned between diethyl ether (150cm3) 
and water (100cm ). The resulting ethereal layer was washed with brine (100cm ), dried 
(MgSCU), filtered and concentrated to give a colourless, mobile oil which was shown by 
!H NMR spectroscopy to be a 1:1 anomeric mixture, and which was used for the next 
step without further purification.
*H NMR (400 MHz; CDCI3) 8H 3.48-3.74 (11H, m, 2 x POCH3a, 2 x POCH3/?, H-2, H-3, 
H-5, H-6a, H-6b), 3.77, 3.78, 3.78, 3.79 (6H, 4s, 4 x 1.5 OCH3), 3.94-3.99 (1H, m, H-4), 
3.94-3.99 (3H, m, 3 x OCHtfAr), 4.70-4.91 (5H, m, 5 x OCHtfAr), 4.94 (0.5 H, dd, J
8.07, H-l/?), 5.54 (0.5H, dd, .73.18, JH.P 8.55, H -la), 6.80-6.85 (4H, m, 2 x H-3 and H-5 
of PMB rings), 7.05-7.12 (2H, m, H-2 and H-6 of PMB rings), 7.20-7.38 (12H, m, 
ArCH); a  and /? subscripts denote signals arising from a  and /?-anomers respectively; 31P 
NMR (36 MHz; CDC13; *H decoupled) Sp 141.14 OP^OMe^, 142.31 OP^OMe^.
7.2.20 2">5,,6,,-Tri-0-benzyl-3,-0-a-D-glucopyranosyl-2l3,,,4"-tri-0-p- 
methoxybenzyl-N6-dimethoxytrityl adenosine (53)
47 (2.42g, 3.50mmol) And 40 (1.36g, 1.75mmol) in dioxane (18cm3) and toluene 
(6cm3) were stirred with 4A molecular sieves (approx. 1.80g) for 2 h, and then dry zinc 
chloride (0.57g, 4.20mmol) and silver perchlorate (1.74g, 8.40mmol) were added. The 
flask was wrapped in foil and stirring was continued for 7 h. Solid NaHC03 (1.50g) and 
water (60cm3) were added and the reaction mixture was diluted with ethyl acetate 
(80cm ), and was stirred for a further 30 min. The mixture was filtered through a Celite 
pad, and was well washed with ethyl acetate. Water (50cm3) was added to the filtrate 
and the resulting aqueous layer was discarded. The organic layer was washed with brine 
(70cm ), dried (MgS04), filtered and concentrated and the residue was subjected to flash 
chromatography (eluent ethyl acetate/hexane 3:7, then 1:1) to yield the title compound as 
a clear oil (1.26g, 53%).
Rf 0.33 (ethyl acetate/hexane 2:3); [a]D21 +10.0 (c 1.5, CHC13); (Found: C, 71.90; H, 
6.18; N, 5.03. Calc for C82H83N5014: C, 72.28; H, 6.18; N, 5.14%); *H NMR (400 MHz; 
CDC13) Sa 3.43-3.79 (7H, m, H-2", H-4", H-5'A, H-5'B, H-5", H-6"A, H-6"B), 3.69, 3.77,
3.78, 3.79 (15H, 4s, 5 x OCH3), 3.96 (1H, dd, J  9.3, H-3"), 4.34-4.76 (14H, m, 9 x 
OCHtfAr, H-2', H-3', H-4’), 4.87 (1H, AB, JAb 10.3 OCH/ZAr), 5.22 (1H, d, J 3.4, H-l"),
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6.21 (1H, d, J  4.9, H-l'), 6.65-6.67 (2H, m, ArCH), 6.79-6.86 (10H, m, ArCH), 
7.01-7.05 (4H, m, ArCH), 7.21-7.36 (24H, m, ArCH), 7.89, 8.04 (2H, 2s, H-2, H-8); 13C 
NMR (100.4 MHz; CDCI3) Sc 55.44, 55.49 (2q, 2 x OCH3), 68.48 (t, C-6"), 69.52 (t, C- 
5'), 70.87 (s, DMTr Cq), 71.09 (d, C-5"), 72.36, 72.50 (2t, 2 x OCH2Ar), 73.01 (d, C-3'), 
73.67, 73.75, 74.97, 75.59 (4t, 4 x OCH2Ar), 77.31 (d, C-4"), 79.65 (d, C-2'), 79.83 (d, 
C-2"), 81.66 (d, C-3"), 82.32 (d, C-4'), 87.10 (d, C-l’), 96.35 (d, C-l"), 113.38, 113.94, 
114.00 (3d, C-3 and C-5 of /7-OCH3 phenyl rings), 121.60 (s, C-5), 127.04, 127.90, 
127.99, 128.04, 128.12, 128.19, 128.28, 128.52, 128.61, 128.74, 129.07, 129.80, 130.36 
(13d ArCH), 129.34, 130.66, 131.30 (3s, 3 x C-l of PMB ring), 137.75, 137.88, 138.08, 
138.39 (4s, C-l of DMTr /7-OCH3 phenyl rings, 3 x C-l of benzyl rings), 139.07 (d, C- 
8), 145.76 (s, C-l of DMTr phenyl ring), 148.83 (s, C-4), 152.51 (d, C-2), 158.49 (s, C-4 
of DMTr /?-OCH3 phenyl rings), 159.37, 159.46, 159.61 (3s, 3 x C-4 of PMB ring); m/z 
(FAB+) 1362 [(M+H)+, 8%], 303 (100), 121 (75).
7.2.21 2,,,5,>6,,-Tri-0-benzyl-3,-0-a-D-glucx)pyranosyl adenosine (54)
To 53 (1.28g, 0.94mmol) in DCM (63cm3), was added TFA (7cm3). The 
resulting bright orange solution was stirred for 1.75 h before being poured into saturated
>5 <>
aqueous NaHC03 solution (500cm ). DCM (150cm ) was added and the now colourless 
mixture was stirred vigorously for 15 min. The organic layer was collected and the 
aqueous layer was back-extracted with DCM (2 x 150cm ). The combined organic 
layers were dried (MgSCU), filtered and concentrated. The resulting crude product was 
purified by flash chromatography (eluent ethyl acetate/ethanol 14:1) to yield the title 
compound as a white solid (530mg, 81%).
broad mp 95-115°C (ethanol); Rf 0.28 (ethyl acetate/ethanol 14:1); [< z ]d 25 -2.3 (c 2.6, 
CHC13); (Found: C, 63.30; H, 5.92; N, 9.80. Calc for QS7H41N5O9, C 63.51; H, 5.91; N, 
10.01%); *H NMR (400 MHz; (CD3)2CO) Sa 3.45-3.51 (2H, m, H-2", H-4"), 3.66-3.81 
(4H, m, H-5fA, H-5'b, H-6"a, H-6"b), 3.93-3.96 (1H, m, H-5"), 4.04 (1H, dd, .79.0, H-3"), 
4.38-4.39 (1H, m, H-4'), 4.50-4.56 (4H, m, 2 x OCtf2Ar), 4.61-4.64 (2H, m, H-3', OH),
4.81-4.87 (5H, m, OC/72Ar, H-2', 2 x OH), 5.22 (1H, d, J  3.9, H-l"), 6.12 (1H, d, J5 .4 , 
H -l’), 6.91 (2H, br s, NH2), 7.20-7.42(15H, m, ArCH), 8.21, 8.25 (2H, 2s, H-2, H-8);
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13C NMR (100.4 MHz; (CD3)2CO) Sc 70.68 (t, C-6"), 70.74 (t, C-5’), 71.51 (d, C-4"),
73.21 (d, C-5"), 73.75, 73.88, 73.96 (3t, 3 x OCH2Ar), 74.30 (d, C-3"), 75.11 (d, C-2’),
78.49 (d, C-3'), 80.23 (d, C-2"), 83.05 (d, C-4'), 89.14 (d, C-l’), 99.10 (d, C-l"), 120.35 
(s, C-5), 128.11, 128.25, 128.35, 128.46, 129.02, 129.08, 129.15 (7d, ArCH), 139.19,
139.78 (2s, 3 x C-l of Bn rings), 140.03 (C-8), 150.73 (s, C-4), 153.77 (d, C-2), 157.04 
(s, C-6); m/z (FAB'") 700 [(M+H)+, 100%], 91 (99).
7.2.22 Imidazolium triflate (161)
Triflic acid (2.00cm3, 22.6mmol) was added dropwise to imidazole (1.54g, 
22.6mmol) in DCM (30cm3) at 0°C. The cooling bath was removed and the mixture was 
stirred for 20 min, after which diethyl ether (40cm3) was added. The resulting 
precipitated product was then collected by filtration (4.88g, 99%). 
mp 196-197°C [lit.157 197-198°C]
7.2.23 2",5,,6,,-Tri-0-benzyl-2,,3l,,4"-tris(dibenzyloxyphosphoryl)-3,-0 -a -  
D-glucopyranosyl adenosine (55)
A solution of 54 (lOOrng, 0.14mmol) in DCM (3cm3) with 
bis(benzyloxy)(diisopropylamino)phosphine (0.16cm , 0.47mmol) and imidazolium 
triflate (lOOmg, 0.46mmol), was stirred for 30 min, after which time TLC (ethyl 
acetate/hexane 7:3) indicated some starting material remaining; therefore a further 1.0 
equivalent each of bis(benzyloxy)(diisopropylamino)phosphine and imidazolium triflate 
was added. TLC after a further 30 min indicated complete conversion to the tris 
phosphite (Rf 0.68). Water (1 drop) was added and the solution cooled to -78°C, after 
which MCPBA (139mg, 0.49mmol) was added. After 10 min 10% aqueous Na2S03 
solution (15cm3) and ethyl acetate (20cm3) were added and the mixture allowed to warm 
to room temperature. The resulting organic layer was washed with 15cm each of 
saturated aqueous NaHC03 solution and brine, and then dried (MgSCU), filtered and 
concentrated to a clear oil that was subjected to flash chromatography (eluent
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chloroform/acetone 4:1, then 7:3). Concentration of the appropriate fractions gave the 
title compound as a clear oil (148mg, 70%).
Rf 0.11 (chloroform/acetone 9:1); [a\v°  +11.7 (c 3.0, CHCI3); (Found: C, 63.90; H, 
5.72; N, 4.56. Calc for CyctfgoNsC)^: C, 64.09; H, 5.45; N, 4.73%); *H NMR (400 
MHz; CDCI3) Sh 3.54-3.69 (4H, m, H-2", H-5'A, H-5'B, H-6"A, H-6"B), 3.83-3.86 (1H, 
m, H-5"), 4.30 (1H, AB, Jab 11.7, OCtfHAr), 4.36-4.81 (14H, m, H-4', H-3', H-4", 11 x 
OC//HAr), 4.88-5.07 (8H, m, H-3", 7 x OC//HAr), 5.33 (1H, d, J 3.4, H-l"), 5.62-5.65 
(1H, m, H-2"), 6.09 (2H, br s, NH2), 6.35 (1H, d, J  6.3, H-l'), 6.95-7.40 (45H, m, 
ArCH), 7.92, 8.24 (2H, 2s, H-2, H-8); 13C NMR (100.4 MHz; CDC13) Sc 68.51 (t, C-6"), 
68.28-70.07 (7t, C-5', 6 x POCH2Ar with C-P coupling), 70.27 (d, C-5'), 71.77, 73.53, 
73.76 (3t, 3 x OCH2Ar), 73.87, 74.54 (2d, C-3', C-4' with C-P coupling), 77.00 (d, C-2"), 
77.40 (d, C-2' with C-P coupling), 78.28 (d, C-3" with C-P coupling), 82.60 (d, C-4'),
85.78 (d, C-l'), 95.60 (d, C-l"), 119.98 (s, C-5), 127.80, 127.93, 128.02, 128.17, 128.26, 
128.48, 128.61, 128.65, 128.68, 128.74, 128.79, 129.03, 129.10 (13d, ArCH), 
135.16-135.32 (2s, 2 x C-l of benzylphospho ring with C-P coupling), 135.88, 136.03, 
136.38 (3s, 4 x C-l of benzylphospho ring with C-P coupling), 137.55, 137.81, 138.21 
(3s, 3 x C-l of Bn rings), 139.60 (d, C-8), 150.26 (s, C-4), 153.06 (d, C-2), 155.57 (s, C-
6); 3IP NMR (CDCI3, 161.7 MHz, 'H decoupled) Se -1.31, -2.02, -2.19 (3s); m/z (FAB4) 
1478 [(M+H)4, 6%], 91 (100).
7.2.24 3-O-a-D-Glucopyranosyl adenosine 2',3",4"-trisphosphate (27)
A mixture of 55 (59mg, 0.04mmol) and wet 20% palladium hydroxide on carbon 
(177mg), in methanol (7cm3), cyclohexane (3.5cm3) and water (0.5cm3) was heated at 
reflux for 2.5 h. After cooling the reaction mixture was filtered through a membrane 
filter and the catalyst was washed copiously with methanol and water. Concentration of 
the filtrate afforded a clear residue that was purified by application to an MP1 AG ion 
exchange resin column and eluting with a gradient of 0-100% 150mM TFA. 
Concentration of the appropriate fractions (being careful to keep the temperature below 
20°C) gave the desired product as the free acid (24mg, 92%), which was dissolved in 
water and eluted through a short column of Na+ dianion WK-40 ion exchange resin to 
give, after concentration, the sodium salt.
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(Found: M \ 668.039. Calc for QsHhsNsOigPs (M-H)': 668.040); *H NMR (400 MHz; 
D20) Sn 3.60-3.73 (6H, m, H-2", H-5'A, H-5'B, H-5", H-6"A, H-6"B), 3.97 (1H, ddd, J8.9, 
H-4"), 4.28 (1H, m, H-4'), 4.37 (1H, ddd, J  9.3, H-3"), 4.48 (1H, m, H-3'), 5.10-5.14 
(2H, m, H-l", H-2'), 6.18 (1H, d, J  6.4, H-l'), 8.24, 8.34 (2H, 2s, H-2, H-8); 31P NMR
(161.7 MHz; D20; JH decoupled) Sp 0.32, 0.87, 1.22 (3s); UV (H20) Xmax 259nm, 8  15 
400, pH 7.5; m/z (FAB') 668 [(M-H)', 100%], 266 (34), 113 (44).
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7.3 Synthesis of ribophostin
7.3.1 Allyl D-glucopyranoside (64)
A solution of D-glucose (100.23g, 0.60mol) in allyl alcohol (500cm3) was heated 
at reflux with Dowex 50X2-100 (25.00g) for 3 h. The resulting orange solution was 
cooled, filtered and the residue washed well with ethanol (100cm ). The filtrate and 
washings were combined and concentrated. The syrupy orange residue was subjected to 
flash chromatography (eluent ethyl acetate/methanol 9:1). Fractions containing the title 
compound were combined and concentrated to yield an anomeric mixture as a yellow oil 
that became a white solid on standing (86.54g, 71%), which was shown by!H NMR (270 
MHz; D2O) to be a ca. 2:1 «:/?-anomeric mixture (<5h 4.48, J  7.9, H -l$ <5h 4.94, J  3.7, H- 
1*).
Crystals of the or-anomer were isolated from three fractions, 
mp 101-102°C (ethyl acetate/methanol), [lit.214 100.5-101.5°C].
7.3.2 Allyl 2,6-di-O-benzyl-a-D-glucopyranoside (65)
The 7:3 anomeric mixture of 64 (43.57g, 0.20mol) was heated under reflux in dry
-j
toluene (1000cm ), with dibutyl tin oxide (127.00g, 0.50mol). Continuous azeotropic 
removal of water was carried out by means of a Dean-Stark trap over 3 h. The solution 
was cooled and concentrated to give a white residue, which was dried in vacuo for 5 h. 
Benzyl bromide (350cm ) was added to the powdered residue and the mixture was stirred 
for 3 days at 80-90°C under an atmosphere of nitrogen. The resulting yellow solution 
was cooled and diluted with diethyl ether (600cm ). Saturated aqueous NaHCC>3 
solution (500cm ) was added, and the mixture stirred vigorously for 30 min. The 
resulting suspension was filtered through Celite and the organic layer was separated, 
dried (MgSC>4), filtered and concentrated to give a dark yellow oil, which was subjected 
to flash chromatography (eluent hexane/ethyl acetate 8:2 to remove benzyl bromide, then 
1:1, then 2.5:7.5). Fractions containing a mixture of benzylated products were combined
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(13.18g Rf 0.30-0.51 ethyl acetate) and crystallisation from diisopropyl ether gave the 
title compound (7.90g, 10%).
Rf 0.22 (ethyl acetate/hexane 3:2); mp 73-75°C [lit.170. 74—'77°C] (diisopropyl ether); !H 
NMR (270 MHz; CDC13) Sn 2.68-2.72 (2H, m, H-6 A, H-6 B), 3.39 (1H, dd, J  3.5, 9.7, H-
2), 3.61-3.78 (4H, m, H-4, H-5, 2 x OH), 3.92-3.97 (2H, m, H-3, C//HCH=CH2), 4.11- 
4.18 (1H, m, CHtfCH=CH2), 4.55 (1H, AB, Jab 12.1, OCtfHAr), 4.59-4.66 (3H, m, 3 x 
OCtfHAr), 4.83 (1H, d, J3 .5 , H-l), 5.20 (1H, m, V  10.4, C H iC H K ^ C H ^ ) ,  5.31 
(1H, m, V  17.2, CH2CR=CHcisCHtrans), 5.86-5.91 (1H, m, CH2Gtf=CH2), 7.25-7.34 
(10H, m, ArCH).
7.3.3 Allyl 2,6-di-0-benzyl-3J4-di-0-p-methoxybenzyl-a-D- 
glucopyranoside (66)
Sodium hydride (1.98g of a 60%w/w dispersion in mineral oil, 0.05mol), and p- 
methoxybenzyl chloride (4.10cm , 0.03mol) were added sequentially to a stirring 
solution of 65 stirring in dry DMF (50cm ). Stirring was continued for 3 h when TLC 
(ethyl acetate/hexane 3:2) showed consumption of starting material (Rf 0.22) to give a 
product (Rf 0.71). Methanol (20cm3) was added and stirring continued for 15min. The 
solvents were evaporated and the residue was dissolved in chloroform (600cm ). This 
organic solution was washed with water (3 x 100cm ), dried (MgSCU), filtered and 
concentrated. Flash chromatography of the residual oil (eluent hexane/ethyl acetate 
19:1) gave the title compound as a pale yellow oil (7.9 lg, 88 %).
JH NMR (270 MHz; CDC13) Sn 3.55 (1H, dd, J 3.5,9.5, H-2), 3.59-3.63 (2H, m, H-4, H- 
6a), 3.68-3.75 (2H, m, H-5, H-6B), 3.78, 3.80 (6H, 2s, 2 x OCH3), 3.94^1.16 (2H, m, H- 
3, Ctf2CH=CH2), 4.36-4.93 (9H, m, 4 x OC/72Ar, H-l), 5.20 (1H, dd, V  10.3, 2J  0.9, 
CH2CH=Cit/ciyHtrans)» 5.29 (1H, dd, V  17.2, 2J  1.0, CH2CH=CHciJ / /ra„,), 5.92 (1H, m, 
CH2C//=CH2), 6.78-6.88 (4H, m, 2 x H-3 and H-5 of PMB rings), 7.04 (2H, d, J8 .4 , H- 




A solution of 66 (7.90g, 0.01 mol) and freshly sublimed potassium f-butoxide 
(6.9g, 0.06mol), in dry DMSO (100cm3) was stirred at 50°C in for 3 h. TLC 
(hexane/ethyl acetate 4:1) indicated consumption of starting material (Rf 0.33) to give a 
product (Rf 0.37). After cooling, water (80cm ) was added to the dark brown solution, 
and the system extracted with diethyl ether (3 x 275cm ). The combined organic extracts 
were washed with saturated aqueous KC1 solution (3 x 200cm3), dried (MgSCU), filtered 
and concentrated to a pale yellow oil. Crude (c/s-prop-1 -enyl) 2,6-di-0-benzyl-3,4-di-0- 
p-methoxybenzyl-a-D-glucopyranoside was then dissolved in acetone (160cm ), and the 
solution was heated to 50°C. Aqueous 1M HC1 (24cm ) was added and stirring 
continued for 50 min, when TLC (ethyl acetate/hexane 1:4) indicated consumption of 
starting material (Rf 0.37) to give a product (Rf 0.03). Solid NaCC>3 (lOg) was added and 
stirring continued as the suspension was allowed to cool to rt. The solvents were 
evaporated and the residue was extracted with diethyl ether (3 x 250cm3). The combined 
organic extracts were washed with saturated aqueous NaHCC>3 solution (200cm ) and 
water (200cm3), dried (MgS04), filtered and concentrated. Recrystallisation from a 
minimum of diethyl ether gave the title compound (5.66g, 76%; from allyl D- 
glucopyranoside).
mp 117-120°C [lit.170 120-131°C] (diethyl ether); ]H NMR (270 MHz; CDC13) Sa 1.67 
(0.5H, s, D20  exch., OH/?), 3.18 (0.5H, d, 72.6, D20  exch., OHa), 3.37 (0.5H, d, 7  7.6,
9.9, H-2/?), 3.50-3.80 (4.5H, m, H-2a, H-3„ or H-3# H-5« or H-5# H-4, H-6A, H-6B),
3.78, 3.79, 3.80 (6H, 3s, 2 x OCH3), 3.94 (0.5H, dd, 7  9.2, H-3a or H-3/?), 4.01 (0.5H, 
ddd overlapping with t at 3.94 ppm, H-5a or H-5/?), 4.39-4.93 (8.5H, m, H-l# 4 x 
OCfl^Ar), 5.21 (0.5H, dd, 72.6, simplifies to d on D20  exch., H -la), 6.78-6.87 (4H, m, 
2 x H-3 and H-5 of PMB rings), 7.03-7.07 (2H, m, H-2 and H-6 of PMB ring), 7.21-





To a solution of 46 (l.OOg, 1.67mmol) in freshly distilled dry DCM (10cm3) was 
added freshly flame dried K2CO3 (l.OOg, 7.25mmol), followed by freshly distilled 
trichloroacetonitrile (1.00cm3). The mixture was left to stir at room temperature under 
an atmosphere of nitrogen for 140 min, after which time TLC (chloroform/acetone 30:1) 
indicated a small amount of starting material (Rf 0.14), a major product (Rf 0.47) and a 
minor product (Rf 0.58). The reaction mixture was filtered through a pad of celite and 
concentrated to a clear oil. This oil was purified by flash chromatography (eluent 
chloroform/acetone 50:1), to give the title compound (0.59g, 48%), and its a-anomer 
(0.25g, 20%). The title compound was crystallised from a minimum amount of diethyl 
ether/petroleum ether 1:1, overnight at -4°C.
Analyses for P-anomer (67a): mp 80-81°C (petroleum ether/ether); [ar]D +16.45 (c 4.7, 
CHCI3); (Found: C, 61.40; H, 5.41; N 1.86. Calc for CisiUoNiO&Ch: C, 61.26; H, 5.41; 
N, 1.88%); !H NMR (270 MHz; CDC13) 3.56-3.73 (6H, m, H-2, H-3, H-4, H-5, H-6A, 
H-6b), 3.79, 3.80 (6H, 2s, 2 x OCH3), 4.47-4.78 (6H, m, 3 x OCH2Ai \  4.82 (1H, AB, 
Jab 10.4, OCH/ZAr), 4.93 (1H, AB, Jab 11-0, OCH/ZAr), 5.78 (1H, d, J8 .3 , H-l), 6.79- 
6.85 (4H, m, 2 x H-3 and H-5 of PMB rings), 7.09 (2H, m, H-2 and H-6 of PMB ring), 
7.20-7.31 (12H, m, ArCH), 8.69 (1H, s, C=NH); 13C NMR (100.4 MHz; CDCI3) Sc 
55.27 (q, 2 x OCH3), 68.21 (t, C-6), 73.35, 74.60, 74.91, 75.32 (4t, 4 x OCH2Ar), 75.90, 
77.03, 81.00, 84.29 (4d, C-2, C-3, C-4, C-5), 98.35 (d, C-l), 113.79, (2d, C-3 and C-5 of 
PMB rings), 127.61, 127.76, 127.89, 127.93, 128.36, 128.47, 129.46, 129.64, (7d, 
ArCH), 130.19, 130.63 (2s, 2 x C-l of PMB rings), 138.02, 138.11 (2s, 2 x C-l of Bn 
rings), 159.20 (2s, 2 x C-4 of PMB rings) 161.23 (C=NH); m/z (FAB*) 744 [(M-H)', 
34%], 311 (73),188 (100).
Analyses for cr-anomer (67b): [a]D +13.64 (c 1.3, CHC13); *H NMR (270 MHz; CDC13) 
Sn 3.65 (1H, 0.5 ABX, 2J a b  10.9, 3J a x  1.9, H-6A), 3.71-3.80 (3H, m, H-2, H-4, H-6B),
3.78, 3.79 (6H, 2s, 2 x OCH3), 3.94-^.06 (2H, m, H-3, H-5), 4.45, 4.77 (2H, AB, J  10.3, 
OC/Z2Ar), 4.47, 4.60 (2H, AB, J  12.1, OC7Z2Ar), 4.69, 4.74 (2H, AB, J  11.7, OCZZ2Ar), 
4.76, 4.87 (2H, AB, J  10.4, OC7Z2Ar), 6.51 (1H, d, J3.3, H-l), 6.79-6.85 (4H, m, 2 x H-
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3 and H-5 of PMB rings), 7.05-7.08 (2H, m, H-2 and H-6 of PMB ring), 7.23-7.32 
(12H, m, ArCH), 8.57 (1H, s, C=NH); 13C NMR (100.4 MHz; CDC13) Sc 55.27 (q, 2 x 
OCH3), 68.03 (t, C-6), 72.88, 73.46, 74.94, 75.31 (4t, 4 x OCH2Ar), 73.17, 76.50, 79.43, 
81.07 (4d, C-2, C-3, C-4, C-5), 94.42 (d, C-l), 113.77, 113.83 (2d, C-3 and C-5 of PMB 
rings), 127.59, 127.69, 127.94, 128.36,129.68, 129.74 (6d, ArCH), 130.28, 130.85 (2s, 2 
x C-l of PMB rings), 137.91, 138.04 (2s, 2 x C-l of Bn rings), 159,12, 159.31 (2s, 2 x 
C-4 of PMB rings), 161.32 (s, C=NH); m/z (FAB’) 744 [(M-H)’, 1%], 121 (100).
7.3.6 Methyl 2\5,6^ri-0-benzyl-3-(>a-D-glu(X)pyranosyl-2,3\4,-tri-0-p-
methoxybenzyl-^-D-ribofuranoside (72a)
A mixture of 67a (188mg, 0.25mmol), and methyl 5-0-benzyl-2-O-p- 
methoxybenzyl-y#-D-ribofuranoside (86mg, 0.23mmol) was stirred in dry diethyl ether 
(2.5cm3) at room temperature with 4A molecular sieves (90mg) for 30 min, whereupon
'j
trimethylsilyl triflate (0.01cm of a 0.2M solution in diethyl ether, 0.002mmol) was 
added. After 5 min TLC (chloroform/acetone 30:1) showed formation of a product (Rf 
0.26) from the imidate (Rf 0.32), and the glycosyl acceptor (Rf 0.23). The reaction 
mixture was quenched with triethylamine (6 drops), and concentrated. The resulting 
clear oil was subjected to flash chromatography (eluent chloroform/acetone 30:1), and 
again (eluent chloroform/acetone 35:1), to give an inseparable mixture of the title 
compound, and its y^-D-glucopyranosyl isomer, in a 4:1 ratio (120mg, 54%) calculated 
from lH NMR integral ratios.
(Found: C, 71.5; H, 6.72. Calc for C57H640i3: C, 71.53; H, 6.74%); Selected *H NMR 
data for a-coupled product: !H NMR (400 MHz; CDC13) Sn 4.93 (1H, d, J  2.0, H-l), 
5.09 (1H, d, J 3.4, H-l ); m/z (FAB ) 1109 [(M+153)’, 100%].
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7.3.7 Methyl 2 ,5,6 -tri-0-benzyl-3-0-a-D-glucopyranosyl-/?-D- 
ribofuranoside (73a)
72a (379mg, 0.40mmol) Was stirred with DCM (12cm3) and water (1cm3), for 20 
min, when DDQ (551mg, 2.38mmol) was added. After 60 min TLC 
(chloroform/acetone 30:1) showed consumption of starting material Rf 0.26. The 
reaction mixture was diluted with DCM (60cm3), and the organic layer washed with 10% 
aqueous Na2SC>3 solution (3 x 50cm3), followed by 50cm3 each of saturated aqueous 
NaHCC>3 solution and brine. The organic layer was dried (MgSC^) filtered and 
concentrated to a clear oil, which was subjected to flash chromatography (eluent ethyl 
acetate/hexane 7:3), to give methyl 2 ,5 ,6-tri-0-benzyl-3-0-/?-D-glucopyranosyl-/?-D- 
ribofuranoside (73b) (27mg, 11%).
'H NMR (400 MHz; CDCI3) <5k 2.86,2.30, 3.06 (3H, 3 x br. s, 3 x OH), 3.23-3.27 (1H, 
m, H-2'), 3.33 (3H, s, OCH3), 3.40-3.49 (3H, m, H-3’, H-4', H-5'), 3.56 (1H, 0.5 ABX, 
2J a b  10.5, 3J a x  5.6, H-5A), 3.59-3.63 (2H, m, H-5B, H-6'A), 3.70 (1H, 0.5 ABX, 2J a b
10.5, V a x  3.2, H-6'b),4.11 (1H, d, J4 .4 , H-2), 4.18 (1H, dd, J4 .4 , 6 .8, H-3), 4.28-4.33 
(1H, m, H-4), 4.45 (1H, d, J7.8, H-l'), 4.50-4.54 (4H, m, 2 x OCi/2Ar), 4.58,4.81 (2H, 
AB, Jab 11.5, OC/fcAr), 4.90 (1H, s, H-l), 7.23-7.35 (15H, m, AiCH).
Further elution gave the title compound (73a) (135mg, 57%). Crystallisation 
occurred spontaneously on standing.
mp 103-105°C; [a]D +28.26 (c 3.7, CHC13); (Found: M+, 596.259. Calc for C33H40O10 
M+: 596.262); *H NMR (400 MHz; CDCI3) &  1.69 (1 H, br. s, D20  exch., OH), 2.74, 
2.87 (2H, 2 br s, D20  exch., OH), 3.32 (3H, s, OCH3), 3.38 (1H, dd, J  9.8, 3.4, H-2 ), 
3.45-3.57 (5H, m, H-4', H-5A, H-5B, H-6 A, H-6 B), 3.74 (1H, ddd, .79.8, 3.9, H-5 ), 3.92 
(1H, dd, J  9.3, 9.3, H-3 ), 4.01 (1H, m, H-3), 4.22 (2H, m, H-2, H-4), 4.44, 4.52 (2H, AB, 
J  12.2, OCtf2Ar), 4.51 (2H, s, OCtf2Ar), 4.69, 4.74 (2H, AB, J  11.7, OCtf2Ar), 4.69 
(1H, d, J  3.4, H-l ), 4.88 (1H, s, H-l), 7.23-7.36 (15H, m, ArCH); 13C NMR (100.4 
MHz; CDCI3) 5c 55.03 (q, OCH3), 69.00 (t, C-5 or C-6 ), 70.74 (d, C-4 ), 70.84 (d, C-5 ), 
71.69 (t, C-5 or C-6 ), 73.24 (d, C-3 ), 73.28 (C-3), 73.32, 73.55, 74.14 (3t, 3 xOCH2Ar), 
78.35 (d, C-2 ), 79.11 (d, C-2 or C-4), 80.27 (d, C-2 or C-4), 97.79 (d, C-l ), 108.34 (d, 
C-l), 127.57, 127.63, 127.69, 127.74, 128.33, 128.42, 128.51, 128.75 (8d, ArCH),
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137.18, 137.86, 138.06 (3s, 3 x C-l of Bn rings); m/z (FAB+) 597 [(M+l)+, 12%], 565 
(48), 343 (3), 255 (2).
7.3.8 Methyl^ .S^ -tri-O-benzyl-S-O-ar-D-glucopyranosyl^.S ^'-tris- 
(dibenzyloxyphosphoryl)->0-D-ribofuranoside (74)
A mixture of bis(benzyloxy)(diisopropylamino)phosphine (372mg, 1.08mmol), 
dry DCM (3mL) and tetrazole (113mg, 1.62mmol) was stirred at room temperature for 
30 min, after which time a solution of 73a (107mg, 0.18mmol) in dry DCM (2cm3) was 
added and stirring was continued for a further 30 min. TLC (ethyl acetate/hexane 7:3) 
indicated complete conversion of starting material (Rf 0.14) to a product (Rf 0.49) and 
31P NMR spectroscopy showed phosphite triester signals. The system was cooled to - 
78°C, MCPBA (432mg, 2.15mmol) was added and the system warmed to room 
temperature. After 10 min, TLC showed conversion of the trisphosphite to a new 
product (Rf 0.78). The mixture was extracted with DCM (100cm3) and the organic 
extract was washed with 10% aqueous Na2SC>3 solution (50cm3), saturated aqueous 
NaHCC>3 solution (2 x 50cm ), and brine (50cm ). The organic solution was dried 
(MgSCU), filtered and concentrated to give a white solid. Flash chromatography (eluent 
CHCls/acetone 20:1 then 10:1, then 4:1) to gave the title compound as a colourless oil 
(220mg, 89%).
[a]D +34.70 (c 8.07, CHC13); (Found: M+, 1377.451. Calc for C75H80O19P3 M ) 
1377.450); ‘H NMR (400 MHz; CDCI3) <5h 3.25 (3H, s, OCH3), 3.52 (1H, 0.5 ABX, Vab
10.5, V ax 5.1, H-5a), 3.55-3.60 (2H, m, H-2', H-5B), 3.65 (2H, ABX, 2Jm  10.4, 3Jax = 
V bx 3.9, H-6 a, H-6'b), 3.82-3.84 (1H, m, H-5 ), 4.28^1.31 (2H, AB, Jab 11.7, OCHHAr 
overlapping with H-4), 4.34-4.53 (5H, m, 4 x OCHHAr, H-3), 4.60 (1H, dd, J9 .5 , 18.8, 
H-4), 4.67-4.77 (3H, m, 2 x OCHHAr, H-2), 4.80-5.03 (13H, m, H-l, H-3', 11 x 
OCHHAr), 5.09 (1H, d, J3.4, H -l), 7.01-7.35 (45H, m, ArCH); l3C NMR (100.4 MHz; 
CDCI3) 5c 55.19 (q, OCH3), 67.94 (t, C-5 or C-6 ), 69.01 69.29, 69.41, 69.56, 69.71,
69.78 (6t, 6 x POCH2Ar), 70.57 (t, C-5 or C-6 ), 71.91, 73.19 (2t, 3 x OCH2Ar), 73.95 
and 74.30 (with C-P coupling), 76.86, 77.08 and 78.18 (with C-P coupling), 79.75 (6d, 
C-2, C-3, C-4, C-2', C-3', C-4', C-5'), 95.01 (d, C-l ), 105.85 (d, C-l), 127.39-128.95
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(45d, ArCH), 135.53-136.19 (6s, 6 x C-l of benzylphospho rings, with C-P coupling),
137.62, 138.06, 138.11 (3s, 3 x C-l of Bn rings); 31P NMR (161.7 MHz; CDC13; 'H 
decoupled) <$> -2.25, -1.94, -1.22 (3s); m/z (FAB*) 1377 (M+, 4%), 91 (100).
7.3.9 Methyl 3-0-a-D-glucopyranosyl-/(-D-ribofuranoside 2 ,3 ,4 -  
trisphosphate (62)
10% Palladium on activated charcoal (200mg), was added to a solution of 74 in 
methanol (40cm3) and water (10cm3). This mixture was shaken under 40 psi pressure in 
an atmosphere of hydrogen for 18 h, after which it was filtered through Celite. The 
filtrate was concentrated to a glassy clear solid. The residue was dissolved in de-ionised
•5
water (300cm ) and purified by ion-exchange chromatography on Q Sepharose fast flow 
resin, eluting with a gradient of triethylammonium bicarbonate buffer (0-1M), pH 7.5. 
The triethylammonium salt of the title compound eluted over 800-850 mmol dm'3 buffer. 
After concentration of the appropriate fractions 62 was found to be insoluble in water. 
Therefore 62 was converted into its potassium salt with 0.1M aqueous potassium 
hydroxide solution (2cm ), and subsequently quantified by the Briggs total phosphate 
assay (60pmol, 78%).
[a]d20 +79.1 (c 1.70 calc, for free acid, MeOH); (Found: M', 565.012. Calc for 
C12H24O19P3 (M-H)': 565.012); !H NMR (400 MHz; CD3OD) <5k 3.35 (3H, s, OCH3), 
3.54 (1 H, dd, 7  6.4, 11.9, H-5A), 3.62 (1H, dd, 7  3.8, 9.6, H-2 ), 3.66 (1H, br s, OH), 
3.69-3.73 (3H, m, H-5B, H-5', H-6A), 3.93 (1H, dd, 7  3.5, 13.0, H-6B), 4.04-^1.11 (2H, 
m, H-4, H-4 ), 4.44 (1H, dd, 74.3, 7.3, H-3), 4.45 (1H, dd, 79.0, 18.2, H-3 ), 4.58 (1H, 
dd, 74.3, 9.5, H-2), 4.94 (1H, s, H-l), 5.03 (2H, br s, 2 x OH), 5.13 (1H, d, 73.7, H-l ); 
13C NMR (100.4 MHz; CDC13) 8C 55.18 (q, OCH3), 61.98, 64.87 (2t, C-5, C-6 ), 73.32, 
73.52, 73.78, 76.29, 76.49 (with C-P coupling), 78.83 (6d, C-2, C-3, C-2'-C-5 ), 82.71 
(d, C-4), 98.93 (d, C-l'), 108.96 (dd, 37c p  3.7, C-l) and triethylammonium signals; 31P 




7.4 Synthesis of furanophostin
7.4.1 [(3S,4R)-3-p-methoxybenzyloxy tetrahydrofuran-4-yl] 2,6-di-O- 
benzyl-3,4-di-0-p-methoxybenzyl-c^D-glucopyranoside (76)
A mixture of 47 (1.85g, 2.68mmol) and (+)-(3R,4S)-4-p-methoxybenzyloxy- 
tetrahydrofuran-3-ol (0.30g, 1.34mmol) was stirred together with 4A molecular sieves 
(1.50g) in of toluene (5cm3) and dioxane (15cm3) for 2h under an atmosphere of 
nitrogen. Zinc chloride (0.44g) and silver perchlorate (1.33g) were then added and the 
flask was wrapped in foil. After stirring for 2 h TLC (ethyl acetate/toluene 1 : 4) 
indicated the formation of one major product (Rf 0.44). The foil was removed and water 
(25 cm3) added, the resulting pale pink suspension was filtered through Celite and the 
residue was washed thoroughly with ethyl acetate. The filtrate and washings were 
transferred to a separating funnel with ethyl acetate (150 cm3) and water (100 cm3). The
- j
organic layer was collected, washed with brine (100 cm ), dried (MgSC>4), filtered and 
concentrated. The resulting clear residue was subjected to flash chromatography (eluent 
ethyl acetate/toluene 1:9) yielding the title compound as a clear oil which solidified on 
standing (0.82g, 76%).
mp 80-83°C (diethyl ether/hexane); [a]d20 + 19.0 (c 0.2, CHCI3); (Found: C, 
71.30; H, 6.75. Calc, for C48H54O11: C, 71.45; H, 6.74%); *H NMR (400 MHz; CDCI3) 
Sh 3.54—3.62 (3H, m, H-2, H-4, H-6A), 3.68-3.87 (13H, m, 3 x OCH3, H-2'A, H-5, H-5'A, 
H-6b), 3.93-4.02 (3H, m, H-2'B, H-3, H-5'B), 4.07 (1H, dd, J  10.5, 5.6, H-3'), 4.20 (1H, 
dd, J  10.5, 5.6, H-4'), 4.36-4.89 (10H, m, 5 x OC/f2Ar), 5.18 (1H, d, J3 .4 , H-l), 6.77-
6.83 (6H, m, 3 x H-3 and H-5 of PMB rings), 7.02-7.05 (2 H, m, H-2 and H-6 of PMB 
rings), 7.21-7.32 (14H, m, ArCH); 13C NMR (100.4 MHz; CDC13) Sc 55.17, 55.18 (2q, 2 
x OCH3), 68.33 (t, C-6), 70.23 (t, C-2’, or C-5'), 70.45 (t, C-2', or C-5'), 70.67 (d, C-5),
72.01, 72.30, 73.38, 74.64, 75.24 (5t, OCH2Ar), 75.94 (d, C-4'), 77.17 (d, C-4), 77.33 (d, 
C-3'), 79.74 (d, C-2), 81.33 (d, C-3), 96.90 (d, C-l), 113.69 (3d, C-3 and C-5 of PMB 
rings), 127.51, 127.64, 127.73, 127.84, 128.23, 128.32, 129.47, 129.54 (8d, ArCH),
130.09, 130.36, 130.99 (3s, 3 x C-l of PMB rings), 137.83, 138.34 (2s, 2 x C-l of Bn
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rings), 159.06, 159.13, 159.17 (3d, 3 x C-4 of PMB rings); m/z (FAB+) 829 [(M+Na)+, 
3%]; 121 (100).
7.4.2 [(3S,4ft)-3-Hydroxytetrahydrofuran-4-yl] 2,6-di-O-benzyl a-d- 
glucopyranoside (77)
TFA (2cm3) was added to a solution of 76 (500mg, 0.62mmol) in DCM (18cm3) 
and the resulting purple solution was stirred at rt. for 10 min, then poured slowly into 
saturated aqueous NaHCC>3 solution (300cm3). The aqueous layer was extracted with 
DCM (3 x 100cm ) and the combined organic layer was dried (MgSO/*), filtered and 
concentrated to a yellow oil that was subjected to flash chromatography (eluent ethyl 
acetate/hexane 7 : 3), to give a white solid (234mg, 84%).
mp 83-85°C (diethyl ether); [a]D20 +70.0 (c 0.4, CHC13); (Found: C 64.40; H 6.78. Calc 
for C24H3o08: C 64.56; H 6.77); !H NMR (400 MHz; CDC13) Sa 3.37 (1H, dd, J  9.5, 3.7, 
H-2), 3.47 (1H, ddd, J 9.3, 3.9, H-4), 3.63 (2H, d, /3 .9 , H-6A, H-6B), 3.69 (1H, dd, J 9.8,
4.4, H-2'A), 3.74-3.79 (2H, m, H-5, H-5'a), 3.82-3.90 (2H, m, H-2’B, H-5'B), 3.93 (1H, 
ddd, J 9.0,3.9, H-3), 3.99 (1H, d d d ,/5.4, H-4'), 4.07-4.11 (2H, m, D20  exch., 3'-OH, 4- 
OH), 4.21 (1H, dddd, J  10.3, 5.4, 5.4, H-3'), 4.44 (1H, br s, D20  exch., 3-OH), 4.49,
4.53, (2H, AB, /ab 12.2, OCtf2Ar), 4.63, 4.76 (2H, AB, /ab 11.7, OCH2Ai ), 4.75 (1H, s, 
H-l), 7.22-7.36 (10H, m, ArCH); 13C NMR (100.4 MHz; CDC13) 5C 68.94 (t, C-6), 
70.23 (d, C-4), 70.31 (t, C-2'), 70.60 (d, C-3'), 71.08 (d, C-5), 72.48 (t, C-5'), 72.92 (d, C- 
3), 73.32, 73.93 (2t, 2 x OCH2Ar), 78.81 (d, C-2), 78.90 (d, C-4'), 98.4 (d, C-l), 127.42, 
127.46, 128.19, 128.33, 128.48 (5d, ArCH), 137.11, 137.75 (2s, 2 x C-l of Bn rings); 
m/z (FAB-") 829 [(M+Na)+, 3%]; 121 (100).
7.4.3 [(3S,4f?)-3-Dibenzyloxyphosphoryloxytetrahydrofuran-4-yl] 2,6-di- 
0-benzyl-3,4-bis-0-(dibenzyloxyphophoryl) a-D-glucopyranoside (78)
A mixture of bis(benzyloxy)(diisopropylamino)phosphine (325mg, 0.94mmol), 
dry DCM (5cm ) and tetrazole (99mg, 1.41 mmol) was stirred at room temperature for 30
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min after which the triol 77 (70mg, 0.16mmol) was added and the mixture stirred for a 
further 30 min. The mixture was then cooled to -78°C and MCPBA (406mg) added, the 
cooling bath was removed and the mixture was allowed to warm to room temperature. 
TLC (ethyl acetate) after 15 min indicated conversion of the trisphosphite triester to 
product (Rf 0.28). The reaction mixture was diluted with DCM (50cm3) and washed 
with 25cm3 each of 10% aqueous Na2SC>3 solution, saturated aqueous NaHCC>3 solution 
and brine. The organic layer was dried (MgS04), filtered and concentrated to give an off 
white solid that was subjected to flash chromatography (eluent ethyl acetate/hexane 3:2). 
Concentration of appropriate fractions gave the title compound as a clear oil (188mg, 
98%).
[a]D25 +30.0 (c 1.5, CHC13); (Found: (M+l)+, 1227.382. Calc for C66H70O17P3 (M+l)+: 
1227.382); *H NMR (400 MHz; CDC13) Sa 3.56 (1H, dd, J9.8, 3.7, H-2), 3.69-3.75 (2H, 
m, H-6A, H-6b), 3.77-3.82 (2H, m, H-5, H-5'A), 3.88 (2H, d, J  5.2, H-2'A, H-2'B), 3.92 
(1H, dd, J5.8, 9.2, H-5'B), 4.08 (1H, dd, J  10.4, 5.2, H-4'), 4.36, 4.48 (2H, AB, Jab 12.1, 
OCtf2Ar), 4.50-4.63 (3H, m, H-4, OGtf2Ar), 4.73 (1H, AB, JAB 11.9, JH.P 8.2, 
POC//2Ar), 4.80-5.05 (14H, m, 5.5 x OC/^Ar, H-l, H-3, H-3'), 7.03-7.35 (40H, m, 
ArCH); 13C NMR (100.4 MHz; CDCI3) Sc 68.11 (t, C-6), 68.95-69.76 (6t, POCH2Ar 
with C-P coupling, and d, C-5'), 70.00 (t, C-2’), 72.15 (t, OCH2Ar), 73.21 (t, OCH2Ar), 
74.37 (d, C-4 with C-P coupling), 74.70 (d, C-4' with C-P coupling), 75.42 (d, C-3' with 
C-P coupling), 77.22 (d, C-2), 78.06 (d, C-3 with C-P coupling), 95.76 (d, C-l), 127.53,
127.62, 127.67, 127.79, 127.95, 128.01, 128.19, 128.24, 128.35, 128.44, 128.54 (lid , 
ArCH), 135.50, 135.60, 135.74, 135.81, 136.07, 136.13 (6s, 6 x C-l of benzylphospho 
rings), 137.77, 137.95 (2s, 2 x C-l of Bn rings); 3IP NMR (161.7 MHz; CDC13; 'H 
decoupled) & -2.25, -1.94, -1.10 (3s); m/z (FAB3)  1227 [(M+l)+, 9%], 91 (100).
7.4.4 [(3S,4R)-3-hydroxytetrahydrofuran-4-yl] a-D-glucopyranoside 
3,3',4-trisphosphate (79)
Moist palladium on carbon 10% (200mg) was added to a solution of 78 (75mg, 
61pmol) in methanol (50cm3) and water (10cm3). This mixture was shaken in an 
atmosphere of hydrogen at 50psi for 25 h. The catalyst was removed by filtration 
through a membrane filter, and the filtrate was concentrated to a clear residue. The crude
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product was purified by ion exchange chromatography using Q Sepharose fast flow 
resin, eluting with a gradient of 1M triethylammonium bicarbonate buffer (0-1M) pH 
8.0. The triethylammonium salt of the title compound eluted between 560 and 620 mmol 
buffer (57 pmol, 93%).
[a]D21 +74.8 (c 0.6 calc, for free acid, MeOH); (Found (M-H)' 504.9890. Calc for 
C10H20O17P3 (M-H)' 504.9913); *H NMR (400 MHz; D20) Sa 3.74 (1H, dd, /9 .0 , 3.2, 
H-2), 3.78-3.94 (5H, m, H-2’A, H-5, H-5’A, H-6A, H-6B), 4.01^.09 (3H, m, H-2’B, H-4, 
H-5'b), 4.43-4.50 (2H, m, H-3, H-4'), 4.80-4.89 (1H, m, H-3'), 5.25 (1H, d, J 2.93, H-l); 
31P NMR (161.7 MHz; CD3OD; *H coupled) Sp 0.04 (d, 7.3), 0.82 (d, Jhp 7.6), 1.08
(d, Jw  9.8 ); m/z (FAB') 505[(M-H)', 100%].
170
Chapter seven
7.5 Synthesis of mannophostin
7.5.1 2,6-Di-0-benzyl-3,4-di-0-p-methoxybenzyl-D-mannopyranosyl 
dimethyl phosphite (105)
To a mixture of 2,6-di-0-benzyl-3,4-di-0-p-methoxybenzyl-D-mannopyranose 
(1.29g, 2.15mmol) and tetrazole (0.23g, 3.23mmol) in DCM (15cm3) was added
- j
bis(methoxy)(diethylamino)phosphine (0.46cm , 2.80mmol). After stirring for 20 min 
TLC (ethyl acetate/toluene 1:4) indicated complete conversion to product (Rf 0.69). The 
reaction mixture was partitioned between diethyl ether (80cm ) and water (60cm ). The 
resulting ethereal layer was washed with brine (60cm ), dried (MgSCU), filtered and 
concentrated to give a clear runny oil that was used without further purification.
'H NMR (400 MHz; CDCI3) a  anomer; A  3.39-3.44 (6H, m, OP(OMe)2 with C-P 
coupling), 3.65-3.71 (2H, m, H-2, H-6A), 3.76-3.80 (1H, m, H-6b overlapping with 2 x 
OCH3), 3.76, 3.78 (6H, 2s, 2 x OCH3), 3.90-4.03 (3H, m, H-3, H-4, H-5), 4.44-4.82 
(8H, m, 4 x OCtf2Ar), 5.52 (1H, dd, J  1.8, Jn.p 8.2, H-l), 6.78-6.86 (4H, m, C-3 and C-5 
of PMB ring), 7.08-7.11 (2H, m, C-2 and C-6 of PMB ring), 7.21-7.39 (12H, m, ArCH); 




105 (1.48g, 2.15mmol) And 40 (0.84g, 1.08mmol) in dioxane (12cm3) and 
toluene (4cm3) were stirred with 4A molecular sieves (approx. 1.2g) for 2 h, and then dry 
zinc chloride (0.35g, 2.58mmol) and silver perchlorate (1.07g, 5.16mmol) were added. 
The flask was wrapped in foil and stirring was continued for 8 h. Solid NaHCC>3 (l.OOg) 
and water (30cm3) were added and the reaction mixture was diluted with ethyl acetate 
(40cm3). After stirring for a further 30 min the mixture was filtered through a Celite pad, 
and the residue was well washed with ethyl acetate. Water (20cm3) was added to the
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filtrate, and the resulting aqueous layer was discarded. The organic layer was washed 
with brine (50cm3), dried (MgS04), filtered and concentrated and the residue was 
subjected to flash chromatography (eluent ethyl acetate/hexane 3:7, then 1:1) to yield the 
title compound as a clear oil (0.89g, 61%).
Rf 0.53 (ethyl acetate/toluene 1:4); [<z]d18 -1-0 (c 1.0, CHCI3); (Found: C, 72.10; H, 6.20; 
N, 5.06. Calc for CkHkNsOm: C, 72.28; H, 6.14; N, 5.14%); *H NMR (400 MHz; 
CDCI3) Sh 3.55 (1H, 0.5 ABX, Vab10.7, Vax 2.9, H-5’A), 3.59-3.73 (4H, m, H-3" or H- 
4", H-5'b, H-6"a, H-6"b), 3.66 (3H, s, OCH3), 3.77 (9H, s, 3 x OCH3), 3.79 (3H, s, 
OCH3), 3.79 (3H, s, OCH3), 3.83-3.91 (3H, m, H-2", H-3" or H-4", H-5"), 4.28 (1H, dd, 
J  2.9, H-4f), 4.37-4.60 (13H, m, H-2', H-3', 11 x OCHT/Ar), 4.77 (1H, AB, Jab 10.3, 
OCHtfAr), 5.05 (1H, s, H-l"), 6.16 (1H, d, J  5.4, H-l'), 6.63-6.67 (2H, m, ArCH), 
6.78-6.81 (4H, m, ArCH), 6.86-6.90 (2H, m, ArCH), 6.96-6.99 (2H, m, ArCH), 
7.06-7.08 (2H, m, ArCH), 7.20-7.35 (28H, m, ArCH), 7.90, 8.07 (2H, 2s, H-2, H-8); 13C 
NMR (100.4 MHz; CDCI3) 8c 55.07, 55.15, 55.20 (3q, 5 x OCH3), 69.08 (t, C-6"), 69.52 
(t, C-5'), 70.58 (s, DMTr Cq), 71.75, 72,03, 72.52, 73.29, 73.53, 74.70 (6d, 6 x 
OCH2Ar), 72.37, 74.28, 74.59 (3d, C-3", C-4", C-5"), 73.21 (d, C-3"), 79.62 (d, C-2', C- 
2"), 82.56 (d, C-4'), 86.18 (d, C-l'), 97.81 (d, C-l"), 113.06, 113.65, 113.70 (3d, C-3 and 
C-5 of /?-OCH3 phenyl rings), 121.00 (s, C-5), 126.73, 127.40, 127.48, 127.55, 127.60, 
127.73, 127.17, 128.24, 128.48, 128.76, 129.16, 129.49, 129.63, 130.05, 130.49 (15d, 
ArCH), 128.81, 130.51, 130.57(3s, C-l of PMB rings), 137.42, 138.17 (2s, C-l of DMTr 
/7-OCH3 phenyl rings, 3 x C-l of Bn rings), 138.30 (d, C-8), 145.43 (s, C-l of DMTr 
phenyl ring), 148.62 (s, C-4), 152.29 (d, C-2), 153.99 (s, C-6), 158.20 (s, 2 x C-4 of 
DMTr /7-OCH3 phenyl rings), 159.06,159.11, 159.41 (3s, C-4 of PMB ring); m/z (FAB*) 
1362 (M*, 7%), 436 (6), 303 (100), 121 (88).
7.5.3 2,,,5,J6,,-Tri-0-benzyl-3,-0-a-D-mannopyranosyl adenosine (107)
To 106 (528mg, 0.39mmol) in DCM (27cm3), was added TFA (3cm3). The resulting 
bright orange solution was stirred for 5 h before being poured into saturated aqueous 
NaHCC>3 solution (200cm3). DCM (100cm3) was added and the now colourless mixture 
was stirred vigorously for 30 min. The resulting aqueous layer was extracted with DCM
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(2 x 100cm ) and the combined organic layers dried (MgS04), filtered and concentrated. 
The resulting crude product was purified by flash chromatography (eluent ethyl 
acetate/ethanol 14:1, then 9:1) to yield the title compound as a white solid (223mg, 
82%).
mp 175-178°C (ethanol); Rf 0.22 (ethyl acetate/ethanol 14:1); (Found: M+, 700.296. 
Calc for C37H42N5O9 (M+H)+: 700.298); *H NMR (400 MHz; D6 DMF) <5h 3.68-3.86 
(6H, m, H-4", H-5", H-5’A, H-5'B, H-6"A, H-6"B), 3.93-3.96 (1H, m, H-3"), 3.99-4.00 
(1H, m, H-2"), 4.39 (1H, ddd, J  3.2, H-4'), 4.34-4.62 (5H, m, 2 x OC/72Ar, H-3'), 4.71, 
4.80 (2H, AB, Jab 12.2, OCi/2Ar), 4.97-5.03 (2H, m, H-2’, 3"-OH), 5.13 (1H, d, J  4.7, 
4"-OH), 5.37 (1H, s, H-l"), 5.95 (1H, d, J  6.7, 2'-OH), 6.11 (1H, d, J  6.4, H-l'),
7.24-7.44 (15H, m, ArCH), 8.22, 8.34 (2H, 2s, H-2, H-8); 13C NMR (100.4 MHz; 6* 
DMF) Sc 68.83 (d, C-4" or C-5"), 71.12, 71.24 (2t, C-5’, C-6"), 72.49 (d, C-3"), 73.47, 
73.63, 73.73 (3t, 3 x OCH2Ar), 74.53 (d, C-4" or C-5"), 74.72 (d, C-2’), 76.59 (d, C-3'), 
79.62 (d, C-2"), 83.35 (d, C-4'), 88.10 (d, C-l'), 99.20 (d, C-l"), 120.18 (s, C-5), 127.86,
127.96, 128.00, 128.11, 128.24, 128.77, 128.91, 129.03 (8d, ArCH), 139.21, 139.21, 
139.86 (3s, 3 x C-l of Bn ring), 140.05 (d, C-8), 150.85 (s, C-4), 153.62 (d, C-2), 157.14 
(s, C-6); m/z (FAB+) 700 [(M+H)+, 70%], 91 (100).
7.5.4 2,,l5,,6"-Tri-0-benzyl-2,,3,,J4 ,,-tris(dibenzyloxyphosphoryl)-3,-0 -a -  
D-mannopyranosyl adenosine (108)
A solution of 107 (lOOmg, 0.14mmol) in DCM (3cm3) with 
bis(benzyloxy)(diisopropylamino)phosphine (0.16cm, 0.49mmol) and imidazolium 
triflate (103mg, 0.47mmol), was stirred for 1 h, after which time TLC (ethyl 
acetate/hexane 7:3) indicated conversion to the trisphosphite (Rf 0.67). Water (1 drop) 
was added and the solution cooled to -78°C, after which MCPBA (144mg, 0.50mmol) 
was added. After 10 min 10% aqueous Na2SC>3 solution (15cm3) and ethyl acetate 
(20cm ) were added and the mixture was allowed to warm to room temperature. The 
resulting organic layer was washed with 15cm3 each of saturated aqueous NaHC(>3 
solution and brine, and then dried (MgSCU), filtered and concentrated to a clear oil which
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was subjected to flash chromatography (eluent chloroform/acetone 9:1, then 4:1, then 
3:2) to give the title compound as a clear oil (119mg, 56%).
Rf 0.29 (ethyl acetate/hexane 7:3); -1.9 (c 1.1, CHCI3); (Found: M+, 1480.483.
Calc for CtoHsiNjOisPj (M-H)': 1480.478); *H NMR (400 MHz; CDC13) *  3.53, 3.66 
(2H, ABX, 2J a b  10.9, 3J a x  3.2, 3JBX 2.5, H-5'A, H-5’B), 3.70 (1H, 0.5 ABX, 2J a b  10.8, 
3J a x  5.9, H - 6 " a ) ,  3.75-3.78 (1H, m, H-6”B), 3.82-3.86 (1H, m, H-5"), 4.26-4.29 (1H, m, 
H-41), 4.37-4.44 (5H, m, H-2", 2 x OCJfeAr), 4.54, 4.64 (2H, AB, Jab 11.7, OC//2Ar), 
4.68 (1H, dd, J4 .7 , H-3'), 4.79-5.03 (14H, m, 6 x OCH2Ai, H-3", H-4"), 5.30 (1H, d, J
1.5, H-l"), 5.44 (1H, ddd, J3 .5 , JH.P 8.5, H-2'), 5.86 (2H, br.s, NH2), 6.22 (1H, d, J 5.0, 
H-l'), 7.11-7.32 (45H, m, ArCH), 8.00, 8.23 (2H, 2s, H-2, H-8); 13C NMR (100.4 MHz; 
CDCI3) 69.24-70.34 (8t, C-5', C-6”, 6 x POCH2Ar with C-P coupling), 72.05 (d, C-5" 
with C-P coupling), 72.87 (d, C-4" with C-P coupling), 72.96, 73.60, 73.88 (3t, 3 x 
OCH2Ar), 74.49 (d, C-4"), 76.28 (d, C-3" with C-P coupling), 76.77 (d, C-2"), 77.67 (d, 
C-2’), 82.27 (d, C-4'), 86.84 (d, C-l’ with C-P coupling), 97.75 (d, C-l"), 119.94 (s, C-5), 
127.50, 127.59, 127.72, 127.87, 127.96, 127.97, 128.05, 128.08, 128.13, 128.20, 128.32, 
128.39, 128.49, 128.61, 128.64, 128.69, 128.73 (17d, ArCH), 135.31-135.95 (6s, 6 x C- 
1 of benzylphospho ring with C-P coupling), 137.42, 138.14, 138.39 (3s, 3 x C-l of Bn 
rings), 139.15 (d, C-8), 149.92 (s, C-4), 153.08 (d, C-2), 155.38 (s, C-6); 31P NMR 
(161.7 MHz; CDC13; ‘H decoupled) 8r -1.30, -0.80, -0.35 (3s); m/z (FAB4) 1480 
[(M+H)+, 3%], 91 (100).
7.5.5 3-O-a-D-Mannopyranosyl adenosine 2',3",4"-trisphosphate (97)
A mixture of 108 (61mg, 0.04mmol) and wet 20% palladium hydroxide on
' j  •y *5
carbon (180mg), in methanol (7.2cm ), cyclohexane (3.6cm ) and water (0.7cm ) was 
heated at reflux for 2.5 h. After cooling the reaction mixture was filtered through a 
membrane filter and the catalyst was washed copiously with methanol and water. 
Concentration of the filtrate afforded a clear residue that was purified by application to 
an MP1 AG ion exchange resin column and eluting with a gradient of 0-100% 150mM 
TFA. Concentration of the appropriate fractions (being careful to keep the temperature 
below 20°C) gave the desired product as the free acid (19mg, 71%), which was dissolved
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in water and eluted through a short column of Na+ dianion WK-40 ion exchange resin to 
give, after concentration, the sodium salt.
(Found: NT, 668.039. Calc for C16H25N5O18P3 (M-H) : 668.040); ‘H NMR (400 MHz; 
D20) <5h 3.58-3.72 (5H, m, H-5'A, H-5'B, H-5", H-6"A, H-6"B), 4.15-4.24 (3H, m, H-2', 
H-4', H-4"), 4.39-4.48 (2H, m, H-3', H-3"), 4.98 (1H, s, H-l”), 5.08-5.14 (1H, m, H-21),
6.11 (1H, d, J  6.4, H-l'), 8.24, 8.33 (2H, 2s, H-2, H-8); 31P NMR (161.7 MHz; D20 ; ‘H




7.6 Synthesis of xylophostin
7.6.1 Allyl a-D-xylopyranoside (109)
Allyl alcohol (1000cm3) and acetyl chloride (6cm3) were stirred together for 30 
min, after which time D-xylose (lOO.OOg, 0.67mol) was added. The mixture was 
refluxed for 16 h then cooled. Solid NaHCC>3 (7.00g) was slowly added, and stirring 
continued for 30 min. The mixture was then filtered and the filtrate was concentrated to 
an off-white solid. The solid was dissolved in a minimum of ethanol (700cm3) and the 
solution was kept at -20°C for 24 h. Diisopropyl ether was added immediately before the 
collection of the title compound over three crops as white fluffy crystals (52.25g, 41%). 
Rf 0.47 (ethyl acetate/methanol 9:1); mp 100-102°C (ethanol) [lit.88 101-103°C]; !H 
NMR (400 MHz; D20) <5h 3.51-3.70 (5H, m, H-2, H-3, H-4, H-5A, H-5B), 4.01-4.24 
(2H, m, Ctf2CH=CH2), 4.92 (1H, d, J  3.5, H-l), 5.25 (1H, m, V  10.3, 
CH2CH=C//c/,C H ^ ) , 5.35 (1H, d, V  17.2, CH2CH=CHc/,C / /^ ) ,  5.90-6.04 (1H, m, 
CH2CH=CH2).
7.6.2 Allyl 2-Opivaloyl-c^D-xylopyranoside (116)
A solution of 109 (4.00g, 21.05mmol) in pyridine (30cm3) was cooled to -20°C 
and pivaloyl chloride (2.56cm , 20.79mmol) was added dropwise. TLC (ethyl acetate) 
indicated conversion of starting material to one major product (Rf 0.74). The reaction 
mixture was partitioned between 0.25M aqueous HC1 (100cm3) and ethyl acetate 
(200cm ), and the resulting organic layer was washed with saturated aqueous NaHCC>3
^ 'y
solution (100cm ) and brine (100cm ), dried (MgS04), filtered and concentrated to give 
the title compound of sufficient purity to be used in the next step. A small amount of the 
residue was purified by flash chromatography (eluent ether/hexane 3:2) to yield an 
analytical sample as a clear oil which crystallised on standing, while the remaining crude 
product was carried forward to the next reaction.
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m p  73-75°C (hexane); [< z ]d 17 +164 (c  1.0, CHCI3); (Found: C, 57; H, 8.16. Calc for 
C13H22O6: C, 56.92; H, 8.08%); JH NMR (400 MHz; CDC13) Sa 1.23 (9H, s, 
C(0)C(CH3)3), 3.27 (1H, br. s, D20  exch., 3-OH), 3.51 (1H, br. s, D20  exch., 4-OH), 
3.56 (1H, dd, 2J=  V  12.0, H-5ax), 3.67-3.74 (2H, m, H-4, H ^ ) ,  3.91-3.96 (2H, m, H- 
3, C//HCH=CH2), 4.15-4.20 (1H, m, CHtfCH=CH2), 4.61 (1H, dd, J  3.8, 10.0, H-2), 
4.97 (1H, d, J  3.5, H-l), 5.18 (1H, m, 3J  10.2, CH2CH=Ci/c*CHfra/ls), 5.29 (1H, m, V
17.1, CH2CH=CHcisCHtrans), 5.78-5.89 (1H, m, CH2Ctf=CH2); 13C NMR (100.4 MHz; 
CDCI3) Sc 27.46 (q, C(0 )C(CH3)3), 39.27 (s, C(0)C(CH3)3), 61.65 (t, C-5), 68.69 (t, 
CH2CH=CH2), 70.74 (d, C-4), 72.55 (d, C-3), 73.40 (d, C-2), 95.47 (d, C-l), 117.71 (t, 
CH2CH=CH2), 113.66 (d, CH2CH=CH2), 178.63 (s, C(0)C(CH3)3); m/z (FAB+) 275 
[(M+H)+, 22%], 32 (297), 217 (100), 199 (43), 85 (22).
7.6.3 Allyl 3,4-0-isopropylidene-2-Opivaloyl-<z-D-xylopyranoside (117)
To crude 116 (5.46g, 12.41mmol) in THF (30cm3) was added 2-methoxypropene 
(2.74cm3, 28.64mmol) and pTSA (50mg). After stirring for 1 h TLC (ether/hexane 1:6) 
indicated conversion to one product (Rf 0.29). The reaction mixture was diluted with 
ether (150cm ) and the organic solution washed with saturated aqueous NaHCC>3 
solution, dried (MgS04), filtered and concentrated. Flash chromatography (eluent 
ether/hexane 1:7, then 1:6) to yielded the title compound as a clear runny oil (3.38g, 
51%, over two steps based on allyl or-D-xylopyranoside).
[cc]D20 +143.2 (c 0.4, CHCI3); (Found: C, 61.00; H, 8.29. Calc for Ci6H260 6: C, 61.13; H, 
8.34%); 'H NMR (400 MHz; CDCI3) <5h 1.23 (9H, s, C(0 )C(CH3)3), 1.46 (6H, s, 2 x 
isopropylidene CH3), 3.48-3.54 (1H, m, H-4), 3.76 (1H, dd, 2J  = V  10.2, H-5^), 
3.90-3.96 (3H, m, H-3, H-5eq, C//HCH=CH2), 4.16-4.21 (1H, m, CH/7CH=CH2), 4.82 
(1H, dd, J  3.8, H-2), 5.16 (1H, d, J  3.8, H-2), 5.19 (1H, m, V  10.2, 
CH2CH=C//c«CHIra„), 5.29 (1H, m, V  17.3, CH2CH=CHc&CH(rara), 5.80-5.90 (1H, m, 
CH2Ctf=CH2); 13C NMR (100.4 MHz; CDCI3) Sc 26.54, 26.81, 27.10 (3q, 2 x 
isopropylidene CH3, C(0)C(CH3)3), 38.77 (s, C(0)C(CH3)3), 61.27 (t, C-5), 68.96 (t, 
CH2CH=CH2), 72.88 (d, C-4), 74.12 (d, C-3), 75.75 (d, C-2), 95.10 (d, C-l), 110.86 (s,
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isopropylidene C(CH3)2), 117.83 (t, CH2CH=CH2), 133.50 (d, CH2CH=CH2), 177.96 (s, 
C(0)C(CH3)3); m/z (FAB1)  315 [(M+H)+, 49%], 57 (100).
7.6.4 Allyl 3,4-O-isopropylidene-a-D-xylopyranoside (118)
A solution of 117 (3.07g, 9.78mmol) in methanol (40cm ) containing sodium 
hydroxide pellets (l.OOg) was refluxed for 90 min. After cooling the sodium hydroxide 
was neutralised by careful addition of solid C 02. The solvent was then evaporated under 
reduced pressure and DCM was added to the residue (250cm3), remaining solid NaHC03 
was removed by filtration and the filtrate concentrated to a clear oil which was subjected 
to flash chromatography (eluent ether/hexane 1:1) to yield the title compound as a clear 
runny oil (2.03g, 90%).
[a]D20 +133.7 (c 0.4, CHC13); (Found: C, 57.10; H, 7.94. Calc for CnH180 5: C, 57.38; H, 
7.94%); *H NMR (400 MHz; CDC13) Sr 1.45, 1.46 (6H, 2s, 2 x isopropylidene CH3), 
2.43 (1H, d, J  10.8, 2-OH), 3.38-3.44 (1H, m, H-4), 3.66-3.74 (2H, m, H-5^, H-5eqU),
3.83 (1H, ddd, J  4.1, 10.4, H-2), 3.94 (1H, dd, J  4.4, 9.7, H-3), 4.02-4.07 (1H, m, 
CHHCH=CH2), 4.23-4.28 (1H, m, CH//CH=CH2), 4.95 (1H, d, J  3.8, H-l), 5.24 (1H, 
m, V  10.2, CH2CH=C//C/isCHtrans), 5.32 (1H, m, 17.3, CH2CH=CHcisC i / ^ ) ,  
5.87-5.97 (1H, m, CH2Ci/=CH2); 13C NMR (100.4 MHz; CDC13) 6q 26.40, 26.73 (2q, 2 
x isopropylidene CH3), 61.57 (t, C-5), 68.84 (t, CH2CH=CH2), 71.87, 73.62, 79.33 (3d, 
C-4, C-3, C-2), 97.50 (d, C-l), 110.70 (s, isopropylidene C(CH3)2), 118.07 (t, 
CH2CH=CH2), 133.35 (d, CH2CH=CH2); m/z (FAB+) 231 [(M+H)+, 100%], 59 (75).
7.6.5 Allyl 2-0-benzyl-3,4-0-isopropylidene-a-D-xylopyranoside (119)
Sodium hydride (0.59g of a 60%w/w dispersion in mineral oil, 14.71 mmol) was 
added to 118 (1.78g, 7.74mmol) in DMF (20cm3). Thirty min later benzyl bromide 
(1.10cm3, 8.83mmol) was added and stirring was continued overnight. The reaction 
mixture was partitioned between ether (100cm ) and water (80cm ) and the aqueous 
layer was extracted with ether (100cm ). The combined ethereal layers were dried 
(MgSC>4), filtered and concentrated. The crude product was purified by flash
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chromatography (eluent ether/hexane 1:9) to yield the title compound as a clear oil 
(2.4lg, 97%).
Rf 0.19 (ether/hexane 1:9); [a]D20 +30.6 (c 0.5, CHC13); (Found: C, 67.40; H, 7.53. Calc 
for C18H24O5: C, 67.48; H, 7.55%); 'H NMR (400 MHz; CDCI3) A  1.46,1.47 (6H, 2s, 2 
x isopropylidene CH3), 3.35-3.41 (1H, m, H-4), 3.65 (1H, dd, J  3.5, 10.2, H-2), 3.73 
(1H, dd, 2J=  3J  10.2, H-5K), 3.86 (1H, dd, 2J  9.7,3J 4.7, H-5,*,), 3.91-4.00 (2H, m, H-3, 
CHHCH=CH2), 4.15-4.20 (1H, m, CHHCH=CH2), 4.64 (1H, AB, Jab 12.3, OC//HAr),
4.83-4.86 (2H, m, H-l, OCHHAr), 5.21 (1H, m, 3J  10.2, CH2CH=C//^CH;raM), 5.34 
(1H, m, 3J  17.3, CH2CH=CHcisC77ra«), 5.86-5.96 (1H, m, CH2C//=CH2), 7.24-7.39 
(5H, m, ArCH); 13C NMR (100.4 MHz; CDC13) Sc 26.43, 26.82 (2q, 2 x isopropylidene 
CH3), 61.09 (t, C-5), 68.44 (t, CH2CH=CH2), 71.82 (t, OCH2Ar), 74.13, 77.91, 77.97 
(3d, C-4, C-3, C-2), 96.24 (d, C-l), 110.54 (s, isopropylidene C(CH3)2), 117.80 (t, 
CH2CH=CH2), 127.62, 127.86, 128.26 (3d, ArCH), 133.69 (d, CH2CH=CH2), 138.05 (s, 
C-l of Bn ring); m/z (FAB4) 321 [(M+H)+, 14%], 91 (100).
7.6.6 Allyl 2-O-benzyl-a-D-xylopyranoside (113)
A solution of allyl 119 in methanol (30cm ) containing 1M aqueous HC1 (3cm ) 
was stirred for 20 min after which time TLC (ether/hexane 4:1) indicated conversion of 
starting material to one product (Rf 0.17). Solid NaHCC>3 was carefully added until 
effervescing ceased and the reaction mixture was concentrated under reduced pressure. 
The residue was partitioned between DCM (100cm3) and water (75cm3), and the aqueous 
layer extracted with DCM (3 x 50cm ). The combined organic layers were dried 
(MgSCU), filtered and concentrated and the remaining crude product subjected to flash 
chromatography (eluent ether/hexane 9:1) to yield the title compound as a clear oil that 
slowly crystallised on standing (1.70g, 97%).
mp 42-44°C (diisopropyl ether) [lit.88 reported no crystals]; ’H NMR (400 MHz; CDCI3) 
Sh 3.31 (1H, dd, J 3.5, 9.5, H-5), 3.45-3.60 (2H, m, H-5ax, H-5eqU), 3.85-3.94 (2H, m, H- 
3, Ci/HCH=CH2), 4.11-4.18 (1H, m, CH/7CH=CH2), 4.63, 4.64 (2H, AB, Jab 12.1, 
OC//2Ar), 4.76 (1H, d, J  3.5, H-l), 5.20 (1H, m, 3J  10.2, CH2CH=CHcfeCHtralK), 5.31
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(1H, m, 3J  17.3, CH2CH=CHcisCff*™), 5.83-5.97 (1H, m, CH2Ctf=CH2), 7.28-7.38 
(5H, m, ArCH).
7.6.7 Allyl 2-0-benzyl-3,4-di-0-p-methoxybenzyl-«-D-xylopyranoside 
(114)
Sodium hydride (2.86g of a 60%w/w dispersion in mineral oil, 71.43mmol) was 
added to 113 (5.00g, 17.86mmol) in DMF (50cm3). Twenty min later p-methoxybenzyl
'j _
chloride (9.69cm , 71.43mmol) was added and stirring was continued overnight. The 
reaction mixture was quenched with water (2cm3) and then partitioned between ether 
(200cm ) and water (150cm ), the aqueous layer was extracted with ether (2 x 150cm ) 
and the combined ethereal layers washed with water (100cm ) before being dried 
(MgSC>4), filtered and concentrated. The remaining crude product was purified by flash 
chromatography (eluent ether/hexane 3:7) to yield the title compound as a clear oil 
(7.84g, 84%).
Rf 0.59 (ether/hexane 3:2); *H NMR (400 MHz; CDC13) Sa 3.43 (1H, J  3.7, 9.5, H-2), 
3.49-3.57 (2H, m, H-5ax, H-5eqU), 3.78, 3.79 (6H, 2s, 2 x OCH3), 3.87-3.92 (1H, m, H-
3), 3.95-4.00 (1H, m, CHHCH=CH2), 4.13-4.17 (1H, m, CH/fCH=CH2), 4.54, 4.68 
(2H, AB, Jab 11.2, OCH2Ai ), 4.64, 4.77 (2H, AB, Jab 12.2, OCtf2Ar), 4.70 (1H, d, J 3.4, 
H-l), 4.79, 4.84 (2H, AB, Ja b  10.3, OCtf2Ar), 5.21 (1H, m, 3J  10.2, 
CH2CH=C//cliyCHfra/w), 5.31 (1H, m, 3J  17.3, CH2CH=CHcz5C / /^ ) ,  5.88-5.97 (1H, m, 
CH2C//=CH2), 6.84-6.87 (4H, m, 2 x H-3 and H-5 of PMB rings), 7.23-7.36 (9H, m, 
ArCH).
7.6.8 2-0-Benzyl-3,4-di-Op-methoxybenzyl-D-xylopyranose (115)
A solution of 114 (6.87g, 13.21mmol) in methanol (60cm3) was cooled to 0°C 
and palladium chloride (0.47g, 2.64mmol) was added. The flask was fitted with a drying 
tube, the cooling bath removed and the reaction mixture was stirred vigorously for 4 h 
after which time TLC (ether/hexane 3:2) indicated conversion of starting material to
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product (Rf 0.24). The reaction mixture was quenched with triethylamine and filtered 
through a Celite pad. The filtrate was concentrated and the dark brown residue subjected 
to flash chromatography (eluent ether/hexane 3:2) to yield the title compound as a white 
solid (5.72g, 90%).
mp 77-80°C [lit.88 88-90°C]; *H NMR (400 MHz; CDC13) 3.20-3.30 (0.6H, m, H-2# 
H-4/f), 3.45 (0.7H, dd, 73.7, 8.9, H-2a), 3.47-3.91 (3.7H, m, H-3, H-4a, H-5ax, H-5equ),
3.79, 3.80 (6H, 2s, OCH3), 4.53-4.89 (6.3H, m, 3 x OC//2Ar, H-l^), 5.08 (0.7H, d, 73.5, 
H -la), 6.83-6.88 (4H, m, 2 x H-3 and H-5 of PMB rings), 7.22-7.37 (9H, m, ArCH). a  
and P  subscripts denote signals arising from a  and /?-anomers respectively.
7.6.9 2-0-Benzyl-3,4-di-0-p-methoxybenzyl-D-xylopyranosyl dimethyl 
phosphite (120)
To a mixture of 115 (1.23g, 2.57mmol) and tetrazole (0.27g, 3.85mmol) in DCM 
(12cm3) was added bis(methoxy)(diethylamino)phosphine (0.55cm3, 3.34mmol). After 
stirring for 20 min TLC (ethyl acetate/toluene 1:4) indicated complete conversion to 
product (Rf 0.63). The reaction mixture was partitioned between diethyl ether (100cm3) 
and water (75cm3). The resulting ethereal layer was washed with brine (75cm3), dried 
(MgSC>4), filtered and concentrated to give a clear runny oil that was used without further 
purification.
*H NMR (400 MHz; CDC13) <5k 3.23 (0.6H, ddd, 79.8, H-4A), 3.40-3.95 (11.4H, m, H-2, 
H-3, H-4a, H-5a, H-5b, P(OCH3)2 with C-P coupling), 3.77 (3.6H, s, OCH3a), 3.77 
(2.4H, s, OCH3/?), 4.54—4.90 (6.6H, H -l* 3 x OCtf2Ar), 5.42 (0.4H, dd, 7  3.4, 7H-p 8.6, 
H -la), 6.81-6.89 (4H, m, ArCH), 7.22-7.37 (9H, m, ArCH); a  and p  subscripts denote
O l  1
signals arising from a  and /^-anomers respectively; P NMR (161.7 MHz; CDC13; H 





120 (1.47g, 2.57mmol) And 40 (l.OOg, 1.28mmol) in dioxane (15cm3) and 
toluene (5cm3) were stirred with 4A molecular sieves (approx. 1.50g) for 2 h, and then 
dry zinc chloride (0.42g, 3.08mmol) and silver perchlorate (1.26g, 6.16mmol) were 
added. The flask was wrapped in foil and stirring was continued for 9 h. Solid NaHCC>3 
(l.OOg) and water (30cm ) were added and the reaction mixture was diluted with ethyl 
acetate (40cm ). After stirring for a further 30 min the mixture was filtered through a 
Celite pad, and the residue well washed with ethyl acetate. Water (30cm3) was added to 
the filtrate and the resulting aqueous layer was discarded. The organic layer was washed 
with brine (75cm3), dried (MgS04), filtered and concentrated and the residue was 
subjected to flash chromatography (eluent ethyl acetate/hexane 3:7, then 2:3, then 1:1) to 
yield the title compound and its y^-xylopyranosyl anomer in an inseparable 1:1 mixture 
(0.76g, 46%).
Rf 0.38 (ethyl acetate/toluene 1:4); Selected NMR data for H-l' of the a  and ft 
coupled products: *H NMR (400 MHz; CDC13) ^  6.13 (0.5H, d, J  1.5), 6.22 (0.5H, d, J  
4.4); m/z (FAB*) 1246 [(M+H)+, 14%], 303 (100), 121 (72).
7.6.11 2^5,-Di-<>benzyl-3,-0-a'-D-xylopyranosyl adenosine (122a)
To 121ab (745mg, 0.60mmol) in DCM (27cm3), was added TFA (3cm3). The 
resulting bright orange solution was stirred for 1 h before being poured into saturated 
aqueous NaHCC>3 solution (150cm3). DCM (75cm3) was added and the now colourless 
mixture was stirred vigorously for 30 min. The resulting aqueous layer was extracted 
with DCM (2 x 75cm ) and the combined organic layers were dried (MgS04), filtered 
and concentrated. The resulting crude product was purified by flash chromatography 
(eluent ethyl acetate/methanol 14:1) to yield 2",5'-di-O-benzyl-3'-0-<2-D-xylopyranosyl 
adenosine (138mg, 40%), with further elution furnishing 2",5'-di-0-benzyl-3'-O-/?-D- 
xylopyranosyl adenosine (143mg, 41%).
Analyses for 2",5'-di-O-benzyl-3 -O- or-D-xylopyranosyl adenosine (122a).
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Rf 0.51 (chloroform/methanol 9:1); [a]d18 +22.1 (c 2.0, acetone); (Found: M+, 580.240. 
Calc for C29H34N50 8 (M+H)+: 580.240); *H NMR (400 MHz; (CD3)2CO) <5h 3.12 (1H, 
br. s, OH), 3.44 (1H, dd, J3 .7 , 9.5, H-2"), 3.60-3.65 ( 3H, m, H-4", H-5"ax, H-5"equ), 
3.74, 3.83 (2H, ABX, Vab 10.9, 3Jax 3.8, 3JBX 3.4, H-5'A, H-5'B), 3.95-3.99 (1H, m, H- 
3”), 4.36 (1H, ddd, J  4.1, H-4’), 4.57-4.63 (4H, m, OC/72Ar), 4.71 (1H, br s, OH),
4.84-4.88 (1H, m, H-2’ obscured by HDO peak), 5.03 (1H, br s, OH), 5.17 (1H, d, J  3.8, 
H-l"), 6.12 (1H, d, J 4.7, H -l’), 6.98 (2H, br s, NH2), 7.19-7.43 (10H, m, ArCH), 8.22, 
8.26 (2H, 2s, H-2, H-8); 13C NMR (100.4 MHz; (CD3)2CO) 5c 62.82 (t, C-5"), 69.91 (t, 
C-5'), 70.59 (d, C-4"), 73.34, 73.66 (2t, 2 x OCH2Ar), 73.96 (d, C-3"), 74.44 (d, C-2’), 
77.47 (d, C-3’), 79.70 (d, C-2"), 82.29 (d, C-4’), 88.66 (d, C-l’), 98.58 (d, C-l"), 119.65 
(s, C-5), 127.72, 127.81, 128.33, 128.40, 128.51 (5d, ArCH), 138.40, 138.43 (2s, 2 x C-l 
of Bn rings), 139.39 (d, C-8), 149.89 (s, C-4), 153.04 (d, C-2), 156.28 (s, C-6); m/z 
(FAB-") 580 [(M+H)+, 100%], 91 (79).
Analyses for 2",5'-di-0-benzyl-3'-0-/?-D-xylopyranosyl adenosine (122b).
Rf 0.43 (chloroform/methanol 9:1); (Found: M+, 580.241. Calc for C^H^NsOg (M+H)+: 
580.240); ]H NMR (400 MHz; CD3OD) <5k 3.18 (1H, dd, 2J  = 3J  10.8, H-5"ax), 3.29 (1H, 
dd, J 7.6, 9.1, H-2"), 3.46 (1H, dd, J  8.9, H-3"), 3.53-3.58 (1H, m, H-4"), 3.61, 3.77 (2H, 
ABX, 2Jab 11.0, Vax 3.1, VBX 2.8, H-5'A, H-5'B), 3.85 (1H, dd, V 11.4, 3J  5.3, H-5"equ),
4.34 (1H, ddd, J  2.9, 5.6, H-4’), 4.43, 4.48 (2H, AB, Jab 12.0, OCtf2Ar), 4.46 (1H, d, J
7.9, H-l"), 4.53 (1H, dd, J5 .1 , H-3'), 4.66 (1H, dd, J4 .2 , H-2'), 4.78, 4.86 (2H, AB, Jab
11.1, OCtf2Ar), 6.11 (1H, d, J3.8, H-l'), 7.19-7.39 (10H, m, ArCH), 8.18, 8.30 (2H, 2s, 
H-2, H-8); 13C NMR (100.4 MHz; CD3OD) Sc 67.17 (t, C-5"), 70.30 (t, C-5'), 71.22 (d, 
C-4"), 74.63, 75.97 (2t, OCH2Ar), 76.11 (d, C-2'), 77.62 (d, C-3"), 79.79 (d, C-3'), 82.81 
(d, C-2"), 83.12 (d, C-4’), 90.27 (d, C-l'), 105.19 (d, C-l"), 120.31 (s, C-5), 128.62,
128.97, 128.01, 129.33, 129.61 (5d, ArCH), 139.14, 140.13 (2s, 2 x C-l of Bn rings), 
140.63 (d, C-8), 150.36 (s, C-4), 153.91 (d, C-2), 157.11 (s, C-6); m/z (FAB+) 580 





A solution of 122a (lOlmg, 0.17mmol) in DCM (3.5cm3) with 
bis(benzyloxy)(diisopropylamino)phosphine (0.19cm3, 0.58mmol) and imidazolium 
triflate (125mg, 0.58mmol), was stirred for 1 h, after which time TLC (ethyl 
acetate/hexane 7:3) indicated some starting material remaining; therefore a further 1.0 
equivalent each of bis(benzyloxy)(diisopropylamino)phosphine and imidazolium triflate 
was added. TLC after a further 30 min indicated conversion to the trisphosphite (Rf 
0.63). Water (1 drop) was added and the solution cooled to -78°C, after which MCPBA 
(170mg, 0.59mmol) was added. After 10 min 10% aqueous Na2SC>3 solution (15cm3) 
and ethyl acetate (20cm ) were added and the mixture was allowed to warm to room
-j
temperature. The resulting organic layer was washed with 15cm each of saturated 
aqueous NaHCOs solution and brine, and then dried (MgSCU), filtered and concentrated 
to a clear oil which was subjected to flash chromatography (eluent chloroform/acetone 
9:1, then 7:1, then 6:1, then 4:1, then 3:2) to give the title compound as a clear oil 
(161mg, 68%).
Rf 0.11 (ethyl acetate/hexane 7:3); [<z]d20 +6.5 (c 1.7, CHCI3); (Found: M+, 1360.425. 
Calc for C71H73N5O17P3 (M+H)+: 1360.421); NMR (400 MHz; CDC13) <5k 3.49 (1H, 
dd, J 3.5, 9.4 H-2"), 3.52 (1H, dd, 2J = V  11.0, H-5"ax), 3.62, 3.76 (2H, ABX, Vab 10.8, 
Vax 3.2, VBx 3.4, H-5'a, H-5'b), 3.95 (1H, dd, V  11.1, V5.9, H ^ u X  4.33-5.02 (14H, 
m, H-3', H-3", H-4', H-4", 6 x POCtf2Ar, 2 x OC//2Ar), 5.29 (1H, d, J  3.2, H-l"), 
5.61-5.66 (1H, m, H-2"), 5.98 (2H, br. s, NH2), 6.34 (1H, d, J  5.9, H-l'), 6.98-7.39 
(40H, m, ArCH), 7.93, 8.25 (2H, 2s, H-2, H-8); 13C NMR (100.4 MHz; CDC13) Sc 60.25 
(t, C-5"), 69.40-70.23 (7t, C-5', 6 x POCH2Ar with C-P coupling), 72.12 (t, OCH2Ar), 
73.59 (d, C-4" with C-P coupling), 73.97 (t and d, OCH2Ar and C-3’), 77.07 (d, C-2"), 
77.71 (2d, C-2', C-3" with C-P coupling), 82.55 (d, C-4’), 86.01 (d, C-l'), 95.81 (d, C-l"), 
120.05 (s, C-5), 127.78, 127.91, 127.98, 128.15, 128.19, 128.22, 128.26, 128.34, 128.48,
128.53, 128.68, 128.72, 128.79 (13d, ArCH), 135.14-136.23 (6s, 6 x C-l of 
benzylphospho rings), 137.14, 137.64 (2s, 2 x C-l of Bn rings), 139.54 (d, C-8), 150.14 
(s, C-4), 153.14 (d, C-2), 155.54 (s, C-6); 3IP NMR (161.7 MHz; CDC13; ’H decoupled) 
St -0.63 (s, 2P), -0.20 (2s); m/z (FAB4) 1360 [(M+H)4,5%], 91 (100).
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7.6.13 3-0-a-D-xylopyranosyl adenosine 2',3"J4M-trisphosphate (98)
A mixture of 123 (84mg, 0.06mmol) and wet 20% palladium hydroxide on 
carbon (252mg), in methanol (11cm3), cyclohexane (5cm3) and water (1cm3) was heated 
at reflux for 2.5 h. After cooling the reaction mixture was filtered through a membrane 
filter and the catalyst washed copiously with methanol and water. Concentration of the 
filtrate afforded a clear residue that was purified by application to an MP1 AG ion 
exchange resin column and eluting with a gradient of 0-100% 150mM TFA. 
Concentration of the appropriate fractions (being careful to keep the temperature below 
20°C) gave the desired product as the free acid (33mg, 85%), which was dissolved in 
water and eluted through a short column of Na+ dianion WK-40 ion exchange resin to 
give, after concentration, the sodium salt.
(Found: M \ 638.030. Calc for C15H23N5O17P3 (M-H)‘: 638.030); 'H NMR (400 MHz; 
D20) <5h 3.50 (1H, dd, 2J=  3J  10.8, H-5V), 3.61 (1H, dd, J  3.4, 9.2, H-2"), 3.65-3.71 
(2H, m, H-5'a, H-5'b), 3.76 (1H, dd, J  5.6, 11.4, H-5”equ), 4.02-4.10 (1H, m, H-4"),
4.25-4.32 (2H, m, H-3”, H-4"), 4.34-4.56 (1H, m, H-3'), 5.07 (1H, d, J  3.5, H-l"), 
5.08-5.14 (1H, m, H-21), 6.16 (1H, d, /6 .2 , H-l'), 8.23, 8.33 (2H, 2s, H-2, H-8); 3IP 
NMR (161.7 MHz; D20; 'H decoupled) <$> 0.23, 0.67, 0.78 (3s); UV (H20) Xmax 259nm,
S 15 400, pH 7.5; m/z (FAB ) 638 [(M-l)\ 100%].
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7.7 Synthesis of a versatile disaccharide intermediate
7.7.1 3,5-0-Benzylidene-1,2-0-isopropylidene-<2-D-xylofuranose (126)
A solution of 1,2-O-isopropylidene-«-D-xylofuranose (2.00g, 10.52mmol), 
benzaldehyde dimethyl acetal (1.74cm3, 11.04mmol) and PTSA (54mg, 0.53mmol) in 
DMF (40cm3) was heated at 70°C in a flask fitted with an air condenser attached to a 
water pump. After heating for 2h under reduced pressure the reaction mixture was 
cooled and saturated aqueous NaHCC>3 solution (20cm ) and water (40cm ) were added.
-j
The resulting mixture was extracted with ether (3 x 40cm ), and the combined ethereal 
extracts were dried (MgSC>4), filtered and concentrated and the title compound was 
isolated as fine white needle-like crystals by crystallisation from ethanol (2.18g). 
Subjection of the mother liquor to flash chromatography, (eluent chloroform/acetone 9:1, 
1:2 with pentane) gave the further product (0.42g), total yield (2.60g, 89%). 
mp 125°C (ethanol); [<z ] d 18 +3.8 ( c  1.1, CHCI3); (Found: C, 64.6; H, 6.57. Calc for 
Ci5H190 5: C, 64.74; H, 6.52%); *H NMR (400 MHz; CDC13) Sa 1.33, 1.52 (6H, 2s, 2 x 
isopropylidene CH3), 4.12-4.16 (2H, m, H-5A, H-5B), 4.42^1.47 (2H, m, H-4, H-3), 4.64 
(1H, d, J  3.4, H-2), 5.45 (1H, s, CHAr), 6.07 (1H, d, J  3.9, H-l), 7.33-7.48 (5H, m, 
ArCH); 13C NMR (100.4 MHz; CDCI3) Sc 26.17, 26.74 (2q, 2 x isopropylidene CH3),
66.79 (t, C-5), 72.20 (d, C-3 or C-4), 79.04 (d, C-2), 83.87 (d, C-3 or C-4), 99.34 (d, 
benzylidene CH), 105.69 (d, C-l), 111.81 (s, isopropylidene C(CH3)2), 126.10. 128.25,
129.11 (3d, ArCH), 137.47 (s, C-l of Bn ring); m/z (FAB+) 279 [(M+H)+, 100%].
7.7.2 5-0-Benzyl-1,2-0-isopropylidene-a-D-xylofuranose (125)
To a mixture of 126 (200mg, 0.72mmol), 3 A molecular sieves (200mg) and 1.0M
*5
sodium cyanoborohydride in THF (10cm ) was slowly added a solution of 1.0M
>3
hydrochloric acid in ether (9cm ). TLC (chloroform/acetone 9:1) after 5min indicated 
consumption of starting material (Rf 0.79) and appearance of product (Rf 0.40). The 
reaction mixture was diluted with DCM (60cm ) and filtered. The filtrate was washed
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with water (50cm ) and saturated aqueous NaHCC>3 solution (50cm ). The organic layer 
was dried (MgSC>4), filtered and concentrated to leave a clear yellow residue that was 
subjected to flash chromatography (eluent chloroform/acetone 9:1), to give the title 
compound (137mg, 68%).
mp 45-47°C (hexane); [afo17 +2.9 (c 1.0, CHC13); 'H NMR (400 MHz; CDCI3) <5h 1.31, 
1.48 (6H, 2s, 2 x isopropylidene CH3), 3.68 (1H, br s, D2O exch., OH-3), 3.86-3.96 (2H, 
m, H-5a, H-5b), 4.23-4.26 (2H, m, H-3, H-4), 4.49 (1H, d, J  3.7, H-2), 4.57, 4.61 (2H, 
AB, Jm  11.9, OC//2Ar), 5.96 (1H, i , J  3.7, H-l), 7.29-7.38 (5H, m, ArCH); 13C NMR 
(100.4 MHz; CDC13) <5fc 26.15, 26.72 (2q, 2 x isopropylidene CH3), 68.16 (t, C-5), 74.05 
(t, OCH2Ar), 76.19 (d, C-3 or C-4), 78.15 (d, C-2), 85.28 (d, C-3 or C-4), 104.83 (d, C-
1), 111.58 (s, isopropylidene C(CH3)2), 127.87,128.03, 128.55 (3d, ArCH), 137.14 (s, C- 
1 of Bn ring).
A sample of 125 (lOOmg) was converted to its 3-0-acetyl ester by stirring in a 
mixture of acetic anhydride (1cm3) and pyridine (4cm3) overnight. Concentration of the 
mixture yielded the desired product as a clear oil. Rf 0.65 (chloroform/acetone 14:1).
*H NMR (270 MHz; CDC13) Sh 1.30, 1.51 (6H, 2s, 2 x isopropylidene CH3), 2.00 (3H, s, 
CH3CO), 3.65 (2H, d, J  5.9, H-5A, H5-B), 4.45^4.50 (3H, m, OCHtfAr, H-4, H-2), 4.59 
(1H, AB, Jab 12.1, OCHtfAr), 5.25 (1H, d, J2 .9 , H-3), 5.91 (1H, d, J  3.9, H-l), 7.26-
7.34 (5H, m, ArCH).
7.7.3 5-OBenzyl-1,2-0-isopropylidene-a-D-3-ulose (129)
A solution of 125 (400mg, 1.43mmol) in DMSO (1.5cm ) was added dropwise to 
acetic anhydride (2cm3) in DMSO (3cm3). After stirring for 18h the resulting mixture 
was added dropwise over 30min to stirred saturated aqueous NaHC03 solution (50cm ), 
and then left to stir for a further lh before being extracted with DCM (3 x 50cm3). The 
combined organic layers were dried (MgS04), filtered and concentrated, to give the 
crude unstable ullose (286mg, 72%).
A small amount of the residue was subjected to flash chromatography (eluent 
chloroform/acetone 19:1) to provide a purified sample for NMR analysis.
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*H NMR (400 MHz; CDCI3) <5h 1.43,1.46 (6H, 2s, 2 x isopropylidene CH3), 3.73 (2H, d, 
J 2.4, H-5a, H-5b), 4.34—4.35 (1H, m, H-2), 4.44-4.46(lH, m, H-4), 4.49, 4.52 (2H, AB, 
J a b  12.0, OCtf2Ar), 6.13 (1H, d, J4.4, H-l), 7.24-7.36 (5H, m, ArCH); 13C NMR (100.4 
MHz; CDCI3) & 27.16, 27.60 (2q, 2 x isopropylidene CH3), 70.06 (t,C-5), 73.72 (t, 
OCH2Ar), 76.81 (d, C-4), 79.91 (d, C-2), 103.57 (d, C-l), 114.15 (s, isopropylidene 
C(CH3)2), 127.52, 127.87, 128.47 (3d, ArCH), 137.43 (s, C-l of Bn ring), 210.02 (s, C- 
3).
7.7.4 5-0-Benzyl-1,2-0-isopropylidene-a-D-ribofuranose (130)
To a pre-cooled solution (0DC) of crude 129 (ca 400mg) in ethanol (5cm ) and 
water (4cm3) was added sodium borohydride (70mg, 1.85mmol). TLC (chloroform/ 
acetone 9:1) after lh indicated loss of starting material (Rf 0.65), and appearance of a 
new product (Rf 0.55). Water (25cm ) was added and this mixture extracted with DCM 
(3 x 25cm3). The combined organic extracts were dried (MgSCU), filtered and 
concentrated. The product was purified by flash chromatography (eluent 
chloroform/acetone 19:1) to yield l,2-O-isopropylidene-5-0-benzyl-<z-D-ribofuranose as 
a crystalline solid (199mg, 50% over two steps).
mp 83-85°C (hexane), [lit.171 81-83°C]; [a ]D17 +40.2 (c 1.0, CHC13), [lit.171 [a]D20 +31.2 
(c 1.87, CHCI3)]; ’H NMR (400 MHz; CDCI3) A  1.35, 1.55 (6H, 2s, 2 x isopropylidene 
CH3), 2.52 (1H, d, J  9.8, D20  exch., OH-3), 3.62, 3.77 (2H, ABX, 2Jab 10.9, 3/ a x  3.9, 
3Jbx 2.0, H-5a, H-5b), 3.76-3.98 (2H, m, H-3, H-4), 4.53 (1H, dd, J4 .4 , H-2), 4.59 (1H, 
s, OCifcAr), 5.81 (1H, d ,/3 .9 , H-l), 7.26-7.34 (5H, m, ArCH); l3C NMR (100.4 MHz; 
CDCI3) Sc 26.36, 26.43 (2q, 2 x isopropylidene CH3), 68.51 (t, C-5), 71.59 (d, C-3 or C-
4), 73.43 (t, OCffcAr), 78.29 (d, C-2), 79.65 (d, C-3 or C-4), 103.98 (d, C-l), 112.46 (s, 
isopropylidene C(CH3)2), 127.55,127.59, 128.26 (3d, ArCH), 137.83 (s, C-l of Bn ring).
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7.7.5 Allyl 3,4-di-0-acetyl-2,6-di-0-benzyl-a-D-glucopyranoside (131)
A solution of 65 (5.00g, 12.5mmol) in acetic anhydride (10cm3) and pyridine 
(50cm3) was stirred for 20 h, and then concentrated repeatedly from toluene to yield the 
diacetylated product as a clear oil in quantitative yield (6.05g).
m/z (FAB+) 507 [(M+Na)+, 4%], 427 (5), 91 (100); *H NMR (400 MHz; CDC13) &  1.89,
2.00 (6H, 2s, 2 x CH3CO), 3.46, 3.50 (2H, ABX, 2Jab 10.8, 3Jax 3.9, 3JBX 2.5, H-6A, H- 
6b), 3.59 (1H, dd, J  10.0, 3.7, H-2), 3.94 (1H, ddd, J  10.3, 2.9, H-5), 3.98^1.03 (1H, m, 
CtfHCH=CH2), 4.15-4.20 (1H, m, CH#CH=CH2), 4.44, 4.58 (2H, AB, Jab 12.2, 
OC/72Ar), 4.58, 4.62 (2H, AB, Jab 12.5, OC//2Ar), 4.85 (1H, d, J3 .4 , H-l), 5.07 (1H, 
dd, J  9.8, H-4), 5.22 (1H, d, J  10.3, CH2CH=C^cwC H ^ ) ,  5.32 (1H, d, J  17.1, 
CH2CH=CHdsCHtrans), 5.45 (1H, dd, J  9.8, H-3), 5.87-5.97 (1H, m, CH2Ctf=CH2),
7.26-7.34 (10H, m, ArCH); 13C NMR (100.4 MHz; CDC13) Sc 20.70, 20.76 (2q, 2 x 
CH3CO), 67.89 (t, C-6), 68.34 (d, C-5), 68.56 (t, CH2CH=CH2), 69.23 (d, C-4), 72.22 (d, 
C-3), 72.95, 73.48 (2t, 2 x OCH2Ar), 76.73 (d, C-2), 95.56 (d, C-l), 118.27 (t, 
CH2CH=CH2\  127.72, 127.91, 127.94, 127.98, 128.35, 128.46 (6d, ArCH), 133.47 (d, 
CH2CH=CH2), 137.62, 137.84 (2s, 2 x C-l of Bn ring), 169.82,170.24 (2s, 2 x CH3CO).
7.7.6 3,4-Di-0-acetyl-2,6-di-Obenzyl-D-glucopyranose (132)
Palladium chloride (305mg, 1.72mmol) was added to a vigorously stirred 
solution of 131 (4.16g, 8.60mmol) in methanol (20cm3) and DCM (20cm3). 
Triethylamine (4cm3) was added after 3h and the solution concentrated in vacuo. The 
residue was resuspended in ethyl acetate (100cm3) and filtered through a Celite pad. The 
filtrate was concentrated and the remaining crude product subjected to flash 
chromatography (eluent ethyl acetate/hexane 3:7) to yield the desired glucopyranose as a 
white solid (2.99g, 78%).
Rf 0.26 (ethyl acetate/hexane 3:7); mp 71-74°C; [<z]d17 +83.0 (c 1.1, CHC13); (Found: C, 
64.70; H, 6.37. Calc for C24H280 8: C, 64.85; H, 6.35%); *H NMR (400 MHz; CDC13) <5k
1.88, 1.89. 1.90. 1.96 (6H, 4s, 2 x CH3COa, 2 x CH3CO^), 3.80 (0.4H, dd, J7 .6 , 9.5, H- 
2/?), 3.46-3.49 (2H, m, H-6A, H-6B), 3.57 (0.6H, dd, J3.7, 10.0, H-2a), 3.64 (0.4H, ddd, J
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4.2, 10.3, H-5^), 4.18 (0.6H, ddd, 73.9, 10.2, H-5a), 4.41^.64 (3.6H, m, OC/f2Ar), 4.74 
(0.4H, d, 77.8, H -la), 4.85 (0.4H, AB, 7a b  11.7, OCH2Ai ), 4.93 (0.4H, dd, 710.3,
5.01 (0.6H, dd, 7  9.8, H-4a), 5.12 (0.4H, dd, 7  9.3, H-3^), 5.25 (0.6H, d, 7  3.4, H -la), 
5.45 (0.6H, dd, 79.8, H-3*), 7,23-7.33 (10H, m, ArCH); 13C NMR (100.4 MHz; CDC13) 
Sc 20.61, 20.65, 20.72, 20.84 (4q, 4 x CH3CO), 68.07 (t, C-6,and d), 68.64 (t, C-6), 
69.22, 69.38, 72.02, 72.73 (4d), 72.90, 73.43, 73.48 (3t, 3 x OCH2Ar), 73.99 (d), 74.19 
(t, OCH2Ar), 76.88, 79.57 (2d, C-2aandfi), 90.76, 97.27 (2d, C -laand/?), 127.72, 127.78, 
127.89, 127.98, 128.03, 128.33, 128.36, 128.42, 128.51 (9d, ArCH), 137.27, 137.40 (2s, 
2 x C-l of Bn ring), 169.86, 169.91, 170.33, 170.41 (4s, 4 x CH3CO); a  and f t  subscripts 
denote signals arising from a  and /?-anomers respectively; m/z (FAB') 443 [(M-H)", 
97%], 597 (100).
7.7.7 3,4-Di-0-acetyl-2,6-di-Obenzyl-D-glucopyranosyl dimethyl 
phosphite (133)
Bis(methoxy)(diethylamino)phosphine (966mg, 5.86mmol) was added to a 
mixture of tetrazole (477mg, 6.76mmol) and 132 in DCM (20cm3). TLC (ethyl 
acetate/hexane 2:3) after 30min indicated complete conversion to product Rf 0.65. The 
reaction mixture was partitioned between ether (100cm3) and water (80cm3). The 
ethereal layer was washed with brine (80cm ), dried (MgS04), filtered and concentrated. 
The resulting clear oil was used without further purification.
*H NMR (400 MHz; CDC13) <5h 1.88, 1.89, 1.90, 2.01 (6H, 4s, 2 x CH3COa, 2 x 
CH3CO^), 3.47 (0.5H, 0.5 ABX, 2J a b  11.0, Vax 3.9, H-6A/?), 3.50-3.59 (8H, m, H-6B, H- 
6a«, H-2# 2 x POCH3), 3.62 (0.5H, dd, J3 .2 , 10.0, H-2a), 3.68-3.73 (0.5H, m, H-5^), 
4.14 (0.5H, ddd, J  3.9, 10.3, H-5«), 4.42-A66 (3.5H, m, OCH2Ar), 4.84 (0.5H, AB, Jab
11.7, OCHtfAr), 4.98-5.05 (1H, m, H-4^, H-l^), 5.11 (0.5H, dd, J  9.8, H-4a), 5.17 
(0.5H, dd, J9.8, H-3^), 5.45 (0.5H, dd, J9.3, H-3a), 5.56 (0.5H, dd, JH.P 8.3, 3.4, H-l„),






A mixture of 130 (1.51g, 5.41mmol), 133 (3.62g, 6.76mmol) and 4A molecular 
sieves (6.00g) in dioxane (36cm3) and toluene (12cm3) was stirred for 2h, after which 
time zinc chloride (1.1 Og, 8.11mmol) and silver perchlorate (3.36g, 16.22mmol) were 
added. The flask was wrapped in foil and the reaction mixture stirred for 20h whereupon 
TLC (ethyl acetate/hexane 3:7) indicated loss of donor (Rf 0.55) and acceptor (Rf 0.24) 
and appearance of product (Rf 0.24). Sodium bicarbonate (3.00g), ethyl acetate (100cm3) 
and water (75cm ) were added and the mixture stirred for 30min before being filtered 
through a celite pad. The organic layer of the filtrate was washed with brine (100cm3), 
dried (MgSCU), filtered and concentrated to a clear oil that was subjected to flash 
chromatography to yield the title compound (3.08g, 81% based on acceptor), 
mp 125-127°C (diisopropyl ether); [a ]D20 +101.6 (c 1.6, CHC13); (Found: C, 66.10; H, 
6.42. Calc for CssHwOu: C, 66.28; H, 6.56%); ‘H NMR (400 MHz; CDCI3) S» 1.36,
1.53 (6H, 2s, 2 x isopropylidene CH3), 1.88, 2.03 (6H, 2s, CH3CO), 3.28, 3.34 (2H, 
ABX, 2Jab 10.7, Vax 3 .9 ,3JBx 2.4, H-6'A, H-6'B), 3.61 (1H, dd, J3 .7 , 10.0, H-2’), 3.72 
(1H, ABX, 2Jab 11.5, 3Jax 3.7, H-5A), 3.79-3.84 (2H, m, H-5B, H-5'), 4.16 (1H, dd, J
9.3, 4.4, H-3), 4.29-4.32 (2H, m, OCHtfAr, H-4), 4.48^1.71 (6H, m, 2.5 x OCJfeAr, H-
2), 5.10 (1H, dd, J  10.0, H-4'), 5.20 (1H, d, J3 .9 , H-l'), 5.38 (1H, dd, J9 .8 , H-3'), 5.83 
(1H, d, J3.9, H-l), 7.23-7.31 (15H, m, ArCH); ,3C NMR (100.4 MHz; CDCI3) Sc 20.68, 
20.89 (2q, 2 x CH3CO), 26.66,26.72 (2q, 2 x isopropylidene CH3), 67.23 (t, C-6'), 67.78 
(t, C-5), 68.49 (d, C-5’), 68.84, (d, C-4’), 71.51 (t, OCH2Ar), 72.06 (d, C-3’), 72.71 (d, C-
3), 73.39, 73.59 (2t, OCH2Ar), 75.62 (d, C-21), 76.21 (d, C-2), 77.56 (d, C-4), 94.31 (d, 
C-l’), 104.32 (d, C-l), 113.04 (s, (CH3)2Q , 127.58, 127.69, 127.74, 127.80, 127.98, 
128.33 (6d, ArCH), 137.49, 137.80,138.80 (3s, 3 x C-l of Bn rings), 169.68,170.23 (2s, 





134 (672mg, 0.95mmol) Was heated at reflux for 15min in a mixture of acetic 
acid/water/ethylene glycol (14/6/3, v/v/v, 25cm3). After cooling, the reaction mixture 
was slowly poured into saturated aqueous NaHCC>3 solution (75cm3). This aqueous 
suspension was extracted with DCM (3 x 75cm ) and the resulting organic layers were 
combined, dried (MgS04), filtered and concentrated repeatedly from toluene to give a 
yellow oil that was subjected to flash chromatography (eluent ethyl acetate/hexane 1:1) 
yielding the title compound (477mg, 75%).
mp 126-128°C (ether); Rf 0.45 (ethyl acetate/hexane 1:1); [a]D20 +116.5 (c 0 .2 , CHC13); 
(Found: C, 64.90; H, 6.34. Calc for C36H42O12: C, 64.85; H, 6.35%); ]H NMR (400 
MHz; CDCI3) Sh 1.88, 1.89, 1.99, 2.00 (6H, 4s, 4x 1 .5  CH3CO), 3.27-3.36 (2H, m, H- 
6'a , H -6 'b ) ,  3.44 (0.4H, d, J  6 .8, D20  exch., 1-OH/?), 3.52-3.67 (3H, m, H-5A, H-5B, H- 
2% 3.72 (0.4H, d, J  6.3, D20  exch., 2-OH/?), 3.82 (0.6H, d, J  9.3, D20  exch., l-OHa), 
3.90 (1H, ddd, J  10.3, 3.4, H-5'), 4.00-4.02 (0.4H, m, H-4/?), 4.12-4.17 (1.2H, m, H-2a, 
H-3a), 4.24-4.29 (1H, m, H-2/?, H-4a), 4.32^1.72 (6.8H, m, 3 x OCtf2Ar, H-3/?, H-l'/?), 
4.98 (0.6H, d, 73.9, H -l'a), 5.01-5.08 (1H, m, H-4'), 5.26-5.31 (1H, m, H-l), 5.33-5.42 
(1H, m, H-3’), 7.22-7.38 (15H, m, ArCH); 13C NMR (100.4 MHz; CDC13) 5C 20.61, 
20.87 (2q, CH3CO), 67.36 (t, C-6 'a), 67.46 (t, C-6'/?), 68.67 (d, C-4'), 69.17 (d, C-5'„), 
69.22 (d, C-5'/?), 69.70 (t, C-5a), 70.10 (t, C-5/?), 70.57 (d, C-2a or C-3a), 72.44 (d, C-3'/?),
72.57 (d, C-3'a), 73.46, 73.53, 73.59,74.21 (4t, 4 x OCH2Ar), 74.63 (d, C-4^), 75.88 (d, 
C-2», 76.01 (d, C-2'a), 77.54 (d, C-2a or C-3a), 78.55 (d, C-3^), 79.83, 80.56 (2d, C-2/? 
and C-4a), 96.98 (d, C-l/?), 97.53 (d, C -l» , 97.86 (d, C-l'«), 102.47 (d, C -la), 127.54, 
127.67, 127.79, 127.82, 127.94, 128.00, 128.27, 128.33, 128.38, 128.51, 128.73, 128.77 
(12d, ArCH), 136.69, 136.74, 137.20, 137.42, 137.86 (5s, 5 x C-l of Bn rings), 169.69, 
170.19 (2s, 2 x CH3CO); a  and f t  subscripts denote signals arising from a  and /?-anomers 





135 (635mg, 0.95mmol) Was stirred in a mixture of acetic anhydride (0.5cm3) 
and pyridine (5cm3) for 20h. The solution was concentrated repeatedly from toluene to 
give a runny clear oil that was subjected to flash chromatography (eluent ethyl 
acetate/hexane 3:7) to yield the title compound (587mg, 82%).
mp 105-107°C (ethyl acetate/hexane); Rf 0.29 (ethyl acetate/hexane 3:7); [a]D20 +98.2 (c 
0.2, CHCI3); (Found: C, 64.00; H, 6.15. Calc for C40H46O14: C, 63.98; H, 6.18%); !H 
NMR (400 MHz; CDCI3) <5h 1.86, 1.87, 1.93, 1.96 (12H, 4s, CH3CO), 3.29, 3.36 (2H, 
ABX, Vab 10.7, Vax 3 .9 ,3JBX 2.4, H-6'A, H-6 'B), 3.56 (1H, J9 .8 , 3.4, H-2'), 3.63, 3.72 
(2H, ABX, 2Jab 11.2, Vax 3 .9 ,3JBX 2.9, H-5A, H-5B), 3.88 (1H, ddd, J  10.3, 2.9, H-5'), 
4.29 (1H, AB, Jab 12.2, OCHtfAr), 4.37-4.40 (1H, m, H-4), 4.47^1.57 (4H, m, 2 x 
OC/^Ar), 4.63-4.64 (2H, m, H-3, OCHHAr), 5.03-5.08 (2H, m, H-l', H-4'), 5.33 (1H, 
d, J 4.9, H-2), 5.38 (1H, dd, J  9.3, H-3'), 6.12 (1H, s, H-l), 7.23-7.34 (15H, m, ArCH); 
13C NMR (100.4 MHz; CDC13) Sc 20.45, 20.56, 20.63, 20.74, 20.83, 20.94, 21.05, 21.16 
(8q, 4 x CH3COaand/e), 67.52 (t, C-6'), 68.85 (d, C-5’), 69.00, 69.28 (2t, C-5amd fi), 71.89,
72.02 (2d, C-3'a and /?)> 73.02 (d, C-2), 73.17, 73.26, 73.35, 73.41, 73.48, 73.55 (4t and 2d, 
C-3a and# OCH2Araand/>), 76.59, 76.76 (2d, C-Tasadfi)9 81.27 (d, C-4), 96.28, 96.47 (2d, 
C-l'aand/?), 98.46, 98.50 (d, C -\amd/}\  127.32, 127.61, 127.74, 127.91, 128.02, 128.36,
128.46 (7d, ArCH), 137.51, 137.76, 138.11 (3s, 3 x C-l of Bn rings), 169.35, 169.69, 
170.17, 170.28 (4s, 4 x CH3CO); a  and subscripts denote signals arising from a  and fi- 
anomers respectively; m/z (FAB^ 750 (M+, 1%), 91 (100).
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7.8 Synthesis of purinophostin
7.8.1 2 \3 \5 ,-Tri-0-acetyl 9-/?-D-ribofuranosidopurine (142)
A suspension of purine in hexamethyldisilazane (7.5cm ) was refluxed for 7 h. 
After cooling the mixture was diluted with toluene and concentrated, the residual white 
powder was the repeatedly concentrated from toluene. 1,2,3,5-Tetra-O-acetyl-D- 
ribofuranose (0.53g, 1.67mmol), dichloroethane (10cm3) and TMSOTf (3 drops) were 
added and this mixture was refluxed for 16 h. The reaction was quenched with 
triethylamine (1cm ) and diluted with DCM (20cm ). This organic mixture was washed 
with 10cm3 each of saturated aqueous NaHCC>3 solution and water and then dried 
(MgSCU), filtered and concentrated. The crude product was purified by flash 
chromatography (eluent chloroform/methanol 14:1) to yield the title compound as a clear 
oil (309mg, 49%).
Rf 0.36 (chloroform/methanol 14:1); *H NMR (270 MHz; CDC13) Sa 2.10, 2.13, 2.17 
(9H, 3s, 3 x CH3CO), 4.37-4.49 (3H, m, H-4', H-5'A, H-5’B), 5.70 (1H, dd, J  5.0, H-3'), 
6.00 (1H, dd, J 5.4, H-2’), 6.27 (1H, d, J5.1, H -l’), 8.27 (1H, s, H-2), 9.02 (1H, s, H-8), 
9.18 (1H, s, H-6); 13C NMR (100.4 MHz; CDC13) Sc 20.39, 20.54, 20.76 (3s, 3 x 
CH3CO), 63.00 (t, C-5'), 70.56 (d, C-3’), 73.06 (d, C-2'), 80.39 (d, C-4'), 86.43 (d, C-l’), 
134.71 (s, C-5), 143.71 (d, C-8), 149.21 (d, C-6), 150.93 (s, C-4), 152.94 (d, C-2), 
169.38, 169.59, 170.32 (3s, 3 x CH3CO).
A sample was converted to the known 9-y7-D-ribofuranosidopurine (143) as 
follows: Concentrated aqueous ammonia (20 drops) was added to purine-9-/?-D-2', 3', 5- 
tri-0-acetyl ribofuranoside (279mg, 0.74mmol) in methanol (35cm3) and the resulting 
solution was stirred in a sealed flask for 4 h. The resulting reaction mixture was 
concentrated and the remaining oil repeatedly concentrated from methanol. The product 
was crystallised from hot methanol (129mg, 70%).
mp 175-178°C. [lit.215 181-182°C]; ‘H NMR (400 MHz; D20) <$j 3.65, 3.73 (2H, ABX, 
J a b  12.9, J a x  3.9, JBX 2.7, H-5'A, H-5'B), 4.07-4.09 (1H, m, H-4'), 4.25 (1H, dd, J4.3, H- 
3'), 4.59 (1H, dd, J4.3, H-2'), 5.93 (1H, d, J5.9, H-l’), 8.44, 8.62, 8.78 (3H, 3s, H-2, H-
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6, H-8); 13C NMR (100.4 MHz; CDC13) Sc 61.52 (t, C-5’), 70.60, 73.98, 85.75 (3d, C-2', 
C-3’, C-4'), 88.50 (d, C-l'), 133.63 (s, C-5), 145.75, 147.93, 151.75 (3d, C-2, C-6, C-8),
150.36 (s, C-4); UV (H20) Xmax 262nm, 8 6 690, pH 7.5.
7.8.2 2,,3,,,4,,-Tri-0-acetyl-2,,,5,J6"-tri-0-benzyl-3,-0-a-D-glucopyranosyl- 
9-yfl-D-ribofuranosidopurine (137)
A suspension of purine (480mg, 4mmol) in a mixture of hexamethyldisilazane 
(10cm ) and chlorotrimethysilane (5 cm ) was refluxed for 20h. The mixture was 
concentrated in vacuo to a white solid to which were added dichloroethane (7.5cm3), 124 
(300mg, 0.40mmol) and TMSOTf (0.8cm3, 0.40mmol); this mixture was refluxed for 7h 
after which time TLC (ethyl acetate/hexane 3:2) indicated loss of starting material (Rf 
0.89) and appearance of one major product (Rf 0.30) and one minor product (Rf 0.11). 
The reaction mixture was quenched with triethylamine (1cm3), diluted with DCM 
(20cm3) and washed with saturated aqueous NaHCC>3 solution (15cm3) and water 
(15cm3). The resulting organic layer was dried (MgSO/j), filtered and concentrated to 
leave a clear oil which was purified by flash chromatography (eluent ethyl 
acetate/hexane 7:3, then 4:1, then ethyl acetate) to give the title compound as a clear oil 
(198mg, 61%).
[a]d18 +73.6 (c 1.4, CHC13); (Found: C, 63.50; H, 5.82; N, 6.87. Calc for C43H46N4O12: 
C, 63.69; H, 5.72; N, 6.91%); *H NMR (400 MHz; CDC13) <5h 1.88, 1.94, 1.99 (9H, 3s, 3 
x CH3CO), 3.36-3.43 (2H, m, H-6"A, H-6"B), 3.57 (1H, dd, J  10.3, 3.4, H-2”), 3.64, 3.73 
(2H, ABX, 2Jab 10.7, Vax 2.9, VBX 2.4, H-5'A, H-5'B), 4.00 (1H, ddd, J  9.8, 3.7, H-5"), 
4.35, 4.62 (2H, AB, Jab 12.0, OCtf2Ar), 4.49-4.60 (5H, m, 2 x OC//2Ar, H-4'), 4.75 
(1H, dd, J 4.4, H-3'), 4.98 (1H, d, J 3.9, H-l"), 5.04 (1H, dd, .79.8, H-4"), 5.45 (1H, dd, J
9.8, H-3"), 5.72 (1H, dd, J  5.1, H-2'), 6.44 (1H, d, J  4.9, H-l’), 7.24-7.38 (15H, m, 
ArCH), 8.41, 8.98, 9.15 (3H, 3s, H-2, H-6, H-8); 13C NMR (100.4 MHz; CDC13) & 
20.36, 20.68, 20.87 (3q, 3 x CH3CO), 67.92 (t, C-6"), 69.02 (d, C-4"), 69.17 (t, C-5'), 
69.28 (d, C-5"), 71.76 (d, C-3"), 73.30, 73.52, 73.72 (3t, 3 x OCH2Ar), 74.49 (d, C-2'), 
76.63 (2d, C-2" and C-3'), 82.86 (d, C-4'), 86.08 (d, C-l'), 98.12 (d, C-l"), 127.82, 
127.94, 128.00, 128.12, 128.36, 128.47, 128.62 (7d, ArCH), 134.42 (s, C-5), 137.12,
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137.40, 137.54 (3s, 3 x C-l of Bn rings), 143.71 (d, C-8), 148.81 (d, C-6), 151. 11 (s, C- 
4), 152.80 (d, C-2), 169.71, 170.21 (2s, 3 x CH3CO); m/z (FAB*) 811 [(M+H)+, 16%], 
691 (13), 91 (100).
Further elution gave the minor product (91 mg, 28%), a regioisomer of the desired 
product which could not be unambiguously identified.
[a ]D18 +50.0 (c 4.0, CHC13); (Found: M+, 811.317. Calc for C43H47N4O12 (M+H)+: 
811.319); *H NMR (400 MHz; CDC13) &  1-98, 2.05, 2.12 (9H, 3s, 3 x CH3CO), 3.50-
3.54 (2H, m, H-6"A, H-6"B), 3.65-3.68 (2H, m, H-2", H-5'A), 3.71 (1H, ABX, 2Jab 11.0, 
3J  1.9, H-5'b), 4.13 (1H, ddd, J  10.2, 4.0, H-5"), 4.47 (1H, AB, Jab 11.7, OCHtfAr), 
4.59-4.75 (7H, m, H-4', H-3', 5 x OCtfHAr), 4.99 (1H, d, J  3.5, H-l"), 5.10 (1H, dd, J
9.8, H-4"), 5.36 (1H, dd, /6 .0 , H-2'), 5.58 (1H, dd, .79.8, H-3"), 6.30 (1H, d, J6 .7 , H-l'), 
7.34-7.48 (15H, m, ArCH), 8.63, 9.25, 9.34 (3H, 3s, H-2, H-6, H-8); 13C NMR (100.4 
MHz; CDCI3) Sc 20.73, 21.13, 21.36 (3q, 3 x CH3CO), 68.60 (t, C-6"), 69.03 (t, C-5'), 
69.44 (d, C-4"), 69.91 (d, C-5"), 72.03 (d, C-3"), 73.63, 73.89, 74.04 (3t, 3 x OCH2Ar), 
75.59 (d, C-2'), 76.86 (d, C-2"), 77.76 (d, C-3'), 84.06 (d, C-4'), 88.58 (d, C-l'), 99.20 (d, 
C-l"), 124.24 (s, C-4 or C-5), 127.81, 127.67, 128.10, 128.15, 128.56, 128.33, 128.39, 
128.59, 128.64, 128.73, 128. 89 (lid,  ArCH), 136.96, 137.51, 137.54 (3s, 3 x C-l of Bn 
rings), 141.82, 146.43, 153.81 (3d, C-2, C-6, C-8), 161.34 (s, C-4 or C-5), 170.24, 




A solution of 137 (480mg, 0.59mmol), concentrated aqueous ammonia (5cm3), 
and methanol (25cm3) was stirred in a sealed flask for 20h, and then concentrated. The 
remaining oil was subjected to flash chromatography (eluent ethyl acetate/ethanol 19:1) 
to give the desired triol (392mg, 97%).
Rf 0.29 (ethyl acetate/ethanol 19:1); [o]d20 +23.5 (c 1.0, CHCI3); (Found: C, 64.80; H, 
5.93; N, 8.11. Calc for C37H40N4O9: C, 64.90; H, 5.89; N, 8.18%); 'H  NMR (400 MHz;
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CDCI3) Sh 3.45 (1H, dd, J9.5, 3.6, H-2"), 3.57, 3.62 (2H, ABX, Vab 11.0, Vax 2.4, VBX
2.4, H-5’a, H-5'b), 3.67-3.74 (3H, m, H-4", H-6"A, H-6"B), 3.94 (1H, ddd, J  9.3, 4.2, H- 
5"), 4.08-4.13 (1H, m, H-3"), 4.23 (1H, dd, J  5.1, 2.2, H-3'), 4.33 (1H, br.s., D20  exch., 
OH), 4.42-4.43 (1H, m, H-4'), 4.46-4.57 (6H, m, 5 x OCtfHAr, D20  exch., OH), 4.66- 
4.73 (3H, m, H-2’, OCHtfAr, D20  exch., OH), 4.82 (1H, d, J  3.4, H-l"), 6.30 (1H, d, J
6.4, H-l'), 7.24—7.38 (15H, m, ArCH), 8.40, 8.89, 9.14 (3H, 3s, H-2, H-6, H-8); 13C 
NMR (100.4 MHz; CDCI3) Sc 69.39 (t, C-5’), 69.77 (t, C-6"), 70.08 (d, C-4"), 71.87 (d, 
C-5"), 72.84 (d, C-3"), 73.66, 73.77, 74.18 (3t, 3 x OCH2Ar), 75.95 (d, C-2’), 79.19 (d, 
C-2"), 80.58 (d, C-3’), 83.16 (d, C-4'), 87.97 (d, C-l'), 99.72 (d, C-l"), 127.67, 127.82,
127.87, 128.14, 128.42, 128.58, 128.64, 128.73 (8d, ArCH), 134.56 (s, C-5), 136.67, 
137.20, 137.76 (3s, 3 x C-l of Bn rings), 143.93 (d, C-8), 148.90 (d, C-6), 151.21 (s, C-
4), 152.28 (d, C-2); m/z (FAB+) 685 [(M+H)+, 65%], 91 (100).
7.8.4 2,,,5,,6,,-Tri-0-benzyl-2,,3,,,4,,-tris(dibenzyloxyphosphoryl)-3,-0 -a -  
D-glucopyranosyl-9-^-D-ribofuranosidopurine (139)
Bis(benzyloxy)(diisopropylamino)phosphine (0.34cm3, 1.02mmol) and tetrazole 
(107mg, 1.53mmol) were stirred together in DCM (4cm3) for 30min, the mixture thus 
obtained was then added to the starting triol (138) (116mg, 0.17mmol). After a further 
30min TLC (ethyl acetate/hexane 4:1) indicated conversion of starting material to a 
single trisphosphite product (Rf 0.80). The reaction mixture was then cooled to -78°C 
and MCPBA (317mg, l.lOmmol) added, after 5min TLC (ethyl acetate/hexane 4:1) 
indicated the formation of one product Rf 0.26. 10% Aqueous Na2SC>3 solution (20cm3) 
and ethyl acetate (25cm3) were added and the mixture was allowed to warm to RT. The 
organic layer was washed with 20cm each of saturated aqueous NaHCC>3 solution and 
brine, dried (MgS04), filtered and concentrated. Purification of the residue by flash 
chromatography (eluent ethyl acetate/toluene 4:1) yielded the fully protected 
trisphosphate (198mg, 80%).
[a ]D25 +17.9 (c 1.4, CHCI3); (Found: M \ 1465.469. Calc for CtoHsoOisPs tvC: 
1465.468); 'H NMR (400 MHz; CDC13) A  3.53-3.72 (5H, m, H-2", H-5'A, H-5’B, H -6" a , 
H -6 " b ) ,  3.84-3.88 (1H, m, H-5"), 4.30-4.80 (14H, H-3’, H-4’, H-4", 11 x OCHHAr),
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4.89-5.07 (8H, m, H-3", 7 x OCtfHAr), 5.34 (1H, d, J  3.5, H -l”), 5.56 (1H, m, H-2'),
6.46 (1H, d, J 6.4, H-l'), 6.93-7.42 (45H, m, ArCH), 8.20, 8.85, 9.04 (3H, 3s, H-2, H-6, 
H-8); 13C NMR (100.4 MHz; CDC13) 8c 68.75 (t, C-6"), 69.51-70.21 (7t, C-5', 6 x 
OCH2Ar with C-P coupling), 70.50 (d, C-5"), 71.95, 73.71, 73.99 (3t, 3 x OCH2Ar),
74.03 (d, C-3'), 74.70 (d, C-4" with C-P coupling), 77.18 (d, C-3" with C-P coupling), 
78.34 (d, C-2' with C-P coupling), 82.98 (d, C-4'), 85.68 (d, C-l'), 95.70 (d, C-l"),
127.85, 127.92, 127.99, 128.07, 128.18, 128.25, 128.32, 128.33, 128.54, 128.58, 128.69, 
128.76, 128.85, 128.92 (14d, ArCH), 134.50 (s, C-4 or C-5), 134.98-136.39 (6s, 6 x C-l 
of benzylphospho rings with C-P coupling), 137.38, 137.82, 138.19 (3s, 3 x C-l of 
benzyl rings), 144.17, 148.84, 152.80 (3d, C-2, C-6, C-8), 151.51 (s, C-4 or C-5); 31P 
NMR (161.7 MHz; CDC13; *H decoupled) 8p -0.80, -0.68, -0.12 (3s); m/z (FAB-") 1465 
[(M+, 4%], 91 (100).
7.8.5 3'-0-a-D-Glucopyranosyl-9-/?-D-ribofuranosidopurine 2 \3 '\4 n- 
trisphosphate (140)
A mixture of 139 (133mg, 0.09mmol) and wet 20% palladium hydroxide on 
carbon (400mg), in methanol (22cm3), cyclohexane (10cm3) and water (2cm3) was 
heated at reflux for 17h. After cooling the reaction mixture was filtered through a 
membrane filter and the catalyst washed with methanol and water. Concentration of the 
filtrate afforded a clear residue that was purified by application to an MP1 AG ion 
exchange resin column and eluted with a gradient of 0-100% 150mM TFA. 
Concentration of the appropriate fractions (being careful to keep the temperature below 
20°C) gave the desired product as the free acid (33mg, 56%) which was dissolved in 
water and eluted through a short column of Na+ dianion WK-40 ion exchange resin to 
give, after concentration, the sodium salt.
(Found: M', 653.029. Calc for Ci6H24N4Oi8P3 (M-H)': 653.029); lH NMR (400 MHz; 
D20) <5k 3.57-3.75 (6H, m, H-2", H-5?A, H-5'B, H-5", H-6"A, H-6"B), 3.96 (1H, ddd, J  9.5, 
H-4"), 4.30 (1H, dd, J  7.3, 3.8, H-4'), 4.36 (1H, ddd, J 9.2, H-3"), 4.51 (1H, dd, J  5.0, 3.8, 
H-3'), 5.10 (1H, d, J 3.8, H-l"), 5.21 (1H, ddd, J 9.4, 4.8, H-2'), 6.40 (1H, d, J 5.9, H-l');
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31P NMR (161.7 MHz; D20; *H decoupled) <5j> 0.22, 0.71, 1.07 (3s); UV (H20) Xmax 
262nm, 8 6 690, pH 7.5; m/z (FAB ) 653 [(M-H)', 100%], 551 (32).
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7.9 Synthesis of imidophostin
7.9.1 12,,3,,,4,,-Tri-0-acetyl-2,,,5,J6,,-tri-0-benzyl-3,-0-a-D- 
glucopyranosyl)-1 ->fl-D-ribofuranosidoimidazole (145)
124 (412mg, 0.55mmol) In 1,2-dichloroethane (8cm3) was added to N- 
trimethylsilylimidazole (0.09cm3, 0.60mmol) and TMSOTf (0.08cm3, 0.41mmol) in 1,2-
<3
dichloroethane (4cm ). This solution was heated at reflux for 8h after which time TLC 
(chloroform/acetone 24:1) indicated starting material (Rf 0.58) still remaining. Further 
quantities of AMrimethylsilylimidazole (0.05cm3, 0.34mmol) and TMSOTf (0.05cm3, 
0.26mmol) were added and refluxing continued for a further 16h. TLC then indicated 
loss of starting material and appearance of one major product (Rf 0.34) and one minor 
product (Rf 0.23 with streaking). The cooled reaction mixture was diluted with DCM 
(20cm ) and washed with 20cm each of saturated aqueous NaHCOs solution and brine. 
The resulting organic layer was dried (MgS04), filtered and concentrated and the residue 
subjected to flash chromatography (eluent chloroform/acetone 39:1) to yield the title 
compound as a clear oil (238mg, 57%).
[a]Dl8 +52.0 (c 1.6, CHC13); (Found: M+, 759.312. Calc for C41H47N2O12 (M+H)+: 
759.312); *H NMR (400 MHz; CDC13) <5k 1.87, 1.93, 1.99 (9H, 3s, 3 x CH3CO), 3.37-
3.57 (4H, m, H-2", H-5'a, H-6"a, H-6"b), 3.62 (1H, ABX, 2Jab 10.8,3JBX 2.3, H-5'B), 3.98 
(1H, ddd, J  10.2, 3.7, H-5"), 4.35 (1H, AB, Jab  11.7, OCH/fAr), 4.45-4.61 (7H, m, 5 x 
OCHT/Ar, H-3', H-4'), 4.90 (1H, d, J 3.5, H-l"), 5.01 (1H, dd, J 9.8, H-4"), 5.17 (1H, dd, 
J 5.6, H-2'), 5.43 (1H, dd, 79.7, H-3"), 5.89 (1H, dd, 76.2, H-l'), 7.08 (1H, s, H-5), 7.14 
(1H, s, H-4), 7.24—7.35 (15H, m, ArCH), 7.82 (1H, s, H-2); 13C NMR (100.4 MHz; 
CDCI3) Sc 20.76, 21.09, 21.31 (3q, 3 x CH3CO), 68.30 (t, C-6"), 69.34 (d, C-4"), 69.61 
(d, C-5", and t, C-5'), 72.08 (d, C-3"), 73.12, 73.82, 73.94 (3t, 3 x OCH2Ar), 76.41 (d, C- 
2'), 76.84 (d, C-2"), 77.79 (d, C-3'), 83.17 (d, C-4’), 88.49, (d, C-l’), 98.69 (d, C-l"), 
116.84 (d, C-5), 127.94, 128.00, 128.11, 128.17, 128.24, 128.53, 128.66, 128.75 (8d, 
ArCH), 129.52 (d, C-4), 136.25 (d, C-2), 137.39, 137.51, 137.61 (3s, 3 x C-l of Bn 




Further elution gave the C2-symmetrical compound l,3-bis(2',3",4"-tri-0-acetyl- 
2",5',6"-tri-O-benzyl-3'-0-a-D-glucopyranosyl-/?-D-ribofuranosido) imidazolium
(triflate?) (146) (81mg, 20% based on 0.5 equivalents of starting disaccharide).
[a]Dl8 +58.0 (c 2.2, CHC13); (Found: M+, 1449.582. Calc for C79H89N2024 M+: 
1449.580); *H NMR (400 MHz; CDC13) &  1.98, 1.93,1.97 (18H, 3s, 6 x CH3CO), 3.86- 
3.43 (4H, m, 2 x H-6"A, 2 x H-6"B), 3.53, (2H, dd, J  10.0, 3.5, 2 x H-2"), 3.59-3.61 (2H, 
m, 2 x H-5'a), 3.72-3.77 (2H, m, 2 x H-5'B), 3.92 (2H, ddd, J  62, 3.8, 2 x H-5"), 4.34 
(2H, AB, J  12.0, 2 x OCHi/Ar), 4.48^1.50 (10H, m, 4 x OC/^Ar, 2 x H-4'), 4.62-4.65 
(4H, m, 2 x OCH/fAr, 2 x H-3'), 4.99 (2H, dd, J  10.0, 2 x H-4"), 5.34 (2H, dd, J 4.3, 2 x 
H-2'), 5.41 (2H, dd, J  9.7, 2 x H-3"), 5.99 (2H, d, J3 .2 , 2 x H-l'), 7.24-7.34 (30H, m, 
ArCH), 7.51 (2H, br s, H-4, H-5), 9.37 (1H, br s, H-2); 13C NMR (100.4 MHz; CDC13) 
Sc 20.73, 21.09, 21.28 (3q, 6 x CH3CO), 68.56 (t, 2 x C-6"), 68.78 (t, 2 x C-5'), 69.37 (d, 
2 x C-4"), 69.66 (d, 2 x C-5"), 71.88 (d, 2 x C-3"), 73.40, 73.81, 73.90 (3t, 6 x OCtf2Ar), 
75.80 (d, 2 x C-3'), 76.20 (d, 2 x C-2'), 76.77 (d, 2 x C-2"), 84.17 (d, 2 x C-4'), 91.40 (d, 
2 x C-l'), 98.09 (d, 2 x C-l"), 120.13 (d, C-4 and C-5), 127.99, 128.07, 128.13, 128.41, 
128.53, 128.59, 128.85 (7d, ArCH), 134.06 (d, C-2), 137.13, 137.58, 137.72 (3s, 6 x C-l 
of Bn rings), 169.79, 170.27, 170.45 (3s, 6 x CH3CO); m/z (FAB+) 759 [(M+H)+, 54%], 
691 (15), 181 (15), 91 (100).
7.9.2 2,,,5,,6,,-Tri-0-benzyl-3,-0-a-D-glucopyranosyl)-1 
ribofuranosidoimidazole (147)
A solution of 145 (240mg, 0.32mmol), concentrated aqueous ammonia (2cm ), 
and methanol (10cm ) was stirred in a sealed flask for 24h, and then concentrated. The 
residual oil was subjected to flash chromatography (eluent ethyl acetate/ethanol 14:1) to 
give the desired triol (192mg, 96%).
Rf 0.33 (chloroform/methanol 14:1); [a]D18 +25.8 (c 0.7, CHCI3); (Found: M+, 633.280. 
Calc for C35H41N2O!, (M+H)+: 633.281); 'H NMR (400 MHz; CDCI3) <5» 3.44-3.56 (4H, 
m, H-2", H-4", H-5'a, H-5’b), 3.62 (1H, ABX, Vab 10.4, 3Jax 5.8, H-6"A), 3.70-3.73 (1H, 
m, H-6"b), 3.83-3.87 (1H, m, H-5"), 4.02 (1H, dd, J  9.2, H-3"), 4.17-4.18 (1H, m, H-3'), 
4.25 (1H, m, H4'), 4.30 (1H, dd, J  5.6, H-2'), 4.39-4.52 (7H, m, 2 x OC/fjAr, D20
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exch., 3 x OH), 4.68,4.81 (2H, AB, J 11.7, OCZZ2Ar), 4.87 (1H, d, J 2.9, H-l'), 5.49 (1H, 
d, J  5.9, H-l"), 6.97 (1H, s, H-5), 7.07 (1H, s, H-4), 7.22-7.33 (15H, m, ArCH), 7.62 
(1H, s, H-2); 13C NMR (100.4 MHz; CDC13) & 69.84 (t, C-6"), 70.12 (t, C-5'), 70.96 (d, 
C-4"), 72.17 (d, C-5"), 73.81, 73.86, 73.95 (3t, 3 x OCH2Ar), 76.63 (d, C-2'), 78.97 (d, 
C-2"), 79.88 (d, C-3'), 83.09 (d, C-4'), 90.97 (d, C-l'), 99.85 (d, C-l"), 116.86 (d, C-5),
127.88, 127.91, 127.95, 128.16, 128.58, 128.56, 128.81, 128.86 (8d, ArCH), 129.28 (d, 
C-4), 136.56 (d, C-5), 137.46, 137.64, 138.20 (3s, 3 x C-l of Bn rings); m/z (FAB4) 633 
[(M+H)+, 100%], 91 (81).
7.9.3 2",5,,6"-Tri-0-benzyl-2',3",4"-tris(dibenzyloxyphosphoryl)-3'-0-a- 
D-glucopyranosyl)-1 -/to-ribofuranosidoimidazole (148)
Imidazolium triflate (115mg, 0.53mmol) and bis(benzyloxy)
(diisopropylamino)phosphine (0.18cm3, 0.53mmol) were added to a solution of 147 
(104mg, 0.16mmol) in DCM (3cm ). TLC after 30 min indicated complete conversion 
the trisphosphite. The reaction mixture was cooled to -78°C and MCPBA (156mg, 
0.54mmol) was added, TLC (chloroform/methanol 24:1) after a further 5min indicated 
oxidation to the protected trisphosphate (Rf 0.39). 10% Aqueous Na2SC>3 solution
(15cm3) and ethyl acetate (15cm3) were added and the mixture was allowed to warm to 
room temperature. The organic layer was washed with 15cm each of saturated aqueous 
NaHCC>3 solution and brine, dried (MgSCU), filtered and concentrated. Purification of 
the residue by flash chromatography (eluent ethyl acetate/toluene 7:3) yielded the fully 
protected trisphosphate (1 lOmg, 72%).
[a ]D18 +14.5 (c 2.2, CHC13); (Found: M+, 1413.455. Calc for C77H8oN2Oi8P3 (M+H)+: 
1413.461); *H NMR (400 MHz; CDC13) <5h 3.45-3.48 (1H, m, H-5’A), 3.55-3.59 (2H, m, 
H-2", H-5'b), 3.64 (1H, ABX, V ab 10.7, V ax 5.4, H-6"A), 3.70-3.73 (1H, m, H-6"B), 
3.81-3.85 (1H, m, H-5"), 4.29-4.79 (14H, m, 11 x x OCH/ZAr, H-4', H-3’, H-4"), 4.89- 
5.05 (9H, m, 7 x x OCH/ZAr, H-2', H-3"), 5.31 (1H, d, J  3.5, H-l"), 5.80 (1H, d, J  6.4, 
H-l'), 6.99 (1H, s, H-5), 7.01 (1H, s, H-4), 7.04-7.35 (45H, m, ArCH), 7.54 (1H, s, H-2); 
13C NMR (100.4 MHz; CDC13) Sc 68.80 (t, C-6"), 69.38-70.11 (POCH2Ar with C-P 
coupling, C-5’), 70.42 (d, C-5"), 71.66, 73.69, 73.90 (3t, 3 x OCH2Ar), 74.20 (d, C-3’),
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74.68 (d, C-4" with C-P coupling), 78.38 (d, C-3" with C-P coupling), 79.10 (d, C-2' with 
C-P coupling), 82.62 (d, C-4'), 87.67 (C-l1), 95.62 (d, C-l"), 116.81 (d, C-5), 127.83,
127.86, 127.89, 127.94, 127.96, 128.15, 128.20, 128.24, 128.28, 128.40, 128.47, 128.51, 
128.57, 128.63, 128.70, 128.74, 128.85, 128.91 (18d, ArCH), 130.11 (d, C-4), 135.22- 
136.31 (C-l of benzylphospho rings with C-P coupling), 136.72 (d,C-5), 137.37, 137.86, 
138.13 (3s, 3 x C-l of Bn ring); 31P NMR (161.7 MHz; CDC13; 'H decoupled) <$> -0.27, - 
0.83, -0.97 (3s); m/z (FAB*) 1412 (M+, 7%), 91 (100).
7.9.4 3'-0-a-D-Glucopyranosyl)-1 -yff-D-ribofuranosidoimidazole 2',3",4"- 
trisphosphate (149)
A mixture of 148 (82mg, 0.06mmol) and wet 20% palladium hydroxide on 
carbon (250mg) in methanol (11cm3), cyclohexane (5.5cm3) and water (1cm3) was 
heated at reflux for lOh. After cooling the reaction mixture was filtered through a 
membrane filter and the catalyst was washed with methanol and water. Concentration of 
the filtrate afforded a clear residue that was purified by application to an MP1 AG ion 
exchange resin column and eluting with a gradient of 0-100% 150mM TFA. 
Concentration of the appropriate fractions (being careful to keep the temperature below 
20°C) gave the desired product as the free acid (33mg, 94%), which was dissolved in 
water and eluted through a short column of Na+ dianion WK-40 ion exchange resin to 
give, after concentration, the sodium salt.
(Found: NT, 601.024. Calc for C14H24N2O18P3 (M-H)': 601.023); *H NMR (400 
MHz; D20) Sh 3.50-3.68 (6H, m, H-2", H-5", H-5’A, H-5'B, H-6"A, H-6"B), 3.91 (1H, 
ddd, 79.4, H-4"), 4.22-4.31 (3H, m, H-3', H-3", H-4'), 4.68-4.72 (1H, obscured by HDO 
peak, H-2'), 5.00 (1H, d, 73.5, H-l"), 5.98 (1H, d, 75.3, H-l'), 7.29 (1H, dd, 71.5, H-5), 
7.49 (1H, dd, 7  1.5, H-4), 8.79 (1H, dd, 7  1.5, H-2); 31P NMR (161.7 MHz; D20; *H 
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